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          Abstract 
 
African trypanosomiasis and leishmaniasis are caused by parasites which belong to the genera 
Trypanosoma and Leishmania, respectively. These diseases affect a large number of people in 
many parts of the world, and could be fatal if not properly treated. These diseases are also animal 
infective, where they also cause weight loss and significant number of deaths in domestic and 
wild animals, posing a restraint on agricultural outputs and economic prosperity, especially in 
resource poor communities. While these diseases can be treated with the available chemotherapy, 
this is faced with many challenges, including drug resistance, toxicity, high treatment cost and 
lack of guaranteed supply. Hence, there is a need for new treatment approaches. Here, we aim to 
examine the in vitro efficacy of purified natural compounds, and synthetic mitochondrion-
targeting lipocations against these parasites, assay their toxicity to human cells in vitro, and 
investigate the mode of their antiparasite activities. 
 
Natural products such as plant secondary metabolites serve as potent defence chemicals with an 
intrinsic multifunctional mode-of-action on plants pathogens, justifying their folkloric use as 
medicinal herbs, and their remarkable contributions to drug discovery. Consequently, we here 
report the results of the in vitro screening of extracts from seven selected medicinal plant species 
(Centrosema pubescens, Moringa oleifera, Tridax procumbens, Polyalthia longifolia, 
Newbouldia laevis, Eucalyptus maculata, and Jathropha tanjorensis), used traditionally to treat 
various parasitic infections in North central region of Nigeria, the isolation of their bioactive 
principles, and their mode of action. 
 
The selected plants were extracted with hexane, ethyl acetate and methanol. Active principles 
were isolated by bioassay-led fractionation, testing for trypanocidal activity, and identified using 
NMR and mass spectrometry. EC50 values for their activity against wild-type and multi-drug 
resistant Trypanosoma brucei were obtained using the viability indicator dye resazurin.  
The result shows that crude extracts and isolated active compounds from Polyalthia longifolia 
and Eucalyptus maculata, in particular, display promising activity against drug-sensitive and 
multi-drug resistant Trypanosoma brucei. The EC50 value of a clerodane (16α-hydroxy-cleroda-
3,13(14)-Z-dien-15,16-olide, HDK20) isolated from Polyalthia longifolia was as low as 0.38 
µg/mL, while a triterpenoid (3β,13β-dihydroxy-urs-11-en-28-oic acid, HDK40) isolated from 
Eucalyptus maculata displayed an EC50 of 1.58 µg/mL. None of the isolated compounds 
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displayed toxicity towards Human Embryonic Kidney cells at concentrations up to 400 µg/mL. In 
addition, the isolated compounds were also active against Leishmania mexicana, as well as 
against T. congolense.  
 
We further exploited various biochemical approaches to reveal the mode-of-action of HDK-20 
and HDK-40 on Wild-Type Trypanosoma brucei trypomastigotes. Growth curves of T. brucei 
s427 wild-type grown in the continuous presence of HDK20 or HDK40 at concentrations ≥ EC50 
showed the compounds were trypanocidal, and their effects were irreversible after a limited 
exposure time of 1 hour. Fluorescence microscopic assessment of DNA configuration revealed 
cell cycle defects after 8 hours of incubation with either compound: DNA synthesis could not be 
initiated, leading to a dramatic increase in cells with 1 nucleus and 1 kinetoplast (1N1K). DNA 
fragmentation became evident after 10 hours of incubation with compound HDK-20, visualised 
by flow cytometry and Terminal deoxynucleotidyl transferase dUTP Nick-End Labelling 
(TUNEL) assay. HDK-20 and HDK-40 also induced a fast and profound depolarisation of the 
parasites’ mitochondrial membrane potential after 1 hour of incubation and this continued until a 
near complete depolarization was achieved after 12 hours. Intracellular ATP levels of the T. 
brucei were also measured and were found to be depleted by approximately 50% in treated cells. 
However untargeted metabolomic assessments of T. brucei cells did not reveal the targeting of 
any specific metabolic pathway.  
 
Considering that lipophilic cations (LCs) can diffuse across biological membranes (and also cross 
the blood-brain barrier) to achieve therapeutic doses in tissues, we investigated a chemical 
strategy to boost the trypanocidal activity of 2,4-dihydroxybenzoate (2,4-DHB)- and 
salicylhydroxamate (SHAM)-based trypanocides with triphenylphosphonium and quinolinium 
LCs. The synthesized LC conjugates were active in the submicromolar to low nanomolar range 
against wild-type and multi-drug resistant strains of African trypanosomes (T. brucei brucei and 
T. congolense). This represents an improvement in trypanocidal potency of at least 200-fold, and 
up to >10,000-fold, compared with the non-LC coupled parent compounds 2,4-DHB and SHAM 
respectively. Selectivity over human cells ranged from >500 to >23,000. Mechanistic studies 
showed that the LC based inhibitors tested did not inhibit the cell cycle but affected parasite 
respiration in a dose-dependent manner. Mitochondrial functions were also studied for selected 
compounds, and we discovered that the compounds did inhibit mitochondrial function after 1 
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hour, and ATP generation was markedly reduced; suggesting that the trypanosome alternative 
oxidase (TAO) is the likely target of the two series of LC based inhibitors. 
 
In order to carry out direct inhibition of TAO by our synthesized inhibitors, we expressed and 
purified the physiological form of TAO that does not include its N-terminal 25 amino acid 
mitochondrial targeting sequence (∆MTS rTAO), and this was expressed in a haem deficient E. 
coli (FN102). This physiologically relevant rTAO enzyme was used to characterize the inhibitory 
efficacy of 32 cationic and non-cationic compounds and develop structure-activity relationships 
with these series of 2,4-DHB and SHAM derivatives. Kinetics of binding to ∆MTS rTAO 
determined by Lineweaver–Burk plot analysis, and Surface Plasmon Resonance (SPR) 
experiments indicated a non-competitive inhibition similar to the parent compounds. The 
inhibitors, which showed nanomolar IC50 values against ∆MTS rTAO in the same range as 
ascofuranone (IC50 = 2 nM) for the most potent compounds, also displayed in vitro efficacy 
against wild type and resistant strains of T. brucei and T. congolense. The cationic compounds 
were extremely potent trypanocides with EC50 values similar or lower than the reference drugs 
pentamidine and diminazene. Selectivity over human cells was >8 (for non-cationic compounds) 
and between >900 and 344,000 for the cationic derivatives. As a whole, the data are consistent 
with TAO being the primary target of these inhibitors in the parasite cell. 
 
Overall, we isolated several promising trypanocidal compounds from Nigerian medicinal plants; 
these showed low toxicity, no cross-resistance with current treatments, and were efficacious 
against kinetoplastid parasites including L. mexicana and both human-infective and veterinary 
Trypanosoma species. Both compounds showed a parasite-specific multi-target mechanism of 
action, which provides a biochemical explanation for their promising broad spectrum anti-
parasite activity. We also conclude that effective mitochondrial targeting greatly potentiates the 
activity of TAO inhibitors. Hence, further structure activity relationship analysis is required to 
optimise these natural and synthetic lead compounds, while in vivo assays are ongoing to confirm 
their anti-trypanosome and anti-leishmania efficacies.  
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Chapter 1: Introduction 
 
1.1 Trypanosomes and trypanosomiasis 
 
Trypanosomatids, including Trypanosoma and Leishmania species are uniflagellated protists. 
Together with the biflagellated bodonids, trypanosomes are categorized as kinetoplastids, which 
are characterized by the presence of a single mitochondrion possessing a large amount of DNA 
(kDNA) in a distinct organelle, known as the kinetoplast. 
 
Trypanosomes are unicellular flagellated parasitic protozoa which belong to the Genus 
Trypanosoma, of the Trypanosomatidae Class, and of the Protozoa Kingdom. There are many 
trypanosomes species and subspecies already described in literature.  
Some species of trypanosomes infect a diversity of different vertebrates, including humans. Most 
of these species are transmitted by insect vectors such as the tsetse fly - which transmits 
Trypanosoma brucei gambiense and T. b. rhodesiense, causing Human African Trypanosomiasis 
(HAT), as well as other species including T. b. brucei, T. congolense and T. vivax, which cause 
African Animal trypanosomiasis (AAT). However, other Trypanosoma species have alternative 
modes of transmission. For example, through the faeces of an infected triatomine bug, commonly 
known as 'kissing bugs', among several names, depending on the geographical area, in which case 
it is called Chagas disease, also known as American trypanosomiasis. This is a life-threatening 
disease caused by Trypanosoma cruzi which is endemic in 21 countries in the Americas (Barreto-
de-Albuquerque et al., 2015). Some Trypanosoma species such as Trypanosoma equiperdum are 
transmitted by direct contact of the host with the pathogen itself, i. e. without an intermediate host 
or vector. However, the majority of Trypanosoma species are spread by blood-feeding 
invertebrates serving as intermediate hosts, but there are differences in pathology among the 
various species. They are generally found in the mid-gut of an invertebrate host, but usually 
occupy the bloodstream when they invade the mammalian host. 
 
The name Trypanosoma is derived from two Greek words trypano (borer) and soma (body) due to 
their corkscrew-like movement (Gerasimos and Kent, 2014). Except for T. equiperdum, and the 
insect parasites such as all species of Crithidia (insect-to-insect transmission), all other pathogenic 
trypanosomatids are heteroxenous (they need more than one obligatory host to complete their life 
cycle) or are transmitted by animal vectors. Trypanosoma are a group of single-celled flagellates 
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that are transmitted by insects (Sternberg, 2004) and they parasitize vertebrates. A basic 
distinction between parasites with different localizations of their development inside the insect 
vector, and the mode of transmission, necessitated a subdivision of the genus Trypanosoma into 
two sections: Salivaria and Stercoraria. Salivarian trypanosomatids including T. brucei spp., T. 
congolense and T. vivax complete their life-cycle in the salivary glands of the insect and are 
transmitted to the host through saliva following a bite of an infected insect. T. cruzi, on the other 
hand, belongs to the Stercoraria since their development occurs inside the hindgut of the vector 
(triatomine bug) and transmission to the host is through faeces (Edmundo, 2002). In addition, 
transmission of both Trypanosoma types can also occur via blood transfusion, use of 
contaminated needles or via the congenital route (Barret et al., 2003). In addition, although most 
Trypanosoma parasites reside in the blood and tissue fluids of their hosts, T. cruzi lives 
intracellular following entry into their host. The ‘trypanosomiases’ therefore are made up of a 
group of important animal and human vector-borne parasitic diseases, specifically American 
(Chagas’ disease, T. cruzi) and African (sleeping sickness, T. brucei) trypanosomiasis. 
 
Several Trypanosoma species and subspecies are of economic importance on the African 
continent where they cause the human and animal forms of the disease, HAT and AAT (or 
nagana) respectively, in which case are a hindrance to human welfare, both affecting cattle rearing 
and agricultural development in several resource poor communities in Africa. 
 
Two subspecies of Trypanosoma brucei infect humans, with each causing slightly different 
pathologies but whichever case, it is called HAT. Trypanosoma brucei gambiense is found in 
central and western Africa where it causes a relatively chronic form of the disease which may 
develop over a number of years. Trypanosoma brucei rhodesiense on the other hand is found in 
southern and east Africa where it causes an acute illness which could lead to death within weeks 
or months. These two forms of sleeping sickness are usually fatal if left untreated (Rodenko et al., 
2015; Alkhaldi et al., 2016), although there are emerging, sporadic reports of long-term 
asymptomatic cases (Jamonneau et al., 2012). 
 
1.1.1 Morphology and life cycle of Trypanosoma brucei 
 
Trypanosoma brucei is a distinctive unicellular eukaryotic organism measuring between 8 and 50 
µm in length. T. brucei has an elongated body with a streamlined and narrowing shape. The cell 
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organelles including mitochondria, nucleus, endoplasmic reticulum, Golgi apparatus 
and ribosomes are all enclosed by the plasma membrane (Figure 1.1). It also possesses a 
distinctive organelle called the kinetoplast, made up of many DNA molecules (mitochondrial 
DNA) which functions as a single large mitochondrion. In T. brucei, the kinetoplast is situated 
close to (and attached to) the basal body by which it is indistinguishable under the microscope. A 
single flagellum running towards the anterior end emanates from the basal body. The flagellum is 
anchored to the parasites’ cell membrane along its body surface by an undulating membrane. At 
the anterior end, only the tip of the flagellum is free (Gerasimos and Kent, 2014). There is also a 
thick coat of variant surface glycoprotein (VSG) (Figure 1.1) at the cell surface of the 
bloodstream form (BSF); an equal dense coat of procyclins replaces this VSG when T. brucei 
differentiates into the procyclic stage in the midgut of the tsetse fly (Ferrante and Allison, 1989).  
 
VSG is known to be involved in several mechanisms involved in evading the immune response 
system of the host which includes preventing complement activation (Sternberg, 2004) as well as 
the decrease in antibody titres against VSG, which is believed to take place by the endocytosis of 
antibody-VSG complexes, which is subsequently followed by proteolysis of antibody followed by 
the recycling of VSG back to the surface of the parasite (Engstler et al., 2007). VSG is an 
immunodominant antigen, and is capable of stimulating both the T-cell-dependent and -
independent B-cell responses, which depends on its conformation (Mansfield, 1994). 
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Figure 1.1 Schematic diagram of Trypanosoma brucei in its intermediate bloodstream form, 
showing the major organelles. The arrow in the figure shows the direction of parasite movement. 
Adapted from: http://agsavet.blogspot.co.uk/2011/12/trypanosomiasis.html 
 
Trypanosomatids display more than a few different stages of cellular organisation. Among others, 
T. brucei adopt the following two major forms at various stages of their life cycle: 
The epimastigote is the main insect stage of T. brucei and it is found in the salivary glands of the 
tsetse fly (vector) (Figure 1.2). Lying anterior to the nucleus at this stage is the kinetoplast and 
basal body, a long flagellum is also attached along the parasite’s cell body. The flagellum 
originates from the centre of the parasite’s cell body (Stuart et al., 2008). 
The form present in the mammalian hosts is called trypomastigote. The basal body and 
kinetoplast at this stage are posterior of the nucleus.  
 
The name flagellum is derived from the Greek word ‘mastig’ which meaning whip, this refers to 
the parasite’s whip-like motion of the flagellum (Stuart et al., 2008). There are two unique 
structures on the flagellum of trypanosomes, a distinctive flagellar axoneme located parallel to the 
paraflagellar rod, and a lattice structure of proteins which is exclusive to the kinetoplastida, 
dinoflagellates, and euglenoids (Gerasimos and Kent, 2014). 
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Also extending from the basal body of the kinetoplast is a cytoskeletal structure. The flagellum is 
attached to the cytoskeleton of the trypanosome’s main cell body by four specific microtubules 
that run parallel to the flagellar tubulin in the same direction. 
Trypanosomes flagellar functions as an attachment to the fly gut in the procyclic phase and 
locomotion by oscillations along its attached flagellum and cell body. There are additional 
functions, specifically in cell division and driving the very fast rate of VSG 
endocytosis/turnover/recycling (Gerasimos and Kent, 2014). 
 
 
Figure 1.2 Life cycle of Trypanosoma brucei. Image credit: Centres for Disease Control Public Health 
Image Library. 
 
In the life cycle of T. brucei (Fig. 1.2), an infected tsetse fly of the genus Glossina injects 
metacyclic trypomastigotes into the skin tissue of a mammalian host during a blood meal from the 
mammalian host. The parasites gain asses to the lymphatic system and then pass into the host’s 
bloodstream. They transform into bloodstream trypomastigotes when inside the host, they are 
transported to other sites throughout the body, and they reach other body fluids (e.g., lymph, and 
spinal fluid) then continue the cell division by binary fission. The entire duration of the life cycle 
of African Trypanosomes is characterized by extracellular stages. The tsetse fly becomes infested 
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with the bloodstream trypomastigotes once taking a blood meal on an infected mammalian host. 
The parasites change into procyclic trypomastigotes in the fly’s midgut, where it then multiplies 
by binary fission, it leaves the insect’s midgut and transforms into epimastigotes. When the 
epimastigotes reaches the insect’s salivary glands, it continues its division via binary fission. The 
cycle in the fly normally takes about 3 weeks. Although humans are the primary reservoir for T. b. 
gambiense, this species can also be found in animals. Wild animals are the key reservoir of T. b. 
rhodesiense.  
 
1.1.2 Human African Trypanosomiasis (HAT): The disease, pathology and clinical 
manifestation. 
 
Human African trypanosomiasis (HAT) is also known as sleeping sickness, and it is a parasitic 
disease spread by the bite of an infected 'Glossina' insect, known as tsetse fly. HAT commonly 
comes in two forms: West African and East African. Both forms are caused by a protozoan 
parasite belonging to the genus Trypanosoma; HAT has resurfaced over the past few decades as a 
key threat to human health and wellbeing in many parts of Africa. Trypanosoma brucei 
gambiense is a subspecies of trypanosomes that is identified as the causative agent of sleeping 
sickness in West Africa while Trypanosoma brucei rhodesiense is known to be the cause of 
sleeping sickness in East Africa (Williams, 1996). There are distinctive differences between the 
clinical features and biology of T. b. rhodesiense and T. b. gambiense diseases, which perhaps is 
due to an increased adaptation of T. b. gambiense parasite to humans (Kennedy, 2004). 
 
The discovery of HAT was made in 1910 following an earlier discovery of AAT in 1894. Since 
these discoveries, several peaks of epidemics have overwhelmed the African continent (Cox, 
2004). Eventhough an obvious reduction in the prevalence of HAT was noticed between 1949 and 
1965, the disease resurfaced over the past few decades becoming one of the causes of mortality 
and morbidity in humans (Kennedy, 2006). Many factors are responsible for this resurgence, these 
include: the parasites acquiring drug resistance, socio-economic upheavals (especially (civil) war) 
which in turn lead to disruption of disease monitoring and control; inadequate financial provision 
of important resources to the disease in the time of peace; changes to climate and vegetation; 
movements of animal reservoirs; the appearance of novel virulent parasite strains; and changes in 
host disease vulnerability (Atouguia and Kennedy, 2000; Kuzoe, 1993). Many of these itemised 
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factors may operate at the same time, and there have been many substantial epidemics and focal 
emergences of HAT in several regions of Africa in the past few years (Kennedy, 2004).  
 
According to the World Health Organization, in 2006, 60 million people in 36 countries were at 
risk of contracting HAT, while about 500,000 people were reported to be infected with the 
disease, and at least 70,000 new cases were reported annually. However, with sustained control 
efforts from stakeholders, the number of new cases was drastically reduced. In 2009 the number 
of reported cases nosedived below 10,000 for the first time in 50 years, and in 2014 about 3796 
cases were recorded (WHO, 2016). This significant gain notwithstanding, HAT still signifies an 
impediment to the welfare of humans, affecting about one-third of the total land area of Africa 
(Fig. 1.3), and as long as the disease is not completely eradicated, it is likely to resurge once 
control measures are once more relaxed.  
 
Transmission of HAT takes place via the inoculation of metacyclic trypomastigotes, which are the 
infective form of the parasite, into the skin of the host by the bite of an infected vector, the tsetse 
fly. This leads to an inflammatory nodule or ulcer known as a ‘trypanosomal chancre’ which is a 
local skin lesion and may occur between 1–2 days following the bite (Cecchi et al., 2009). After 
this time, parasites move to the draining lymph nodes where they reach the bloodstream, thereby 
initiating the haemolymphatic stage of HAT (Kennedy, 2006). Metacyclic trypomastigotes then 
change into bloodstream trypomastigotes and spread to other sites right through the body; they 
also invade other blood fluids and continue cell division via binary fission. The haemolymphatic 
stage is characterized by fever, headache and malaise (Kuzoe, 1993). Most people usually realise 
their infection only when stage-two symptoms begin to appear and they may not seek out 
treatment until then. In more acute rhodesiense infection, pulmonary oedema, pancarditis and 
congestive heart failure can lead to fatalities even at this early stage (Cecchi et al., 2009). A 
distinctive sign of gambiense infection is a widespread lymphadenopathy which develops after a 
number of weeks, this is usually visible around the neck region and it is known as Winterbottom’s 
sign (Kennedy, 2006). Parasites can be detected in lymph, blood, and other tissue samples at this 
stage. However, they are more often than not below the detection level, particularly in infection 
with gambiense (Kuzoe, 1993); this makes detection of HAT at the early stage very difficult.  
When tsetse flies feed on the blood of an infected mammalian host, they become infected with the 
bloodstream trypomastigotes that they ingest. In the midgut of the fly, bloodstream 
trypomastigotes change into procyclic trypomastigotes then start multiplying by binary fission. 
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They leave the midgut of the insect, transform into epimastigotes, and get into the salivary glands, 
then divide by binary fission and change into metacyclic trypomastigotes. The complete life cycle 
in the tsetse fly lasts about three weeks (Stuart et al., 2008). 
 
In the early stage of HAT, during the process of trypanosome proliferation parasites invade the 
host’s bloodstream and lymphatic system where they cause symptoms that include headache, 
fever, chills, and lymphadenopathy. At this stage, activation of the immune system becomes 
evident as seen in the enlargement of the lymph node, splenomegaly, and hepatomegaly. If left 
untreated, the parasites can transcend the blood-brain barrier where they invade the central 
nervous system (CNS) in just a few weeks. The patient progresses to the CNS stage, where the 
symptoms of this stage include serious headaches, progressive mental deterioration, insomnia, 
tremors, and psychiatric manifestations. If the disease is still left untreated, it may end in 
somnolence, seizures, coma and, eventually, death (Stuart et al., 2008).  
             
Figure 1.3. Map of Africa showing the major subspecies of Trypanosoma brucei, the 
causative agents of HAT according to geographic distribution. Transmission of HAT presently 
take place at a low level in most of the countries in tropical Africa, at least about 50 million people 
are at risk with sporadic epidemic outbreaks. The regions with humans infected with T.b. 
gambiense are shown in red while the areas with T. b. rhodesiense are shown in blue. 
(http://www.dpd.cdc.gov/). 
 
The transmission of HAT is caused as a result of infection with the morphologically identical 
subspecies T. b. gambiense present in West and Central Africa and T. brucei rhodesiense present 
in East and Southern Africa (fig. 1.3). More than 90% of all HAT reported cases are believed to 
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be caused by T. brucei gambiense (Barrett et al., 2003; Sternberg, 2004). T. b. rhodesiense on the 
other hand accounts for fewer than 10% of all reported cases of HAT; nevertheless, it is 
responsible for the most deadly form of the disease as progression to the late stage of the disease 
happens in a matter of weeks, often leading to death within 3 months (Cecchi et al., 2009; 
Simarro et al., 2009). 
 
1.1.3 Diagnosis, Treatment and control of HAT 
 
Diagnosing HAT is commonly centred on both investigative and clinical data sets. A 
characteristic clinical manifestation (e.g. detection of trypanosomes in the blood), put into context 
the geographical region where HAT is identified to be prevalent, is obviously a significant 
diagnostic hint. However, the broad-spectrum nature of various clinical features linked to HAT 
makes it difficult to diagnose the infection and distinguish it from other tropical infections such as 
typhoid, malaria, HIV, tuberculosis, toxoplasmosis, leishmaniasis, viral encephalitis, or 
hookworm infections (Atouguia and Kennedy, 2000). A specific challenge is that antimalarial 
treatment for fever-like symptoms can in fact reduce the fever that is caused by HAT, therefore 
mystifying and delaying accurate diagnosis; indeed the two infections may also occur 
simultaneously. Precise diagnosis, especially at the hemolymphatic stage of HAT, would normally 
include using stained thin and thick films to confirm the presence of trypanosomes in patients’ 
peripheral blood (Atouguia and Kennedy, 2000; Truc et al., 2002). Despite the fact that detecting 
parasites in the blood is often a success in infection with T. rhodesiense, since parasitaemia is 
permanent, it is very difficult using this method in infection with T. gambiense, where a few 
parasites are observed in the peripheral circulation other than at times of cyclic parasitaemia. 
Therefore, diagnosis of T. gambiense infection is critically based on serologic tests. Presently an 
antibody-detecting card agglutination trypanosomiasis test (CATT) which is rapid, simple, and 
easy to perform is commonly used for the serological diagnosis of T. gambiense (Truc et al., 
2002). 
 
The treatment of HAT at the moment is based on five key drugs, which are pentamidine, suramin, 
melarsoprol, eflornithine (difluoromethylornithine, or DFMO), and nifurtimox. However, it 
should be noted that majority of these trypanocides were developed within the first half of the 
twentieth century, actually most of these drugs most likely would not have passed the present high 
safety standards (Fairlamb, 1990). Early-stage of HAT is treated with an intravenous (IV) 
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injection of suramin in T. rhodesiense infection at a dose of 4-5 mg/kg (test dose), then 20 
mg/kg/day with a maximum dose of 1 g per injection, at a rate of one injection per week for five 
weeks or with 4 mg/kg intramuscular injections of pentamidine once a day for seven consecutive 
days in the case of T. gambiense infection (Docampo and Moreno, 2002). This treatment is 
effective only at this stage and prevents the disease from progressing.  
 
Melarsoprol is a trivalent organic arsenical known to have the ability to cross the blood-brain 
barrier (Atouguia and Kennedy, 2000; Legros et al., 2002), and because of that it is used for 
treating late-stage disease in both forms of HAT, although it is presently being phased out for 
gambiense HAT. Precise treatment protocols differ significantly between different places and also 
depending on the parasite strain. Usually, a regimen of 3-4 i.v. doses is administered on a daily 
bases for a period of 3 - 4 weeks (Legros et al., 2002). Normally, patients are followed up every 6 
months for a total of 2 years with CSF examination and clinical evaluation. However, this strategy 
is difficult to execute as a routine practice in the field. While about 80-90% of all patients are 
cured using the standard treatment protocol (Atouguia and Kennedy, 2000), there is increasing 
evidence of drug resistance, for instance, the treatment failure rate was put at 30% among patients 
receiving treatment in Northern Uganda (Legros et al., 1994; Legros et al., 2002). Nevertheless 
the main challenge using melarsoprol is the serious post-treatment reactive encephalopathy 
(PTRE) which follows treatment in up to 10% of all cases, and has a fatality rate of about 50% 
(Pepin and Milord, 1994). Consequently the overall death rate from melarsoprol treatment is 
approximately 5%, which is still unacceptably high.  
 
Eflornithine (difluoromethylornithine [DFMO]) an inhibitor of ornithine decarboxylase initially 
developed as an anticancer drug is used as a monotherapy for treating late stage of HAT. Different 
open studies showed its efficacy however, studies against placebo were difficult due to ethics 
(Pepin et al., 1987). DFMO was at first unavailable due to some production problems and high 
pricing. It is now used for the treatment of T. b. gambiese in several countries where it showed its 
potency and appeared safer than melarsoprol (Franco et al., 2012). DFMO is also used in 
combination with Nifortimox (Nifurtimox Efflornitine Combination Therapy, NECT). NECT is 
currently the preferred treatment for late stage gambiense due to its reduced toxicity and relative 
efficacy however; it is not used against rhodesiense disease (Franco et al., 2012).  
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Control of HAT would involve eliminating the vector but this is difficult because of the large area 
occupied by the tsetse fly vector. However, a committed effort aimed at controlling HAT like the 
one which led to the recent decline in HAT incidence will require an increased public health 
awareness strategy that will significantly reduce, and eventually eliminate the human-tsetse fly 
contact by spraying insecticides, using sophisticated fly traps in the infected areas, and using 
molecular genetics strategies like the exchange of vulnerable insect phenotypes with an 
engineered refractory ones to reduce transmission of HAT (Aksoy, 2003). Additionally, a 
combination of political will and stability, and a significant increase in funding will be needed to 
improve infrastructure, a better surveillance strategy and screening humans and domestic animals 
in areas at risk of HAT infection. Also, a more effective treatment regimen is required for treating 
human disease and of animal reservoirs. 
  
1.1.4 African Animal Trypanosomiasis (AAT) 
 
African animal trypanosomiasis (AAT) is a parasitic disease caused by trypanosomes, and results 
primarily in anaemia and severe weight loss, which leads to great economic losses in livestock 
and reduced agricultural output. In most cases it is fatal if left untreated (Acha, 2013). AAT is 
commonly found mostly in those areas of Africa where its vector, the tsetse fly, is present. One 
organism, Trypanosoma vivax, is reported to have established itself in South America, and it is 
spread by biting flies that act as mechanical vectors (Batista et al., 2009; Davila and Silva, 2009). 
Protecting livestock from trypanosomiasis is very hard to achieve in the endemic regions, as bites 
from the primary vector, the tsetse flies as well as other insects would have to be prevented, or the 
transmission cycle broken by successfully treating every infected animal.  
 
About 50 million heads of cattle are being threatened by African animal trypanosomiasis (AAT) 
per year, resulting in about 3 million deaths a year (Acha, 2013); this has a serious impact on the 
production of cattle in sub-Saharan Africa. AAT is known to be caused by a variety of species: T. 
b. brucei, T. congolense, T. evansi, and T. vivax, cause “nagana” in cattle while T. equiperdum is 
known to causes “dura” in horses (Raper et al., 2001; Picozzi et al., 2008). Numerous classical 
parasitological and molecular approaches have been put to use in order to characterize 
representative strains of T. evansi, and T. equiperdum and these have in fact shown to be definite 
petite mutants of T. brucei. Interestingly, these trypanosomes have lost all (akinetoplastidy, Ak) or 
part (dyskinetoplastidy, Dk) of their kinetoplast DNA (kDNA); consequently, they were 
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considered as two subspecies, T. brucei evansi, and T. brucei equiperdum respectively, that 
recently arose spontaneously (Gibson et al., 2001; Lai et al., 2008).  
 
T. congolense can be grouped into three types, which are called the kilifi, savannah, and the forest 
types. Other Trypanosoma species such as T. godfreyi and T. simiae can also cause AAT (Asbeck 
et al., 2004). There are some trypanosome infections in Africa that are not known to be classified 
as any of the currently recognized species (Hamilton et al., 2008). Co-infections can take place 
with more than one species of trypanosome. 
 
All domestic animals can be infected with trypanosomes; the disease has been reported in goats, 
cattle, sheep, camels, cats, pigs, dogs, water buffalo, horses, donkeys, alpacas, llamas and other 
animal species (Doko et al., 1997; Gow et al., 2007; Dietmar, 2008). In most parts of Africa 
where the disease exist, cattle are the major species known to be affected. This is likely to be due 
to the feeding preference of tsetse flies; in effect, because of the size differentials in grazing 
animals, cattle can ‘shield’ other domestic animals like sheep, pigs and goats from the tsetse fly 
bites. In addition, over 30 species in the wild, in game reserves or in zoos, including ruminants 
like the antelopes and African buffalos, white-tailed deer, duikers, lions, leopards, as well as wild 
equidae, warthogs, elephants, capybaras, nonhuman primates and a range of rodents’ species are 
also known to be at risk of AAT (Brown, 2008; Gustave et al., 2015). The DNA of T. vivax has 
been observed by PCR in monitor lizards (Varanus ornatus) and crocodiles in Africa, but it is not 
clear at the moment whether T. vivax can become established in reptiles or it is simply inoculated 
momentarily by insects (Desquesnes and Dia 2004; Njiokoua et al., 2004). Experimental 
infections have been reported in laboratory animals like rats, mice, rabbits, and guinea pigs 
(Albright and Albright, 1981). The preferences for a suitable host by each species of trypanosome 
differ, but T. congolense, T. b. brucei, and T. vivax have a broad range of hosts among 
domesticated animals (Davila and Silva, 2009). Though T. suis and T. godfreyi infections occur in 
pigs however, T. simiae appears to be dominant in pigs’ infection (Njiokou et al., 2004), 
nevertheless, it has also been reported in camels, cattle, and horses by PCR (Pinchbeck et al., 
2008; Salim et al., 2011). 
 
The major clinical symptoms of AAT are weight loss, anaemia, an intermittent fever, and 
lymphadenopathy. Animals become increasingly emaciated, Milk yield decreased in dairy animals 
(Dietmar, 2008). In addition, neurological symptoms, diarrhoea, dependent oedema, cardiac 
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lesions, appetite loss, keratitis, lacrimation, and other clinical symptoms have also been reported 
(Njiokoua et al., 2004). Also, there is an established effect on reproduction like premature births, 
perinatal losses, abortions and testicular damage in male animals. Deaths are also very common in 
animals that are chronically infected, and animals that are said to have clinically recovered may 
relapse when they are stressed (Sekoni, 1994). Trypanosomes can also cause immunosuppression 
in animals, and coexisting infections may increase the severity of this disease (Thumbi et al., 
2014; Olifiers, 2015). Also reported among African cattle infected with T. vivax is acute 
hemorrhagic syndrome (Desquesnes and Dia, 2004). More often than not, affected animals will 
have enlarged lymph nodes coupled with signs of severe anaemia, and they will develop 
widespread mucosal and visceral haemorrhages, mainly in the gastrointestinal tract (GIT). This 
syndrome can be rapidly fatal (Gutierrez et al., 2006; Magona et al., 2008; Olifiers, 2015).  
 
Morbidity and mortality is known to vary with the animal breed, the strain and the inoculating 
dose from the infecting organisms (Jones and Davila, 2001). It has been reported that some breeds 
of small ruminants and African cattle on the basis of their genetics are resistant to developing 
clinical trypanosomiasis; this phenomenon is known as trypanotolerance (Dietmar, 2008; Ilboudo 
et al., 2014 Yaro et al., 2016). Known trypanotolerant breeds of cattle in Africa include West 
African Shorthorn (also known as Muturu, Laguna/ Lagune, Baoule, Samba/ Somba or Dahomey 
cattle, Namchi) and the N’Dama breed of cattle (Yaro et al., 2016). 
 
1.1.5 Chemotherapy of African trypanosomiasis 
 
HAT is particularly problematic to treat due to the unacceptable toxicity and the intricate 
administration of the chemotherapies presently available for treatment. Besides, resistance to 
current drugs by trypanosomes is another threat to chemotherapy. 
A few drugs are at the moment registered for use in treating HAT: pentamidine, melarsoprol, 
suramin, eflornithine, and nifurtimox eflornithine combination therapy (NECT). NECT is really 
the current recommended treatment for late stage T. b. gambiense HAT. However, none of these 
drugs are absolutely safe as all of them have certain degree of toxicity. Pentamidine and suramin 
are used in the first or early stage of T. b. gambiense and T. b. rhodesiense infections respectively. 
Meanwhile three key drugs are used to treat AAT: diminazene aceturate (DA), homidium salts 
(chloride or bromide), and isometamidium chloride (ISM). 
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1.1.5.1 Pentamidine 
 
Pentamidine (PMD) is an aromatic diamidine that is soluble in water, and was introduced in 1937. 
It is the first choice of drug for treating early-stage of HAT caused by T. b. gambiense. 
Pentamidine (Fig. 1.4) is reasonably well tolerated. It is administered by intramuscular injection 
(i/m), with the most frequently reported adverse events been site pain, transient swelling, 
abdominal pain, gastrointestinal complications, and hypoglycaemia. The use of PMD may, 
nevertheless, be circumscribed owing to pancreatic or renal function in immune deficient patients, 
cardiac dysrhythmias and hypotension, acute deterioration of bone marrow, or induction of 
abortion when used in pregnancy (Steverding, 2010).  
Several researches have concentrated on the mode of action of PMD; however, none seems to 
convincingly define the target (Soeiro et al., 2008). PMD, being an aromatic diamidine, is a 
compound that belongs to a class of the DNA minor groove binders. It is thought that formation 
of complexes between diamidines and DNA may prevent transcription, and/or may act through 
inhibition of DNA-dependent protein complexes.  
 
1.1.5.2 Melarsoprol 
 
Melarsoprol is used for treating HAT, and is an extremely toxic compound that contains arsenic 
and displays very strong reactivity with thiols (Gurib-Fakim, 2006).  
Melarsoprol (Fig. 1.4) was formulated in 1949 for the treatment of HAT. Up until 1990, the only 
chemotherapy existing for treating the late stage of both west and east African HAT was 
melarsoprol. To the current date, it remains the only chemotherapy that is effective (and licensed) 
for treating second-stage of HAT caused by T. b. rhodesiense. However, toxicity remains a key 
issue with the use of melarsoprol. The most important side effects is the encephalopathic 
syndrome which take place in about 8.0% of T. b. rhodesiense and 4.7% of T. b. gambiense 
patients, with an unacceptable high fatality rate (Steverding, 2010). Exfoliative dermatitis and 
cardiotoxicity are the other side effects that are serious and, in the latter case, potentially life-
threatening. Treatment regimens are usually long and will normally need hospitalisation. Besides, 
melarsoprol-resistant trypanosomes are well reported from a growing list of countries. In more 
than a few areas, treatment failures reached 30% in treated patients (Steverding, 2010).  
Though the mode of action of melarsoprol has been comprehensively studied, it still remains 
vague. Melarsoprol is unstable in plasma of patients and is quickly metabolised to melarsen oxide 
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(Keiser and Burri, 2000). It has been suggested that trivalent arsenicals like melarsoprol have a 
greater affinity for sulfhydryl-containing agents like intracellular thiol in the cell, plus 
dihydrolipoate and the closely neighbouring cysteine residues of several proteins. For instance 
trypanothione has been shown to form a stable adduct with the aromatic arsenical drug melarsen 
oxide [p-(4,6-diamino-s-triazinyl-2-yl) aminophenyl arsenoxide] (Fairlamb et al., 1989).  
 
1.1.5.3 Suramin 
 
Suramin is a sulphonated naphthylamine (Fig. 1.4) that was developed in 1916, and it is used for 
treating the early-stage of HAT caused by T. b. rhodesiense. It causes certain unwanted side 
effects especially allergic reactions and urinary tract diseases. There are several hypotheses that 
have been put forward for suraminʼs mechanism of action, but none of these have been proven 
(Zoltner et al., 2016).  
It has been shown that suramin inhibits the glycolytic enzymes, including 6-phosphogluconate 
dehydrogenase, which is an enzyme present in the pentose-phosphate pathway, as well as 
dihydrofolate reductase and thymidine kinase (Keiser and Burri, 2000). However, suramin has six 
negative charges which it uses for binding via an electrostatic interaction with positively charged 
areas of several enzymes; therefore suramin may elicit its trypanocidal action via several targets. 
Thus, the pertinent question is how it selectively enters trypanosomes rather than host cells.  
 
1.1.5.4 Eflornithine 
 
Eflornithine, also called α-difluoromethylornithine, DFMO, (Fig. 1.4) was approved for use in 
1990; it still remains one of the newest drugs used for treating HAT. Although it was originally 
developed for use as an anticancer drug, it was later discovered to be active against the late-stage 
of HAT caused by T. b. gambiense, particularly in patients that were not responding to treatment 
with melarsoprol. Eflornithine is an irreversible inhibitor of the enzyme ornithine decarboxylase 
(ODC) - the initial enzyme in the biosynthetic pathway of polyamine (Oredsson et al., 1980). The 
result of ODC inhibition is the reduction in the synthesis of the polyamines spermidine and 
putrescine; because of that it results in the loss of the distinctive and very important antioxidant 
metabolite trypanothione. These metabolic changes prevent parasite cell division and the drug 
treatment therefore must rely on an active immune system to eliminate the cell-cycle arrested 
forms from the host’s system (Steverding, 2010).  
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A major shortcoming of eflornithine use is the difficult nature of the regimen. For instance, 
because of the short half-life of the drug in plasma, it is necessary to administer four i.v. infusions 
per day, lasting for two weeks. The most common side effect is bone marrow suppression which 
leads to leucopenia, anaemia, thrombocytopenia, gastrointestinal symptoms.  
 
1.1.5.5 Nifurtimox-eflornithine combination therapy (NECT) 
 
Nifurtimox-eflornithine combination therapy (NECT) was recently (2009) approved for use in 
treating late-stage HAT caused by T. b. gambiense. NECT comprises of a basic co-administration 
of intravenous eflornithine and oral nifurtimox (Yun et al. 2010).  
Nifurtimox is a derivative of nitrofuran that was formulated in the 1960s. Its anti-trypanosomal 
activity was experimentally reported and ever since 1967 it has been put to use for treating 
trypanosomiasis (Chagasʼ disease) caused by Trypanosoma cruzi in Latin America. NECT is now 
the present day treatment for late-stage of HAT (Zoltner et al., 2016). This is because it is more 
effective and less toxic than melarsoprol, it is easier to administer and cheaper than eflornithine 
monotherapy: just two injections a day are administered over a 10 days period (Yun et al. 2010). 
The biological relevance for this treatment most probably lies in the ability of eflornithine to 
deplete the level of trypanothione and the capability of nifurtimox to produce reactive oxygen 
species in trypanosomes, however, the mechanism of action of nifurtimox is not well understood. 
 
1.1.5.6 Diminazene aceturate 
 
Diminazene aceturate (DA) (Figure 1.4) is structurally an aromatic diamidine that was obtained 
from the experimental drug Surfen. DA is sold as an aceturate salt and is made up of two 
amidinophenyl moieties joined by a triazene bridge: p,p-diamidinodiazoaminobenzene diaceturate 
tetrahydrate. 
When trypanosomes take up DA, it is mainly associated with the kinetoplast DNA (kDNA), 
where it binds specifically and interacts with sites that are rich in adenine-thymine (A-T) base 
pairs. DA has a significantly greater affinity towards the 5´-AATT-3´ than it has for the 5´-TTAA-
3´ regions of DNA. It has been established that DA binds to the minor groove of double stranded 
DNA via hydrogen-bond and electrostatic forces (Peregrine and Mamman, 1993). Consequently, 
DA inhibits the biosynthesis of RNA primers, leading to the build-up of replicating intermediates 
and consequent prevention of kDNA replication.  
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Moreover, DA has been shown to inhibit mitochondrial type II topoisomerases in trypanosomes 
and blocks DNA replication (Roy, et al 2010). There have been proposals for its use in human 
patients, but its safety and potential for cross-resistance with melarsoprol (with P2 transporter 
being the primary uptake route) remain a serious concern and it is highly unlikely that funding for 
clinical trials could be obtained, especially since DA does not cross the blood-brain barrier, and 
can not be used against late stage trypanosomiasis. 
 
1.1.5.7 Homidium salts 
 
Homidium is chemically 3,8-diamino-5-ethyl-6-phenylphenanthridinium (Figure 1.4). Homidium 
is commonly known by its bromide salt (ethidium bromide) or its chloride salt called Novidium®. 
Homidium is known to be active against T. vivax and T. congolense infections in cattle. In the 
field, homidium is basically used as a curative drug; but a prophylactic effect, which varies from 2 
to 19 weeks, has also been reported (Dolan et al., 1990; Stevenson et al., 1995). Homidium was 
extensively used in the 1960s, however, the parasite soon developed resistance, which spread. In 
addition, it was highly mutagenic and, consequently, its use has been significantly reduced 
(Stevenson et al., 1995). The recommendation is really to discontinue its use in treating animals. 
This is reasonable seeing the level of precautions taken by laboratory technicians when staining 
DNA with this compound (ethidium bromide). Phenanthridinium drugs exert their trypanocidal 
activity through the inhibition of nucleic acid synthesis. The drugs intercalate with DNA, thereby 
inhibiting DNA and RNA polymerases (Ullu et al., 2010). However, other biochemical 
mechanisms are involved in the anti-trypanosome activity of these drugs, these including selective 
cleavage of kDNA minicircles, membrane transport, the modulation of glycoprotein biosynthesis, 
and lipid metabolism (Roy et al., 2010). 
 
1.1.5.8 Isometamidium chloride 
 
Isometamidium (ISM) is a phenanthridinium salt which is chemically known as 8-[(m-
amidinophenyl-azo) amino]-3-amino-5-ethyl-6-phenylphenanthridinium chloride hypochloride 
(Figure 1.4) and differs from homidium by an additional moiety of m-amidinophenyl-azo-amine. 
This means ISM is essentially diminazene coupled to homidium (Delespaux and de Koning, 
2007). 
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ISM is cationic drug which is amphiphilic, and is sold as a dark reddish-brown powder. ISM 
product comprises 30% of a mixture of its two isomers and a little amount of a bis-compound and 
70% of ISM and homidium (as Novidium® and Ethidium®). ISM is used in aqueous solution 
mostly by deep intra muscular route. 
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Figure 1.4 Some of the chemical structures of substances known to be active against 
African trypanosomiasis. 
 
1.1.5.9 Drugs in development 
 
Pafuramidine/furamidine (DB289/DB75) was designed for the treatment of HAT and has got to 
advanced clinical trials (phase III). Pafuramidine is an amidoxime prodrug (Figure 1.5) which is 
converted by cytochrome P450 to its active diamidine derivative, furamidine. Because 
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Pafuramidine can cross the intestinal epithelium and accumulates to a significant level in the 
blood, it can be administered through an oral route. Uptake of pafuramidine occurs primarily 
through the P2 transporter (Ward et al., 2011).  
                             
 
Figure 1.5 Chemical structures of the prodrug pafuramidine (DB289) and the active drug 
furamidine (DB75). 
 
However the active compound, furamidine is only effective in treating first stage of HAT, but 
ineffective against the late stage. Initially, there were reported minor side effects such as fever and 
intermittent pruritis, but unfortunately, pafuramide failed at the end of the trials due to serious 
concerns of nephrotoxicity in patients (Brun et al., 2010). 
 
Fexinidazole, and oxaborole SCYX-7158 are also molecules currently in clinical development for 
use as trypanosomiasis drugs (Grewal et al., 2016).  
 
SCYX-7158 is reported to be orally active, and the pharmacokinetic and biological properties 
suggest that this compound is efficacious and safe to treat the neurological stage of HAT (Jacobs 
et al., 2011). 
 
On the other hand, pharmacokinetic data of fexinidazole shows that the in vivo killing activity is 
caused by its sulfone and sulfoxide metabolites. Fexinidazole and its metabolites however need 
up to 48 h of exposure to induce maximal trypanocidal activity in vitro. The in vitro and in 
vivo trypanocidal activities of fexinidazole as well as its two main metabolites offer proof that this 
compound has the prospects to be an effective oral chemotherapy for both the T. b. 
rhodesiense and T. b. gambiense forms of HAT and both stages of the disease (Kaiser et al., 
2011). 
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1.1.6 Transporters involved in drug uptake and mechanisms of drug resistance in 
trypanosomes. 
 
The phenomenon of drug resistance was first discovered in trypanosomes by Paul Ehrlich and co-
workers (Ehrlich, 1907). Consequently, Paul Ehrlich was the first to conduct an experiment to 
determine a T. brucei mechanism of drug resistance. Using acridine dyes while carrying out vital 
staining reactions, he discovered that sensitive trypanosomes stained more readily than drug-
resistant ones. As a result of these results, Ehrlich propounded the ‘chemoreceptor’ hypothesis, 
suggesting that drugs act through specific receptors, also that a reduction of affinity of the 
individual receptor is responsible for drug resistance. Following this finding, Hawking studied 
tryparsamide resistance in trypanosomes using chemical quantification of arsenic in trypanosomes 
and in post-incubation medium. He submitted that only the tryparsamide-susceptible 
trypanosomes absorbed the drug (Hawking, 1936). 
 
More recently, reduced import of pentamidine was observed in a multidrug-resistant T. b. brucei 
(Carter et al., 1995), and isometamidium-resistant T. congolense field isolates were observed to 
accumulate less isometamidium than the susceptible ones (Sutherland et al., 1991). There was 
also a decreased accumulation of DFMO but increased ornithine accumulation in procyclic 
DFMO-resistant T. b. brucei than in the drug-sensitive ones, suggesting at least two mutations, as 
excess ornithine did not inhibit DFMO uptake (Phillips and Wang, 1987); rather, passive 
diffusion is believed to be responsible for trypanosomal DFMO uptake (Bitonti et al., 1986).  
 
The recurring link of drug resistance with reduced drug uptake highlights the significance of drug 
transport in African trypanosomes. Either increased drug export or decreased drug import 
(chemoreceptor hypothesis) is responsible for the reduction of net drug uptake. Any of these 
mechanisms suggest mutations in specific transporters since most anti-trypanosomal drugs do not 
diffuse freely across the plasma membrane. Identifying specific drug transporters as well as 
finding out whether such transporters are mutated in the drug-resistant types is a worthwhile 
strategy to elucidating the mechanisms of drug resistance in trypanosomes at the molecular level. 
This mutation could involve loss of a drug importer, overexpression of a drug exporter or a drug 
transporter changing specificity for substrate. Examples are discussed below. 
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1.1.6.1 Reduced drug import is the mechanism for resistance associated with purine 
transporters in trypanosomes. 
 
Carter and Fairlamb performed an in vitro screen of various metabolites and nutrients for their 
ability to block melarsen-induced killing of bloodstream forms T. b. brucei, this they did in order 
to ascertain the transporter that facilitates melarsoprol uptake in trypanosomes (Carter and 
Fairlamb, 1993). Of all the various physiological compounds studied, only adenosine and adenine 
protected trypanosomes, signifying that the arsenical is taken up through an adenine 
nucleoside/nucleobase transporter. This transporter was named P2 (Figure 1.6), and melarsen 
competitively inhibited it as was determined by an in vitro transport assays on trypanosomes 
(Carter and Fairlamb, 1993). Other trypanosomal nucleoside and purine base uptake systems have 
been studied (de Koning and Jarvis, 1997a,b, 1999; Goldberg et al, 1998; de Koning et al., 1998), 
but none of them was able to transport clinical trypanocides. 
It was afterwards discovered that pentamidine uptake was also through the P2 transporter (Carter 
et al., 1995; de Koning, 2001); this provided a rationale for the repeated incidence of cross-
resistance involving diamidines and melaminyl arsenicals in T. brucei species (Fairlamb et al., 
1992; Pospichal et al., 1994). 
 
1.1.6.2 LAPT1 and HAPT1 are also involved in pentamidine transport and resistance in 
trypanosomes 
 
Only a marginal level of pentamidine resistance was conferred on trypanosomes by loss of the 
TbAT1 gene alone. This means a non-P2 transport mechanism is also involved in pentamidine 
uptake, as demonstrated by TbAT1 negative trypanosomes retaining sensitivity to modest 
concentrations of pentamidine in vitro (Bridges et al., 2007; Teka et al., 2011). Two adenosine-
insensitive transporters for pentamidine have been reported: a low-affinity pentamidine 
transporter (LAPT1) and a high affinity pentamidine transporter (HAPT1) (Figure 1.6) (De 
Koning, 2001). Although diminazene, a diamidine, is structurally related to pentamidine, it is not 
a good substrate for LAPT1 or HAPT1 (Matovu et al., 2003; Bridges et al., 2007; Munday et al., 
2015). Studies have also revealed recently that HAPT1 similarly contributed to the in vitro uptake 
of the arsenical melarsen oxide by TbAT1-/- trypanosomes, despite the relatively low affinity of 
the transporter for this drug (Bridges et al., 2007; Munday et al., 2015).  
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Figure 1.6 Model showing the main transport proteins involve in the uptake of the commonly 
available anti-trypanosomal drugs. LAPT (Low affinity pentamide transporter); HAPT (High 
affinity pentamide transporter); P2 (Purine transporter protein). 
 
1.1.6.3 Loss of Trypanosoma brucei aquaporin 2 (TbAQP2) is also responsible for 
melarsoprol-pentamidine cross resistance 
 
Using an RNAi library screen, T. brucei aquaporins 2 and 3 were identified to be candidate 
resistance genes for melarsoprol-pentamidine cross resistance. These two genes are near-identical, 
sharing 83% sequence identity, and are arranged on chromosome 10 in a tandem array (Alsford et 
al., 2012; Munday et al., 2015). It was revealed that TbAQP2 was responsible for arsenical and 
pentamidine sensitivity/resistance when these two genes were individually expressed in aqp2–
aqp3 double null cells (Baker et al., 2012). 
The sensitivity of trypanosomes to cymelarsan and pentamidine was however restored upon re-
expressing TbAQP2 in B48 cells, re-establishing the lost HAPT1 activity, establishing the 
surprise identity of HAPT1 as an aquaporin channel (Munday et al., 2015). The B48 cell line, a 
derivative of T. brucei brucei, which had the TbAT1 gene deleted through homologous 
recombination, was shown to have additionally lost the HAPT1 activity after passage in 
increasing pentamidine concentrations, was shown to have a recombined mutant AQP2 locus 
instead of the wild-type allele (Bridges et al., 2007). Recently, it has been shown that there is a 
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correlation between mutations in the AQP2 locus and melarsoprol treatment failure in central 
Africa (Graf et al., 2015).  
 
1.1.6.4 Increased drug export is responsible for the ABC transporters associated drug 
resistance in Trypanosomes. 
 
The ABC transport proteins are large membrane bound proteins having distinctive ATP-binding 
cassettes, two of them per transporter. Substrates range from whole proteins to inorganic ions 
(Higgins, 1992). Substrate translocation coupled to ATPase activity enables active transport to 
occur. Many ABC transport proteins can serve as a detoxification efflux pump that can lead to 
drug resistance (Maser et al., 2003). 
Members of the ABC transporter super family are the main transport proteins involved in drug 
export.  
Mäser and Kaminsky (1998) characterised three T. brucei ABC transporter genes: TbABC1, 
TbABC2, and TbABC3. All the three genes were expressed in both the procyclic and bloodstream 
forms, but to date it is unclear whether they contribute significantly to clinical levels of drug 
resistance; however, in Leishmania and Plasmodium species the evidence for involvement of 
ABC transporter in drug resistance is much stronger (Mäser and Kaminsky, 1998). 
 
1.1.6.5 Alternative mechanisms for drug resistance also exist in Trypanosomes. 
 
There is information in literature regarding alternative mechanisms for drug resistance in 
trypanosomes, unconnected to drug transport.  
A pentamidine-resistant T. b. brucei BSF cell line has been reported with unchanged drug uptake 
and a P2 transporter that was fully functional (Berger et al., 1995), although only one such report 
has been made and there has been no other confirmation of such a mechanism.  
 
In addition to the loss of P2 transporter, a reduced lipoic acid content was reported to be 
associated with melarsen resistance in T. b. brucei (Fairlamb et al., 1992). Also, T. b. brucei 
procyclics selected for high-level resistance to DFMO showed not only a reduced DMFO uptake 
and increased ornithine uptake, but also increased levels of ODC mRNA, although the gene copy 
number of ODC was unaffected (Bellofatto et al., 1987; Mäser et al., 2003). 
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Another drug been investigated for mechanism of resistance is Isometamidium (ISM), and was 
reported to have other mechanism of resistance. Transport of ISM into the parasite is energy 
dependent. From the cytoplasm, ISM crosses into the mitochondrion of the cell by the same 
energy dependent process (Delespaux et al., 2008). Development of resistance could therefore be 
due to: alteration of a potential transporter situated in the mitochondrial inner membrane, reduced 
diffusion across mitochondrial membranes, or increased export of the drug through a transporter 
which is situated in the cytoplasmic membrane or it could possibly be a combination of these 
processes. It was recently shown that ISM-resistant trypanosomes have a much-reduced 
mitochondrial membrane potential due to a mutation in the gamma subunit of the FoF1 ATPase, 
and this greatly reduces the accumulation of the drug in the mitochondrion (Eze et al., 2016).  
 
A totally different cause of drug resistance in trypanosomes is the failure to undertake 
programmed cell death (apoptosis). Damage which is caused by drugs may not kill the parasites 
directly but would activate apoptosis. DNA-binding drugs can induce apoptosis which could also 
be applicable to diamidines. However, there is no direct evidence so far that this potential 
mechanism is involved in actual drug resistance in protozoa. 
 
A more important one is the nitroreductase that activates nitro compounds such as benznidazole 
and nifurtimox in trypanosomes. A single point mutation in this gene can lead to a substantial 
level of resistance to nitro drugs (Wilkinson et al., 2008; Mejia et al., 2012). 
 
Different mechanisms of drug resistance are not mutually exclusive but are rather often 
multifactorial (Campos et al., 2014). Mechanisms like increased drug export, reduced drug 
import, and other mechanisms go together and can mutually lead to a higher resistance level. For 
instance, resistance to sinefungin of more than one thousand-fold has been observed for a T. b. 
brucei field isolate that is multidrug-resistant (Kaminsky and Zweygarth, 1989). Conversely, 
modest changes in the susceptibility of drug, as explained above, may yet be important to the 
effect of drugs on trypanosomes. 
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1.2 Leishmania and leishmaniasis 
 
Leishmaniasis is a disease caused by an obligate intracellular protozoan parasite belonging to the 
genus Leishmania. Transmission of the protozoa parasite is achieved through the bite of an 
infected tiny insect vector (about 2 – 3 millimetre-long) known as Lutzomyia sandfly in the new 
world and the phlebotomine sandfly in the old world. Although leishmaniasis is mostly a zoonotic 
disease affecting predominantly domestic animals, about 20 species of Leishmania are known to 
be pathogenic in humans however; the taxonomic importance of a number of them is disputed 
(Rogers and Bates 2007). These include the L. mexicana complex with three main species (L. 
mexicana, L. venezuelensis, L. amazonensis), the Leishmania donovani with 3 other species (L. 
infantum, L. donovani, L. chagasi), L. major; L. aethiopica; L. tropica; and the subgenus Viannia 
having four main species (L. (V.) peruviana, L. (V.) guyanensis, L. (V.) braziliensis, L. (V.) 
panamensis). These species are indistinguishable morphologically; however they can be 
distinguished by molecular methods, monoclonal antibodies, or isoenzyme analysis (Singh et al. 
2014). 
 
Clinical infection caused by Leishmania comes in three main forms: visceral leishmaniasis, 
cutaneous leishmaniasis, and mucocutaneous leishmaniasis. However, asymptomatic cases have 
been reported in endemic areas, which act as the main reservoir for re-infection (Singh, Hasker et 
al., 2014). Usually, Leishmania infection follows two distinct transmission cycles: a strictly 
anthroponotic cycle, which is characteristically seen in densely populated urban areas with 
humans being the host; and a zoonotic cycle, with dogs as the host being the main animal 
reservoir, which can also include other mammals.  
 
1.2.1 Morphology and life cycle. 
 
Leishmania is a unicellular protist belonging to a class known as the Kinetoplastida. All 
kinetoplastids are flagellated at some stage in their life cycle, and also have a distinctive DNA-
containing organelle called a kinetoplast, which is present inside their mitochondrion, at the base 
of the flagellum (Figure 1.7). The kinetoplast consists of many circular copies of kinetoplast DNA 
(kDNA), performing the same role as the mitochondrial genome in higher eukaryotes.  
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Figure 1.7 Schematic illustrations of the major intracellular organelles present 
in Leishmania promastigote (left) or the amastigote (right) forms. The anterior end of the cell is 
marked by the flagellar pocket (Besteiro et al., 2007). 
 
Leishmania has a life cycle which is digenetic, and alternates between the mammalian host and 
the sand fly vector (Figure 1.8). When an infected female sand fly feeds on a blood meal of a 
suitable host, the parasite (metacyclic promastigotes) is introduced into the host’s skin. 
Metacyclic promastigotes are the extracellular, non-dividing, and infectious stage (Bates, 2007). 
Impaired uptake of the host blood results in the insect trying to feed with increased frequency, 
thereby increasing the likelihood of transmitting the parasite (Rogers and Bates 2007). The 
parasite is therefore introduced into the skin of the host, as are the pro-inflammatory salivary 
constituents. The resident phagocytic cells inside the skin tissues of the host are then invaded by 
the parasites.  
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Figure 1.8 Sand fly and human stages of leishmaniasis. The vectors that spread Leishmania are the 
sand flies, when they feed on the host blood they inject infective promastigotes. The promastigotes then 
invade macrophages of the host via receptor-mediated endocytosis, they then transform into amastigotes 
and start multiplying by binary fission. The cycle continues as sand flies get infected when they ingest 
infected cells as they take a parasite-containing blood from an infected host. The amastigotes then 
transform into promastigotes, then develop to an infective metacyclic promastigotes inside the midgut of 
the sand fly (Image credit: NIAID, http://www.niaid.nih.gov/topics/leishmaniasis/pages/lifecycle.aspx). 
 
Once the parasite gets inside the host cell, it differentiates into the non-flagellated obligate 
intracellular form known as amastigote. The parasites carry on multiplying through mitotic cell 
division, as intracellular amastigote, and re-invade other phagocytic cells, waiting to be picked up 
in the blood meal of the next sand fly.  
Once inside the midgut of sand fly, the amastigote further differentiates into the early procyclic 
promastigotes, which rapidly multiply by cell division, at the same time attaching itself to the 
inside wall of the insect’s midgut. This attachment to the midgut wall by the parasite is made 
possible by lipophospoglycan (LPG) which covers the cell surface of the parasite (Pimenta et al. 
1994). This attachment to the midgut wall prevents the parasite from being expelled like the 
digested blood meal as part of the sand fly’s excrement. The parasite further differentiates into the 
replicating promastigote form; it then moves further to the midgut anterior and continues 
replicating. This stage is followed by differentiation into the metacyclic promastigotes that infect 
mammals. 
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1.2.2 Leishmaniases: pathology and clinical manifestation 
 
The obligate intracellular protozoa parasite belonging to the genus Leishmania is the cause of 
leishmaniases. It has a broad range of clinical symptoms: cutaneous, diffuse cutaneous, 
mucocutaneous, and visceral. 
 
1.2.2.1 Cutaneous leishmaniasis (CL) 
 
The most common form of leishmaniases is the cutaneous form (50-75% of all cases). It is caused 
by Leishmania species such as L. mexicana, L. major, L. braziliensis, L. tropica, and L. 
panamensis. They usually affect the exposed parts of the body such as legs, face, neck, and arms. 
The infection can cause large number of lesions – at times up to 200 – resulting in severe 
disabilities which always lead to patients having permanent scars, a stigma which can lead to 
social discrimination (Bates, 2007). 
 
1.2.2.2 Diffuse cutaeneous leishmaniasis (DCL) 
 
L. aethiopica is the causative agent of this form of leishmaniasis and causes chronic and dispersed 
skin lesions similar to those of leprosy. Treatment often fails since it mostly takes place in 
patients having a reduced cell-mediated immune response (Singh et al. 2014).  
 
1.2.2.3 Mucocutaeneous leishmaniasis (MCL) 
 
L. braziliensis is the causative agent of the mucocutaeneous forms of leishmaniasis and can result 
in partial or the total damage of mucous membranes of the mouth, nose, and throat cavities as 
well as surrounding tissues. Secondary fungi and bacteria infections are also common (Rogers and 
Bates 2007). 
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1.2.2.4 Visceral leishmaniasis 
 
Visceral leishmaniasis is also known as dumdum or kala azar fever. This form of leishmaniasis is 
caused by L. infantum, L. donovani, and L. chagasi. It is associated with considerable weight loss, 
irregular bouts of fever, swelling of the liver and spleen, and anaemia. It is the most serious form 
of leishmaniasis and if not treated, the death rate can be as high as 100% in developing countries 
(Singh et al. 2014). 
 
1.2.3 Treatment and control of leishmaniases 
 
The chemotherapy presently available for treating leishmaniasis is far from ideal. Pentavalent 
antimonials remain the first-line drug treatment; however, resistance to these drugs is extensive in 
India. Nevertheless, clear progress has been made with miltefosine, amphotericin B, and 
paromomycin, but treatment challenges remain a serious issue. 
 
1.2.3.1 Pentavalent antimonials 
 
Pentavalent antimonials are the first-line treatment drug for cutaneous leishmaniasis (CL), and 
visceral leishmaniasis (VL). These drugs include meglumine antimoniate and sodium 
stibogluconate. They were made available for the first time in 1945 and continue to be effective 
but the variable efficiency against CL and VL and the condition for up to 28 days of parenteral 
administration are the main limiting factors to the drug’s usefulness (Yesilova, et al., 2016). Also, 
the occurrence of significant levels of resistance, which are most serious in India, makes the drug 
outdated in these areas. They also have serious side effects such as renal toxicity, pancreatitis, and 
cardiac problems. Their mode of action is understood to be via the inhibition of glycolytic 
enzymes and other metabolic pathways (Yesilova, et al., 2016). The cause of antimonial 
resistance in India has recently been identified as a mutation in the L. donovani AQP1 gene 
(Imamura et al., 2016). 
 
1.2.3.2 Amphotericin B 
 
The anti-fungal, polyene macrolide antibiotic amphotericin B (Figure 1.9) has been demonstrated 
to be very effective for treating antimonial-resistant L. donovani visceral leishmaniasis and cases 
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of mucocutaeneous leishmaniasis. However, it is an unpleasant drug due to the requirement for a 
4 h infusion administration, and its high toxic side-effects. Nevertheless, lipid-associated 
preparations of this drug have been formulated which reduced the nature of the drug and also 
prolonged the plasma half-life. The most tested of these drugs is Ambisome® (liposome 
formation), which since has been given approval by FDA but then again high cost has restricted 
its use. Amphotericin B interacts with ergosterol, and in so doing changes the composition and 
permeability of the membrane, killing the parasite (Ordonez-Gutierrez et al., 2007). 
  
1.2.3.3 Pentamidine 
 
The use of this diamidine (Pentamidine) has been limited by its toxicity, as it needs to be given at 
higher dosage to treat leishmaniasis than African trypanosomiasis. Consequently, it is only used 
as a second-line drug via the intramuscular route of administration. Due to the unacceptable side-
effects elicited by the use of pentamidine, including hypoglycaemia, and hypotension, this drug is 
suggested for use in: (i) leishmaniasis resistant to antimony (ii) when severe cardiac or hepatic 
toxicity arises in the course of antimonial therapy (iii) when antimonials are contraindicated 
(Croft et al., 2005). 
 
1.2.3.4 Miltefosine 
 
The first effective oral treatment of visceral leishmaniasis is with miltefosine (Figure 1.9), and it 
is one of the most recent progresses made in anti-leishmanial drug discovery. Miltefosine is an 
alkylphosphocholine which was initially developed as an anticancer agent. It is likewise active 
against cutaneous leishmaniasis. The mode of action of miltefosine is by changing the sterol and 
phospholipid structure of the parasites membrane. Its main constraint is teratogenicity; 
consequently pregnancy is a contra-indication for this treatment (Sindermann and Engel, 2006).  
 
1.2.3.5 Paromomycin 
 
Paromomycin (Figure 1.9) was initially formulated as an oral aminoglycoside for the treatment of 
intestinal infections and had previously shown effectiveness as a topical treatment for cutaneous 
leishmaniasis in 1985, and as a parenteral chemotherapy for visceral leishmaniasis in 1990. 
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However, it took until 2005 for the phase III clinical trials against visceral leishmaniasis to be 
finished – reflecting the inadequate funding sources (Croft, et al., 2002).  
 
1.2.3.6 Allopurinol and azoles 
 
The purine analogue allopurinol (Figure 1.9) was recognized for its anti-leishmanial efficacy over 
30 years ago, because it was extensively used for other clinical conditions, and has good oral 
bioavailability it moved into clinical trials for leishmaniasis. But unfortunately, the outcome was 
disappointing. At the moment, allopurinol is only part of a maintenance treatment for canine 
leishmaniasis. Azoles, like fluconazole, ketoconazole, and itraconazole have gone through a 
number of trials for visceral leishmaniasis and cutaneous leishmaniasis but presented an 
unsatisfactory efficacy in the end (Martinez et al., 1997; de Macedo-Silva et al., 2013).       
 
 
 
     Sodium stibogluconate 
 
 
Meglumine antimoniate 
 
 
     Amphotericin B 
 
 
   
             Pentamidine 
        
 
 
      Miltefosine 
        
 
               Paromomycin 
      
 
Allopurinol (left) and 
fluconazole (right). 
 
 
    Ketoconazole 
 
 
                Itraconazole 
 
Figure 1.9 Bioactive molecules used for the treatment of leishmaniases. 
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1.2.3.7 Drugs in development 
 
Several potential drugs are right now at different stages of development. An oral chemotherapy 
that might be effective on visceral leishmaniasis is a derivative of 8-aminoquinoline called 
sitamaquine, which causes oxidative stress in Leishmania donovani promastigotes by targeting 
succinate dehydrogenase, but then again resistant Leishmania lines have previously been reported 
(Loiseau et al., 2011). However, 2-subtituted quinolines were found to be effective against these 
resistant lines, which suggest that the 8-aminoquinoline and 2-substituted quinolin perhaps are 
affecting different targets in L. donovani (Loiseau et al., 2011). Bisphosphonates like pamidronate 
and risedronate have also been reported for their anti-leishmanial efficacies in experimental 
animals. Their major target is believed to be the farnesyl pyrophosphate synthase, an important 
enzyme in the biosynthesis of isoprenoids (Shakya et al., 2011). The search for more active drugs 
against leishmaniasis is ongoing. 
 
1.2.3.8 Control of leishmaniasis 
 
Vector control may be beneficial under certain circumstances but are not appropriate in all 
epidemiological situation and need infrastructure and vigilance beyond the ability of several 
endemic nations. The disease can be stopped by preventing sandfly bites through the use of 
insecticides or insect repellents. Vaccination still remains the best option for control of all types 
of the leishmaniasis. 
 
1.3 Natural products in drug discovery 
 
The historical source of disease treatments has been natural products such as plants, animals, and 
minerals. However, antique wisdom remains the source of contemporary medicine and a vital 
basis of future medicine and therapeutics. 
 
In contrast to the typical combinatorial chemistry, natural products continue to offer a unique 
structural diversity, presenting the prospects for discovering mostly new low molecular weight 
lead compounds. Not more than 10% of global biodiversity has yet been explored for possible 
biological activity (Cragg and Newman, 2005), consequently, countless quantities of beneficial 
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natural leads with a tremendous diversity of structures and pharmacological activities await 
discovery. 
 
The prospect for using natural products in combating diseases can be understood with traditional 
medicines. Historically, natural products have played a significant part in combating and 
preventing human diseases throughout the world. The first annals were found in cuneiform 
inscribed on clay tablets, and date from around 2600 BC, from Mesopotamia (Purvis, 2000). 
According to WHO, two thirds of the world’s population continue to depend largely on traditional 
medicine for their health care needs. Natural product medicines originate from several organism 
types including plants, bacteria, fungi, sponges, protists, and other invertebrates present in various 
environments such as rain forests, hot springs, and deep seas.  
 
1.3.1 Natural products from fungi: Antibiotics 
 
For thousands of years now, micro and macro fungi have been playing a major role in human life. 
They were used, and continue to be used for various needs. For instance, yeast is being used for 
the preparation of alcoholic beverages, mushrooms are used as food, and some are used as 
medications in traditional medicine, while others are for cultural purposes.With the present 
improvements in microbiology, their usage has been extended to antibiotics, enzymes, biological 
control, and other pharmacologically active products (Lorenzen and Anke, 1996). 
 
Fungi are more normally found in the environment, some of them have part of their life cycle 
residing in various tissues of plants without producing any noticeable sign of infection (Tan and 
Zou, 2001). They can be seen inhabiting grasses, trees, herbaceous plants where they reside within 
the intercellular space of plant stem, roots and leaves, algae and petioles, without affecting the 
host organism. These fungi are altogether known as endophytes. New bioactive molecules 
obtained from these fungal sources have produced many important leads for the pharmaceutical 
industry (Cragg and Newman, 2005). 
 
One of the well-known natural product breakthroughs obtained from a fungus is undoubtedly 
penicillin (Figure 1.10), obtained from the fungus Penicillium notatum, which was discovered in 
1929 by Fleming. Old strategies for identifying β-lactams were in use up until 1968, when it was 
decided that all the β-lactams of natural origins had been discovered. However, the case was 
35 
 
different with the 1970’s introduction of some new methods of screening, the production of β-
lactams supersensitive bacterial strains, β-lactamases inhibition tests and sulphur containing 
metabolites specificity led to the discovery of new structural classes of antibiotic (carbapenems, 
norcardicins, monobactams, imipenem and aztreonam) (Fabbretti and Gualerzi, 2011). 
 
Polypores are macro fungi and are of the phyla Ascomycota and Basidiomycota (basidomycetes); 
they produce many pharmacologically active molecules. Around 75% of all tested polypores have 
strong antimicrobial activities, and may therefore create a possible basis for the development of 
new antibiotics (Zjawiony, 2004).  
 
Edmund Kornfeld in 1953 isolated vancomycin, a glycopeptide antibiotic made in Amycolatopsis 
orientalis cultures, and was active against a broad spectrum of gram-positive microorganisms 
such as Streptococci and Staphylococci and against gram-negative bacteria such as, fungi and 
mycobacteria and as a result FDA in 1958 approved it for use in the treatment of chronic 
infections and against susceptible organisms in patients hypersensitive to penicillin (Butler, 
2004).  
                    
Figure 1.10 Structure of the natural product based antibiotics: Penicillin G sodium salt (left), 
vancomycin hydrochloride (middle), and erythromycin (right). 
 
The antibacterial drug, erythromycin (Figure 1.10) which is a macrolide antibiotic was isolated 
from the microorganism Saccharopolyspora erythraea. Erythromycin has a wide range of 
activities against gram-positive bacilli and cocci and is used for respiratory tract infections 
(Dewick, 2002; Butler, 2004).  
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1.3.2 Natural products from plants: Secondary metabolites 
 
The synthesis and breakdown of carbohydrates, proteins, nucleic acids, and fats, which are 
indispensable to all living organisms, is termed primary metabolism and the molecules involved 
in these pathways are called primary metabolites. The mechanism with which a living organism 
synthesize molecules known as secondary metabolites (or natural products) is frequently found to 
be exclusive to a particular living organism or is simply an expression of the distinctiveness of the 
species and this is termed secondary metabolism (Maplestone et al., 1992). These secondary 
metabolites are normally not critical for the development, growth, or reproduction of a living 
organism but are synthesized either to act as a likely mechanism for the survival of the organism 
by defending it against herbivores, protecting their reproductive elements, protecting it from 
disease-causing microorganisms (bacteria, fungi, nematodes or viruses), preventing other plants 
from growing and competing with it, or could be a result of a general adaption of the organism to 
its surrounding environment (Dewick, 2002; Colegate and Molyneux, 2008).  
 
The biosynthesis of secondary metabolites is the result of the basic processes associated with 
photosynthesis, glycolysis and citric acid cycle to produce biosynthetic intermediates which, 
eventually, leads to the biosynthesis of secondary metabolites, which are generally referred to as 
natural products (Dewick, 2002). It can however be seen that even though the number of the 
precursor molecules are limited, the diversity of new secondary metabolites is virtually unlimited. 
The most significant precursor molecules used for synthesizing secondary metabolites are the 
ones obtained from the intermediates: Shikimic acid, Acetyl coenzyme A (acetyl-CoA), 1-
deoxyxylulose-5-phosphate, mevalonic acid. They play a significant role in many biosynthetic 
pathways, involving several different reactions and mechanisms (e.g., decarboxylation, alkylation, 
Claisen, aldol and Schiff base formation (Dewick, 2002).  
 
It is therefore hypothesized that the secondary metabolic pathways make use of the acetate, amino 
acids and shikimate pathways to make intermediates also called shunt metabolites, which adopt 
an alternate biosynthetic pathway resulting in the biosynthesis of secondary metabolites (Sarker et 
al., 2006). Natural causes (such as environmental changes or viruses) or unnatural causes (such as 
radiation or chemicals) may be the reason for this alteration in the biosynthetic pathways, which 
could be an adaptation strategy or to make the organism live longer (Sarker et al., 2006). It is this 
distinctive biosynthesis of important natural products, synthesized by so many marine and 
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terrestrial organisms that bring about the typical chemical structures that have an assortment of 
biological activities. 
Natural products from plants are useful against various groups of disease-causing organisms such 
as fungi, bacteria, and viruses. Therefore these natural compounds from plants like phenolics, 
quinones, terpenes, alkaloids, saponins, and their derivatives are quite beneficial for human 
consequent of their anti-parasitic activities and highly selective mechanisms of action. In addition 
to direct use of natural product from plants such as quinine, morphine, etc., the scaffolds of many 
of these metabolites have been effectively utilized to create pharmacologically more active 
molecules. 
 
1.3.3 Compounds derived from plants as anti-protozoal agents 
 
A number of well-established anti-protozoal drugs are natural products or derived from them. 
These include those from microorganisms such as amphotericin B and paramomycin for treating 
leishmaniasis; as well as those obtained from plants such as artemisinin and quinine used for 
treating malaria. The bark of Cinchona species have been used for centuries by the natives in the 
Amazon area for treating fevers particularly malaria. It was not until 1820 that the French 
pharmacists, Pelletier and Caventou isolated the active compound quinine from the bark of 
Cinchona officinalis. In those early days, the curative agent for malaria was quinine but afterward 
synthetic derivatives (amodiaquine, chloroquine, mefloquine and primaquine) have been 
developed (Dias et al., 2012). Regardless of the long history of usage, first as plant extract 
preparations and later on as a pure compounds, malaria treatment, to an extent, is still depend on 
quinine, particularly cerebral malaria.  
 
The anti-plasmodial activities in the extracts of Artemisia annua, was discovered in 1969. 
Artemisia annua is another plant that was long used for treating fevers in Chinese folkloric 
medicine. The successful isolation of the active compound artemisinin one year later from 
Artemisia annua represented one of the most important discoveries in the fight against infections 
caused by protozoan parasites. Presently, a number of semisynthetic artemisinin derivatives have 
been approved and registered for use (artesunate, artemether, and dihydroartemisinin) (Chris and 
Jay, 2014). 
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1.3.4 Treatment of trypanosomiasis with natural products and their derivatives 
 
Several compounds isolated from natural source have been shown to inhibit the growth of 
trypanosomes in vitro with EC50 values in the submicromolar range and for some of these 
products this activity seems to be quite selective. But there is as yet a paucity of information in the 
literature regarding their experimentally determined mode of action. 
 
Cordycepin (Figure 1.11-A) is a metabolite produced by the fungus known as cordyceps militaris. 
Cordycepin was initially used with deoxycoformycin (DCF), which is a potent inhibitor of the 
enzyme adenosine deaminase. DCF prevents the inactivation of cordycepin in vivo, and was used 
for treating certain forms of malignant tumours in human subjects, but it is not considered safe 
enough for the treatment of sleeping sickness together with cordycepin (Cuadros et al., 2000), 
although coadministration of these compounds was found to be effective against late-stage 
infections in mice experimentally infected with T. b. gambiense and T. b. rhodesiense (Salcedo et 
al., 2003).  
                      
                      A                                     B                                                 C 
         
 Figure 1.11 structures of cordycepin (A), Quercetin (B), and proanthocyanidin (C) 
 
The mechanisms responsible for the anti-trypanosomal activities were experimentally studied and 
found that cordycepin causes apoptosis in trypanosomes; secondary necrosis was observed 
afterwards upon propidium iodide aided measurement of DNA degradation, also observed was the 
translocation of plasma membrane phosphatidylserine to the outer leaflet from the inner leaflet 
(Salcedo et al., 2003).  
 
Quercetin (Figure 1.11-B) and its derivatives are polyphenolic flavonoids commonly found in 
plants such as tea, onions, biloba, and ginkgo. Quercetin has been reported to directly promote T. 
b. gambiense death via apoptosis (Mamani-Matsuda et al., 2004). 
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A proanthocyanidin (Figure 1.11-C) has been purified from Kola acuminata nut and was reported 
to have anti-T. brucei properties in vitro in a mouse model (Alvarez-Miranda et al., 2003). 
Ultrastructural alterations were seen using an electron microscopy, and these were reported to be 
caused by the rupture of plasma membranes and the release of cellular contents.  
 
1.3.5 Treatment of leishmaniasis with natural products and their derivatives  
 
There is significant progress with leishmanial research in recent time but an effective, safe, 
inexpensive, and true antileishmanial drug is still missing. Several molecules especially of plant 
origins have displayed potential as anti-leishmanial lead.  
 
A bis-naphthoquinone, diospyrin extracted from the bark of the plant Diospyros montana 
(Ebenaceae), was shown to exhibit a substantial level of activity against L. donovani 
promastigotes (de Araújo et al., 2014). The mode of action of this compound is thought to be via 
binding to topoisomerase I, thereby inhibiting the enzyme’s catalytic activity, or through 
stabilization of topoisomerase I-DNA binary complex. 
 
The monoterpene linalool, purified from the plant Croton cajucara (Euphorbiaceae), also 
displayed strong anti-leishmanial potentials with an IC50 of 28 nM against promastigotes and an 
IC50 of 143 nM against intracellular amastigotes of L. amazonensis (Usta et al., 2009). In vitro 
experiments in mouse macrophages show that treating with 15 ng/mL of the essential oil to 
already infected macrophages of mice lowered the association between parasites and macrophages 
by about 50% coupled with an elevated production of nitric oxide. Further treatment with linalool 
for 1 h resulted in a 100% complete elimination of intracellular amastigotes, and promastigotes, at 
the same time exhibiting no toxicity to the murine macrophages. The mode of action was reported 
to be likely through the destruction of the kinetoplast, and swelling of the mitochondrial followed 
by disintegration of the parasite (Usta et al., 2009). 
 
Also, the diterpene ribenol, an ent-manoyl oxide derivative purified from the plant Sideritis varoi 
(Lamiaceae), as well as a 15-monomethyl ester of dehydropinifolate purified from the stem bark 
of another plant, Polyalthia macropoda (Annonaceae), were reported to have in vitro activity 
against L. donovani promastigotes (Garcia-Granados et al., 1997). 
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In addition, the triterpene betulinaldehyde isolated from the stem of the plant Doliocarpus 
dentatus (Dilleniaceae), and ursolic acid purified from the bark of the plant Jacaranda copaia, 
both had activity against L. amazonensis amastigotes (Takahashi et al., 2004). 
 
Furthermore, the saponin, mimengoside-A, purified from Buddleja madagascariensis 
(Loganiaceae) leaves (Ding et al., 1992), had activity against L. infantum promastigotes. Another 
saponin, muzanzagenin, isolated from Asparagus africanus (Liliaceae) roots, was active against 
promastigotes of L. major. 
 
Flavonoids can also have a significant level of antileishmanial activity, which is thought to be 
through the inhibition of polyamine biosynthetic enzymes. Therefore, they remain promising 
candidates to be developed as drugs used for treating all forms of leishmaniasis (Muzitano et al., 
2006). Consequently, the flavonoids 8-prenylmucronulatol, smiranicin and glyasperin H, all 
purified from the plant Smirnowia iranica, was reported to inhibit the growth of promastigotes of 
L. donovani. These compounds’ mode of action was reported to be perhaps via the induction of 
kinetoplastid DNA cleavage and arrest of the cell cycle in the G0/G1 phase which is mediated by 
topoisomerase II, leading to a programmed cell death in both promastigotes of L. donovani and 
intracellular amastigotes (Singh, et al., 2008). 
 
Many of these isolated compounds were reported to have immuno-modulatory properties coupled 
with anti-leishmanial activity, which makes them even more beneficial. This is because 
leishmaniasis is associated with a compromised immune response. 
 
1.4 Mitochondrial biology of T. b. brucei 
 
Most of the existing data concerning T. brucei mitochondrial function or structure is obtained 
from the parasite’s procyclic form, while relatively little is known regarding the mitochondrion of 
the bloodstream form (Schneider et al., 2007). In T. brucei procyclics the mitochondrion performs 
a significant function in the synthesis of cellular ATP through substrate level and oxidative 
phosphorylation, (Bringaud et al., 2012; Schneider et al., 2007), however, it is also believed to 
contribute to the pentose phosphate pathway, cellular redox balance maintenance (Bringaud et al., 
2012), metabolism of carbohydrate, biosynthesis and conversion of amino acids, nucleotides and 
lipids.  
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The structure of the mitochondria of T. brucei is made up of a matrix, mitochondrial inner 
membrane; mitochondrial intermembrane space; and a mitochondrial outer membrane (Panigrahi 
et al., 2008), which is identical to other eukaryotes’ mitochondria. The T. brucei mitochondrion, 
however, contains other features that differ from that of other eukaryotes. For instance, T. brucei 
has a single tubular mitochondrion which stretches all over the entire length of the cell. T. brucei 
can alter the structure and function of its mitochondrion as a response to the different 
environment of the host, as well as the substrates availability, that the trypanosomes meet in the 
course of their life cycle (Fenn and Matthews, 2007). The tubular shape of the mitochondrion can 
also be branched, and depending on the T. brucei life cycle stage, it may in fact form a cellular 
network (Schneider, 2001).  
 
In procyclic forms of T. brucei most of the cellular ATP is obtained through degradation of 
proline, as well as substrate level and oxidative phosphorylation that occur in the parasite 
mitochondrion (Schneider et al., 2007; Bringaud et al., 2012). In addition, the mitochondrion also 
has a well established mitochondrial respiratory chain, which is concerned with the task of 
maintaining the cellular redox balance and ATP synthesis through an ATP synthase (complex V) 
which is situated on the inner membrane of the mitochondria (van Hellemondt et al., 2005). The 
mitochondrion of T. brucei procyclics is very much branched to enhance the function of its 
membrane surface, which is in line with its role in producing ATP (Schneider, 2001). This is in 
contrast to the parasite’s bloodstream form (BSF), where the single mitochondrion has little or no 
branching at all as it is reduced into a simple tubular structure (Schneider, 2001). The 
bloodstream form of the parasite is completely dependent on the compartmentalised glycolytic 
pathway and the glycosomes for its cellular ATP provision considering that it resides in the 
glucose-rich human bloodstream (Lamour et al., 2005). The joint action of an ATP synthase and a 
mitochondrial alternative oxidase (TAO) is what maintains the redox balance in BSF of T. brucei 
(Schnaufer et al., 2005). The mitochondrion of T. brucei BSF also lacks a functional cytochrome 
c, respiratory chain, and TCA cycle. (van Hellemond et al., 2005). 
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1.5 Trypanosome metabolism and drug targets 
 
There are two ways by which the metabolic activity of trypanosomes may affect its host: by 
producing toxic metabolites or depleting the host’s essential nutrients, which the parasite requires 
for growth and proliferation. There are many biochemical pathways present in a trypanosome, 
some of which are very essential for the parasite survival. 
Studies on various biochemical pathways present in trypanosomes have been done using NMR, 
HPLC, and conventional biochemical techniques and enzymology. The pathways most studied 
inclined towards carbohydrate metabolism (Haanstra et al., 2008), or the variations in oxidative 
pathways (trypanothione synthesis) accompanying the developmental cycle of the parasites (Xiao 
et al., 2009). Consequently, the detailed analyses of some metabolic pathways like mitochondrial 
functions and glycolysis have made other areas of trypanosome biochemistry somewhat under-
studied. However, the application of metabolomics and systems biology to these challenges is 
beginning to cover some of these gaps. The differences in the end products of the metabolism of 
glucose, the development of an active cytochrome system in procyclics for which it is absent in 
the bloodstream form, the difference in sensitivity to cyanide between the bloodstream and 
procyclic forms, and the existence of the glycerophosphate oxidase pathway in the bloodstream 
form are all important pieces of information, and the knowledge of the parasites metabolism at 
each stage of their life cycle is key to the development of effective inhibitors capable of killing the 
parasite without harming the host (Abubakar et al., 2016).  
 
1.5.1 Divergent metabolism provides many potential drug targets in trypanosomes 
 
Trypanosomes possess a range of biochemical distinctiveness, some of them are found to be 
pharmacologically important (Opperdoes, 1985). Their single mitochondrion has a genome which 
is structured into a system of more than a thousand DNA circles which is catenated and of 
variable sizes, known as kinetoplast DNA; therefore they are called kinetoplastids. This unique 
characteristic of the kinetoplastids makes mitochondrial replication a likely chemotherapeutic 
target (Shapiro and Englund, 1995). The presence of trypanothione as part of the parasite’s redox 
metabolic pathway is another distinctive characteristic of kinetoplastids. Trypanothione is a 
covalent network of two glutathiones joined together by a spermidine (Fairlamb et al., 1985). The 
protein trypanothione reductase and its substrate trypanothione constitute a critical defence 
against free radicals and oxidative stress (Penketh and Klein, 1986). The existence of spermidine 
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in trypanothione draws pharmacological attention to the biosynthesis of polyamines (Bacchi and 
Yarlett, 1993), specifically to ornithine decarboxylase and S-adenosylmethionine decarboxylase. 
Purine salvage is another anti-trypanosomal chemotherapeutic target, considering that 
trypanosomes cannot synthesise purines de novo, instead they depend completely on the uptake of 
exogenous purine nucleosides and nucleobases from their host’s milieu (Fish et al., 1982). Other 
distinctive features of trypanosomes, and consequently possible drug targets, are the editing of 
mitochondrial RNA, trans-splicing of mRNA (Simpson et al., 2003), acidocalcisomes (Vercesi et 
al., 1994), and the glycosomes (Opperdoes and Borst, 1977).  
 
1.5.2 The glycosome and glucose metabolism 
 
Glycosomes were first discovered in Trypanosoma brucei. Most of the enzymes involved in 
glycolysis are contained in these organelles; this is why they are called glycosomes. 
Compartmentation of glycolysis within these organelles in trypanosomes is very unique because 
in other organisms glycolysis is essentially cytosolic.  
Glycosomes belong to the family of organelle called peroxisome, though initially there were 
various disagreements on this affiliation because catalase, being the hallmark peroxisomal 
enzyme, is absent in glycosomes of trypanosomes and more so that because of the near complete 
glycolytic role of the glycosomes in T. brucei; glycolytic enzymes make up approximately 90% 
glycosomal enzymes in the bloodstream form of these parasites (Hannaert, 2011), consistent with 
glucose being the sole carbon source for the parasites at this life cycle stage. 
 
When T. brucei is being introduced into the mammalian bloodstream by the bite of an infected 
tsetse fly, it finds a basically constant environment within the bloodstream, which is very reach in 
glucose, enabling it to proliferate quickly. Therefore it is able to produce all its ATP via aerobic 
glycolysis or, rather by anaerobic glycolysis at places where the oxygen tension is low. The major 
part of the glycolytic pathway has been sequestered inside glycosomes and has been shown to be 
essential for glycolysis, ATP production and growth of the bloodstream-form of the 
trypanosomes and this has been shown to provide them with a distinctive mechanism for rapidly 
switching from aerobic to anaerobic glycolysis (Albert et al., 2005). Anaerobic glycolysis does 
not allow them to make enough ATP to support growth; however, it permits trypanosomes to 
overcome short periods of anaerobiosis (Caceres et al., 2010). 
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Energy metabolism, particularly glycolysis, is regarded as a key chemotherapeutic target in T. 
brucei for the reason that, when residing in the host bloodstream, the trypanosome is completely 
dependent on the utilization of glucose from blood and body fluids, which it converts to pyruvate 
for its energy (ATP) needs (Figure 1.12). Furthermore, glycolysis in the trypanosomes is 
distinctive because it is compartmentalised, and several of its glycolytic enzymes show some 
distinctive kinetic and structural features, that are likely adaptations to this tight packaging of 
substrate and enzymes (Verlinde et al., 2001). In contrast to glycolysis in other organisms 
including the mammalian host where the enzymes involved in glycolysis are situated in the 
cytosol, the seven glycolytic enzymes metabolizing glucose and converting it to 3-
phosphoglycerate are present in the glycosomes. However, the last three glycolytic enzymes are 
localized in the cytosol (Fig. 1.12). Consequently a good number of the T. brucei glycolytic 
enzymes have so far been confirmed by RNAi as good chemotherapeutic targets (Albert et al., 
2005; Caceres et al., 2010). 
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Figure 1.12 Schematic representation of glycolysis in the bloodstream-form of T. brucei. Under 
aerobic conditions, glucose is converted into pyruvate. Under anaerobic conditions equimolar amounts of 
glycerol and pyruvate are produced. Abbreviations: 1,3BPGA, 1,3-bisphosphoglycerate; DHAP, 
dihydroxyacetone phosphate; F-6-P, fructose 6-phosphate; FBP, fructose 1,6-bisphosphate; G-3-P, 
glyceraldehyde 3-phosphate; G-6-P, glucose 6-phosphate; Gly-3-P, glycerol 3-phosphate; PEP, 
phosphoenolpyruvate; 3-PGA, 3-phosphoglycerate; Pi, inorganic phosphate; UQ, ubiquinone pool; AQP, 
aquaglyceroporin channel. Enzymes are: 1, hexokinase: 2, glucose-6-phosphate isomerase; 3, 
phosphofructokinase; 4, aldolase; 5, triosephosphate isomerase; 6, glycerol-3-phosphate dehydrogenase; 
7, glycerol kinase; 8, glyceraldehyde-3-phosphate dehydrogenase; 9, glycosomal phosphoglycerate kinase; 
10, phosphoglycerate mutase; 11, enolase; 12, pyruvate kinase; 13, FAD-dependent glycerol-3-phosphate 
dehydrogenase; 14, alternative oxidase. 
 
Inside the glycosome, the glycosomal NADH, obtained as a product of the catalytic reaction of 
glyceraldehyde 3-phosphate dehydrogenase, is re-oxidised to NAD+ followed by transfer of 
electrons to molecular oxygen through a glycerol 3-phosphate oxidase (GPO) system present 
inside the mitochondria. A glycerol 3-phosphate dehydrogenase, which is dependent on NADH 
and present in the glycosome is involved in this process, it is a putative transport protein situated 
in the glycosomal membrane where glycerol-3-phosphate (G-3-P) is exchanged for 
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dihydroxyacetone phosphate (DHAP). The mitochondrial GPO is a system consisting of a 
glycerol 3-phosphate dehydrogenase which is FAD-linked, ubiquinone and a terminal oxidase, 
called the trypanosome alternative oxidase (TAO) which is located in the inner mitochondrial 
membrane (Hannaert, 2011). Since mammalian cells do not have TAO, this indispensable re-
oxidation machinery of T. brucei might be explored as a chemotherapeutic target. 
 
1.5.3 The alternative oxidase in trypanosomes 
 
African trypanosomes can use distinct metabolic systems quite different from that of their hosts to 
adapt and survive the low oxygen tension inside their host. Rather than using the available oxygen 
within their host to synthesize ATP, they prefer to employ anaerobic metabolic pathways 
(Nakamura et al., 2010). 
 
For instance, procyclic forms of Trypanosoma brucei found in the infected tsetse fly vector 
synthesise ATP by oxidative phosphorylation. But once the trypanosomes enters the mammalian 
bloodstream, both the oxidative phosphorylation and cytochrome respiratory pathway vanish and 
are substituted with the trypanosomal alternative oxidase (TAO), which begins to functions as the 
only terminal oxidase, with a task of re-oxidizing the NADH (produced during glycolysis) back to 
NAD+ (Shiba et al., 2013).  
 
Because no cytochrome system is found in the long-slender bloodstream form, this form of the 
parasite instead utilizes the cyanide-insensitive glycerol-3-phosphate oxidase system to re-oxidize 
the NADH produced during glycolysis. This specialized system specifically oxidizes the glycerol-
3-phosphate produced in glycosomes by using the electron transport system present in the inner 
mitochondrial membrane which consists of a glycerol-3-phosphate dehydrogenase, ubiquinone, 
and a terminal oxidase known as Trypanosome Alternative Oxidase (TAO) (Ingrid et al., 2013). 
This is a non-protonmotive ubiquinol oxido-reductase that catalyzes the 4-electron reduction of 
molecular oxygen to water. Genes encoding alternative oxidase were initially thought to be the 
exclusive reserve of higher plants, yeast, algae, slime molds, free-living amoebae, nematodes, and 
eubacteria (Shiba et al., 2013). 
 
 The alternative oxidase (TAO) of the long slender bloodstream form of T. brucei is totally 
different in structure compared with the cyanide-sensitive cytochrome C oxidase present in 
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mammalian (and procyclic) mitochondria (Lukeš et al., 2005). In comparison with other 
alternative oxidases (AOX), TAO contains two atoms of bound iron rather than haem as the 
prosthetic group. It also has a characteristic cyanide-insensitive ubiquinol activity that can be 
inhibited by salicylhyroxamic acid (SHAM) (Kido et al., 2010). It is a mitochondrial inner 
membrane protein, contains four α-helices and has a mass of 30-38 kDa, with a catalytic site that 
contains the binuclear iron centre, which is coordinated by two helices, containing a conserved 
Glu or Asp residue (Nihei et al., 2002). 
 
TAO is considered a good chemotherapeutic target for drug development against trypanosomes 
because this unique oxidase is very essential for their respiration and survival since it re-oxidises 
cytosolic NADH, and because this protein is not found in the mammalian host but present in the 
obligate parasite, trypanosomes, and is critical for its survival.  
 
1.5.4 TAO as a drug target – work done to date 
 
The trypanosome alternative oxidase (TAO) has been genetically and pharmacologically validated 
to be critical for the survival of the parasite bloodstream form (Shiba et al., 2013; Saimoto et al., 
2013). Following this validation, there have been significant attempts to identify a potent inhibitor 
of this interesting enzyme. 
 
 
1.5.4.1 Salicylhydroxamic acid (SHAM) as a TAO inhibitor 
 
Salicylhydroxamic acid (SHAM) (Figure 1.13) was the first inhibitor of TAO to be discovered 
(Opperdoes et al., 1976). SHAM is a potent and irreversible inhibitor of urease in plants and 
bacteria; therefore it is usually used for treating urinary tract infections. Although SHAM is 
similar to urea, it is not hydrolysed by the urease present in the urinary tract. However, it is 
metabolized to salicylamide when administered orally which then exerts analgesic, anti- 
inflammatory and antipyretic effects (Opperdoes et al., 1976). 
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                                     Figure 1.13 Structure of SHAM. 
 
Salicylic hydroxamic acid (SHAM) has been comprehensively studied as an inhibitor of the 
cyanide-insensitive alternative oxidase present in the respiration system of plants. SHAM is 
known to inhibit the alternative oxidase (AOX) enzyme in plants and some fungi mitochondrial 
electron transport chain system, where it inhibits the enzyme by blocking the mainly uninhibited 
electron flow through the AOX. The AOX acts as a short circuit in the normal electron transport 
chain where it dissipates electrons with a rather-reduced translocation of protons therefore 
diminishing the generation of ATP by oxidative phosphorylation (Bonner et al., 1986; Juszczuk et 
al., 2003). But when AOX is inhibited by SHAM, electrons will be forced through the 
cytochrome pathway and more specifically via cytochrome IV, thus allowing the operation of the 
cytochrome pathway with no AOX activity to be studied (Juszczuk et al., 2003). 
 
Following the interesting discovery of an identical cyanide-insensitive alternative oxidase system 
in the various Trypanosoma species, investigators assessed the potency of SHAM as an inhibitor 
of Trypanosoma respiration. As the AOX pathway in Trypanosoma species is found to be the 
exclusive electron transport pathway, SHAM would totally shut down the oxygen consumption of 
this organism. The inhibitory potential of SHAM against the trypanosome alternative pathway has 
been reported against trypanosomes, crude inner membrane extracts, and against purified TAO. 
SHAM was reported to give an IC50 (half-maximal inhibition of trypanosome respiration) at a 
concentration of 15 µM (Evans and Brown, 1973; Opperdoes et al., 1976). At this time in the 
research, the promising in vitro experimental results suggested that it was likely to have 
therapeutic potential that could be developed into a drug for treating Trypanosoma infections.  
 
Regrettably, in vivo research using SHAM alone to treat trypanosome-infected animals was found 
not to have much therapeutic effect (Opperdoes et al., 1976). However, the efficacy was improved 
when glycerol was co-administered with SHAM (Evans and Brightman, 1980; Nihei et al., 2002). 
Taking into consideration the structure of SHAM, it could be deduced why the in vivo activity 
was insufficient. Unlike many cationic trypanocides, such as diamidines (Stewart et al., 2005), 
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choline analogues (Ibrahim et al., 2011) and bisphosphonium salts (Alkhaldi et al., 2016), SHAM 
is not expected to accumulate sufficiently in the mitochondria of trypanosomes because of the 
very negative mitochondrial inner membrane potential. Therefore a good in situ inhibitor of TAO 
would have a functional group to give a dispersed positive charge around the molecule in order to 
enhance rapid accumulation of the inhibitor inside the mitochondria (Alkhaldi et al., 2016). In 
combination with glycerol, SHAM was trypanocidal because the glycerol via mass action would 
inhibit glycerol-3-phosphate dehydrogenase- the key enzyme in the glycerol-producing pathway 
(Yabu et al., 2006), thus blocking the trypanosome’s final route to ATP production (Figure 1.12). 
In the presence of a respiratory inhibitor such as SHAM, as well as under certain anaerobic 
conditions, glycerol-3-phosphate (G-3-P) begins to build-up inside the glycosome, this will 
normally be converted to glycerol through a reverse action of an enzyme known as glycerol kinase 
(Ohashi-Suzuki et al., 2011). Nevertheless, once glycerol concentration in the medium reaches 
several millimolar, mass action will cause the enzyme to reverse the reaction and start producing 
glycerol-3-phosphate from glycerol consequently, anaerobic glycolysis taking place inside the 
glycosome will ultimately stop, leading to respiratory arrest, energy deprivation and inevitable 
death of the parasite (Yabu et al., 2006; Ohashi-Suzuki et al., 2011). Another reason for the poor in 
vivo result observed using SHAM as a TAO inhibitor was its low aqueous solubility, as this limits 
its bioavailability.  
 
1.5.4.2 Ascofuranone as a TAO inhibitor. 
 
Ascofuranone (Figure 1.14) is a prenylphenol antibiotic which was isolated from a 
phytopathogenic fungus, Ascochyta visiae (Yabu et al., 2006). The chemical structure of 
ascofuranone is made up of three distinct moieties: an aromatic ring, a linker and a furanone ring.  
 
                                         
                                 Figure 1.14 Structure of ascofuranone. 
 
Ascofuranone was tested for its inhibitory properties on the mitochondrial electron transport 
system of the ascomycetous yeast, Hansenula anomala, and was reported for its selective 
inhibition of the enzyme succinate dehydrogenase and external NADPH dehydrogenase (Sakajo et 
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al., 1993). Eventually, ascofuranone was found to inhibit the Trypanosoma brucei alternative 
oxidase in the sub-nanomolar range, and is now one of the lead compounds in an effort to produce 
drugs which specifically targets this enzyme for use in the treatment of trypanosomiasis. The 
compound has also been found effective in both in vitro cell culture and in infections in mice 
(Yabu et al., 2006). 
 
Ascofuranone was reported to strongly inhibit both glucose-dependent cellular respiration and the 
glycerol-3-phosphate-dependent mitochondrial O2 utilization in long slender bloodstream forms 
(BSF) of Trypanosoma brucei brucei (Minagawa et al., 1997; Nihei et al., 2003). This observed 
inhibition was thought to be the result of inhibition of the mitochondrial electron transport 
system, which is made up of the glycerol-3-phosphate dehydrogenase (EC 1.1.99.5) and TAO. 
Ascofuranone was found to noncompetitively block the reduced coenzyme Q1-dependent uptake 
of O2 in the mitochondria with respect to ubiquinol (Ki = 2.38 nM). Consequently, the susceptible 
site action was suggested to be the ubiquinone redox machinery linking these two enzyme 
activities (Minagawa et al., 1997). Unfortunately, this interesting observation was, as with 
SHAM, not reproduced in a mouse model. Nevertheless, ascofuranone in combination with 
glycerol potently blocked energy production, and completely inhibited the in vitro and in vivo 
growth of the parasite (Yabu et al., 1998). 
 
In order to elucidate not only the mechanism of TAO inhibition by ascofuranone but also the 
inhibitor-enzyme interaction, derivatives of ascofuranone were recently designed and synthesized, 
and the structure-activity relationship has been evaluated. Saimoto et al. (2013) identified the 
pharmacophore of AF that interacts with TAO base on structure-activity relationship. The 
comprehensive inhibitory profiles of these analogues implicated the 1-formyl and 6-hydroxyl 
groups, as contributing to intramolecular hydrogen bonding and/or may serve as donor for 
hydrogen-bonding, and that these were responsible for the direct interaction with TAO. 
 
1.5.4.3 Ascofuranone derivatives as inhibitors of TAO 
 
For drug development, structural adjustments are often necessary to increase the pharmacological 
potential and the manufacturing process of a drug candidate after absorption, distribution, 
metabolism, elimination and then toxicity studies have been carried out. The identification of the 
charge distribution and steric features on a test compound that is required to guarantee the best 
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interactions with an exact biological target, thereby blocking (or in some cases triggering) its 
biological reaction could open the door to the optimisation of an initial lead compound into a 
novel drug. As part of that process of optimisation, it may be highly advantageous to change the 
innate physical properties of the compound, and design a compound with a simple structure (to 
reduce the cost of synthesis), and, for instance, optimise water solubility for an effective in vivo 
absorption. Information from the study of structure activity relationship (SAR) would therefore be 
an essential component of the design of a promising candidate drug. 
 
Structure activity relationship (SAR) has been performed on ascofuranone in order to establish a 
link between the chemical (3-dimensional) structure of ascofuranone and the observed biological 
activity. This enabled the determination of the chemical group(s) responsible for inducing the 
intended biological effect on TAO. This has allowed the modification of the effect or the potency 
of ascofuranone by modifying its chemical structure (Nakamura et al., 2010; Saimoto et al. 2013).  
 
As stated above, the chemical structure of ascofuranone is made up of three distinct moieties: an 
aromatic ring, a linker and a furanone ring (Figure 1.14). Chemical modifications of the 
functional groups at these three moieties have been performed.  
Many Ascofuranone derivatives have been tested for their inhibitory activity against TAO. 
Saimoto et al. (2013) carried out SAR studies on ascofuranone and revealed the following: (i) the 
furanone ring on AF is not needed for inhibition of TAO; (ii) the 3-chloro and/or 2-methyl groups 
are contributory to the conformation of the enzyme-bound molecule; (iii) only one isoprene in 
juxtaposition with the aromatic ring of AF is recognized by TAO; (iv) The direct interaction 
between TAO and AF is consequent of the intramolecular hydrogen bonding and/or the 6-
hydroxyl and 1-formyl groups’ hydrogen-bonding donor activity (Saimoto et al., 2013). 
 
1.6 Aims 
 
The aims of this work is to develop novel and efficient therapeutic leads by investigating the anti-
trypanosomal efficacies of selected tropical plants and their active constituents, and of synthetic 
trypanosome alternative oxidase inhibitors, establish their selective toxicity in vitro, and 
investigate the mechanism of their anti-parasite activity.  
 
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
                                          Chapter 2: Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 2.1 Parasites, cell lines and cultures 
 
 2.1.1 Trypanosoma brucei and Trypanosoma congolense bloodstream forms (BSF)  
 
A number of different strains of Trypanosoma brucei brucei bloodstream form (BSF) were used 
in this study: (1) Wild type T. b. brucei, strain Lister 427 (s427; MiTat 1.2/BS221); (2) An s427-
WT derived TbAT1 knockout (tbat1−/−), which had both the TbAT1/P2 transporter coding alleles 
in the s427-WT strain deleted; this was achieved by a consecutive replacement of both alleles of 
TbAT1 gene with resistance markers for the antibiotics neomycin and puromycin resulting in 
resistance to diminazene aceturate and some degree of resistance to a number of other 
trypanocides such as melarsen oxide and pentamidine (Matovu et al., 2003); (3) A multidrug 
resistant strain, B48 which was derived from a TbAT1-KO strain after increasing exposure to 
pentamidine and lacks both the TbAT1/P2 transporter and the high affinity pentamidine 
transporter (HAPT1) (Bridges et al., 2007); (4) The pentamidine-resistant Aquaporin 2/3 double 
null, and Aquaporin 1-3 triple null (aqp2/aqp3, aqp1-3 null strains respectively); aqp2/aqp3 null 
was obtained by the knockout of the aquaporin genes specifically implicated in pentamidine – 
melarsoprol cross-resistance in field isolates (Alsford et al., 2012); (5) T. brucei cell line (R0.8), 
which upon increasing exposure became resistant to 0.8 µM of compound A (CpdA), which is 
resistant to inhibitors of cAMP phosphodiesterases (PDEs) such as CpdA, and cross-resistant to 
membrane permeable cAMP analogues (Gould et al., 2013); (6) A Trypanosome Alternative 
Oxidase (TAO) over-expressing cell line obtained from T. b. b s427 WT by over-expressing the 
TAO gene under blasticidin pressure, which should result in reduced sensitivity to TAO 
inhibitors. 
 
All T. b. brucei strains were used only as bloodstream trypomastigotes, and cultured in standard 
Hirumi’s Modified Iscove’s medium 9 (HMI-9), supplemented with 10% heat inactivated Fetal 
Bovine Serum (FBS), 14 µL/L β-mercaptoethanol, and 3.0 g sodium hydrogen carbonate per litre 
of medium (pH 7.4). Parasites were cultured in vented flasks at 37 ºC in a 5% CO2 atmosphere 
and were passage every 3 days (Yang et al., 2015; Rodenko et al., 2015). Bloodstream forms of T. 
congolense savannah-type strain IL3000 were cultured exactly as described by Coustou et al. 
2010. 
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2.1.2 Leishmania mexicana promastigotes 
 
Leishmania mexicana promastigote (MNYC/BZ/62/M379 strain) were grown in haemoflagellate-
modified minimal essential medium (HOMEM) (Gibco®, Life technologies, Ghent, Belgium) (pH 
7.4) supplemented with 10% heat-inactivated fetal calf serum (FCS) at 25 ºC. The medium was 
sterilized using a 0.22 µm filter prior to use and stored at 4 °C. The parasites were passaged three 
times a week in 10 ml of HOMEM with 10% Fetal Calf Serum (FCS).  
 
2.1.3 Mammalian cell cultures 
 
Human Embryonic Kidney (HEK) cells - 293T, or Human Foreskin Fibroblast (HFF) cells were 
grown in a standard culture that comprised 500 ml Dulbecco’s Modified Eagle’s Medium-DMEM 
(Sigma), 5 mL Penicillin/Streptomycin (Gibco), 5 mL L-Glutamax (200 mM, Gibco), and was 
supplemented with 50 mL new-born Calf Serum (NBCS) (Gibco). All components were mixed in 
sterile conditions and filtered with a 0.22 µm filter into a 500 mL sterile bottle, and stored at 4 ºC.  
The cells were cultured and incubated at 37 ºC + 5% CO2 and were passaged three times a week 
when reaching 80-85% confluence in passage ratio in the vented flasks, and removal of the 
adherent cells was achieved with the help of 0.25% Trypsin-EDTA solution. The culture flasks 
were horizontally placed to expose a larger surface area in order to enable cell adherence, which is 
crucial for cell growth as a monolayer. 
 
2.1.4 Bacterial strains 
 
Routine cloning of T. b. brucei genomic sequences was done using the XL1 blue strain of 
Escherichia coli (E. coli). Top 10 E. coli and a kanamycin resistant-haem deficient FN102 E. coli 
were respectively used for the cloning and expression of recombinant TAO. These E. coli cells 
were stored as glycerol stabilates at -80 ºC until used. The bacteria cells were grown in luria broth 
(LB) (sigma) that was complemented with 100 µg/mL of ampicillin (sigma) at 37 ºC under an 
overnight vigorous shaking (250 rpm). 
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2.2 Preparation of stabilates 
 
Stabilates were made from either genetically engineered cells or when necessary from the 
routinely used strains. Usually, a cell suspension of 2 × 106 cells/mL is made in HMI-9 
supplemented with 10% FCS, and diluted 1:1 with HMI-9 containing 30% of glycerol. The 
prepared stabilates were aliquoted into cryo-vials and transferred to a -80 ºC freezer and stored for 
between 24 - 48 h prior to transfer to liquid nitrogen for long-term storage. Stabilates were 
brought out of liquid nitrogen when needed and allowed to thaw at room temperature. Cells were 
harvested by centrifugation at a speed of 3000 × g for 10 minutes at 21 °C to remove the glycerol, 
and the cells were then re-suspended in HMI-9 supplemented with 10% FCS. 
 
2.3 Materials 
 
2.3.1 Growth media and chemicals 
 
Dulbecco’s Modified Eagle’s Medium, 0.25% Trypsin-EDTA solution, and Propidium iodide 
were all acquired from Sigma-Aldrich. L-Glutamax (200 mM), New-borne Calf Serum, 
Penicillin/Streptomycin, HOMEM medium and New-born Calf Serum were purchased from 
GIBCO. Heat-inactivated Fetal Calf Serum (FCS) was bought from Biosera. Alamar blue 
(Resazurin sodium salt) was purchased from Trek Diagnostics (UK), while Troglitazone was from 
Biomol. 
 
2.3.2 Phytochemical extraction materials and solvents 
 
The following materials were purchased: TLC grade silica gel coated aluminum sheet (Pre-coated 
Silica gel PF254, Merck, Germany); p-Anisaldehyde (Sigma-Aldrich, UK); Dragendorf’s reagent 
(Sigma-Aldrich, UK); Silica gel 60 PF254 containing gypsum for preparative TLC (Merck, 
Germany); TLC grade silica gel 60H (Merck, Germany) for vacumn liquid chromatography; 
Lipophilic Sephadex® (LH-20100, Sigma-Aldrich, UK); Column grade silica gel (Silica gel 60, 
mesh size 0.063-0.200 mm, Merck, Germany). 
Dichloromethane, n-Hexane, Ethyl acetate, Methanol, n-Butanol, and Acetone were all of HPLC 
grade, while Acetic acid was of Analytical grade. 
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Solvents listed above were used at different stages of extraction, analytical TLCs, and 
chromatographic separations. They were purchased in 2.5 L glass bottles from Fisher Scientific 
UK Ltd. All the solvents were either stored at room temperature or transferred to 500 mL solvent 
bottles for routine use. 
Deuterated (99.9%) solvents (CDCl3, DMSO-d6, and Acetone-d6) were bought from Sigma-
Aldrich UK Ltd, and were used for NMR analysis of fractions. 
 
2.3.3 Test compounds and extracts. 
 
All extracts and purified natural compounds were soluble in DMSO, therefore were dissolved in 
DMSO at 20 mg/mL, and the stock solutions were stored at –20 °C until use.  
 
TAO inhibitors numbering from TAO-01 to TAO-53 were synthesized and supplied by Dr 
Christophe Dardonville of the Instituto de Química Médica, CSIC, Madrid, Spain. The inhibitors 
were soluble in DMSO, therefore were dissolved in DMSO at 20 mM, and the stock solutions 
were stored at –20 °C until use.  
 
2.4 Phytochemical analysis 
 
Phytochemical analysis of the selected medicinal plants was conducted at the laboratory of Prof. 
Alexander Gray of Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, Glasgow. This was carried out as reported below. 
 
2.4.1 Plant collection and preparation of samples. 
 
Following the method of Adewale et al., 2011, ethnopharmacological method was used to collect 
the plants used in this research between the month of January and February from Anyigba, Kogi 
State, Nigeria. This involved engaging traditional healers via interviews in order to establish 
which plant/part of the plant preparations are in common uses and how it was administered. This 
research area is located on latitude 7o 15′ – 7o 29′ N and longitude 7o 11′ - 7o 32′ E with an altitude 
of 420 – 426 m above sea level. Plants were authenticated by taxonomists at the Herbarium 
section of the department of biological sciences, Kogi State University, Nigeria. The plants were 
confirmed to be: 
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Plant A – Centrosema pubescens; Plant B – Moringa oleifera; Plant C – Tridax procumbens; 
Plant D – Polyalthia longifolia; Plant E – Newbouldia laevis; Plant F – Eucalyptus maculata; 
Plant G – Jatropha tanjorensis. 
 
Following authentication of the plant materials, the leaves of the plants were air dried to a 
consistent weight in the laboratory. The plants were ground to a fine power using a grinder (IKA® 
Werke GmbH & Co. KG, Germany) before extraction. 
The powdered dry leaves (20 g) from plants used in this study were weighed into a thimble and 
placed in a soxhlet apparatus. The plant material was extracted consecutively using solvents of 
increasing polarity starting with n-hexane and followed by ethyl acetate and methanol (3.5 L 
each). Each extraction stage was carried out to exhaustion. All extracts obtained were evaporated 
at 40 ℃. Recovery of solvent and concentration of the extracts was carried out under vacuum 
using a rotary evaporator connected to a condenser. Residual solvents were further allowed to 
evaporate under the fume hood before samples were freeze dried in a freeze dryer. The hexane, 
ethyl acetate, and methanol extracts obtained were labelled as below, then stored at -20 ℃ prior to 
analysis.  
Samples were labelled accordingly as: 
 
HDK-AE; HDK-AH; HDK-AM = Ethyl acetate, Hexane, and Methanol fractions from plant A 
respectively.  
HDK-BE; HDK-BH; HDK-BM = Ethyl acetate, Hexane, and Methanol fractions from plant B 
respectively. 
HDK-CE; HDK-CH; HDK-CM = Ethyl acetate, Hexane, and Methanol fractions from plant C 
respectively. 
HDK-DE; HDK-DH; HDK-DM = Ethyl acetate, Hexane, and Methanol fractions from plant D 
respectively. 
HDK-EE; HDK-EH; HDK-EM = Ethyl acetate, Hexane, and Methanol fractions from plant E 
respectively. 
HDK-FE; HDK-FH; HDK-FM = Ethyl acetate, Hexane, and Methanol fractions from plant F 
respectively. 
HDK-GE; HDK-GH; HDK-GM = Ethyl acetate, Hexane, and Methanol fractions from plant G 
respectively. 
 
2.4.2 Bioassay guided fractionation of crude extracts 
 
Following the exhaustive extraction of the plant materials, 21 crude extracts, itemised above, 
were collected and tested for their anti-trypanosome activity using a standard laboratory strain of 
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Trypanosoma brucei wild type s427 and the multi-drug resistant strain B48. As a selection 
criterion, only crude extracts having their EC50 below 15 µg/mL were selected for further 
purification. In addition to this criterion, samples showing reduced sensitivity to B48 relative to 
the wild type were excluded. The crude extracts which met these selection criteria were carried 
further for isolation of their active principles. 
 
2.4.3 Purification and characterization of promising extracts 
 
Extracts that met the established selection criteria used in this work were further subjected to 
purification using a combination of the several methods outlined below.  
 
2.4.3.1 Thin layer chromatography 
 
Thin layer chromatography plate, which is an aluminium sheet coated with silica gel (Merck 
KGaA, Darmstadt Germany), was used for the separation of compounds. Thin layer 
chromatography (TLC) was used to i) screen the plant material for the presence of compounds; ii) 
determine the best eluting system for column chromatography iii) monitor fractions during 
column chromatography and iv) for preliminary analysis of compounds. Plant extracts, fractions 
or pure compounds were dissolved in an appropriate solvent and spotted approximately 1cm 
above the bottom edge of a TLC plate. The crude extract was also spotted to serve as control 
against the possibility of spotting artefacts. Spots were applied as bands to allow for an easy and 
accurate visualisation and the bands were kept as narrow as possible to minimise the overlapping 
of compounds. Solvent combinations of n-hexane/dichloromethane, n-hexane/ethyl acetate or 
ethyl acetate/methanol were used as mobile phases depending on the expected polarity of the 
sample under analysis. 
 
Plates were first examined under UV light using short (λ=254 nm) and long wavelengths (λ=366 
nm). Short UV is useful to detect aromatic compounds while compounds with conjugated double 
bonds were visible under long UV light. The essence of subjecting the TLC plate to UV light 
(long and short wavelength) is to be able to identify and hence distinguish compounds based on 
their UV properties.  
Then, plates were sprayed with anisaldehyde-sulphuric acid to trigger an oxidation reaction 
between anisaldehyde, sulphuric acid, air, heat, and the compound(s). In addition, vanillin-
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sulphuric acid reagents, which allow visualisation of most compounds (phenols, terpenes, sterols, 
pigments and sugars), was also used. Dragendroff’s reagent was used for alkaloids. Various 
colours were observed after spraying with anisaldehyde-sulphuric acid or vanillin-sulphuric acid 
reagent and heating for 1-2 minutes with a heat gun. Alkaloids were detected as orange spots 
against a yellow background after treating with Dragendroff’s reagent (Sherma and Fried, 2006). 
A combination of the relative mobility of compounds on TLC plate, UV property, and reaction 
with anisaldehyde-sulphuric acid spray was used as the bases for fraction combination for NMR. 
 
2.4.3.2 Anisaldehyde-sulphuric acid spray. 
 
Anisaldehyde-sulphuric acid was used for the detection of sugars, steroid, and terpenes on TLC. 
A solution of 0.5 ml anisaldehyde in 50 ml glacial acetic acid and 1 ml 97% sulphuric acid was 
prepared fresh before use. 
 
2.4.3.3 Treatment of Chromatogram 
  
TLC plates were heated to 100 - 105 ºC until maximal visualization of the spots appeared. The 
background was brightened by the presence of water vapour. Lichen constituents, phenols, 
terpenes, sugars and steroids turned violet, blue, red, grey or green respectively upon heating.  
 
2.4.3.4 Vacuum liquid chromatography 
 
Vacuum liquid chromatography (VLC) was performed in a sintered glass funnel attached to a 
water pump. Silica gel 60H (TLC grade) was loaded onto the funnel and vacuum was applied to 
compress silica gel to a hard layer. The least polar solvent was allowed to run through the column 
to check whether the column was homogenously packed. 
 
Samples were dissolved in an appropriate solvent, absorbed on a small amount of silica gel 60 
(mesh size 0.063-0.200 mm) and dried in the hood to achieve a free flowing powder. The powder 
was loaded and packed as a uniform thin layer on the top of the compressed silica gel column and 
the thin layer was covered with filter paper to prevent distortion of the arrangement when solvent 
is added. The column was eluted starting with the least polar solvent (n-hexane) followed by ethyl 
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acetate/n-hexane mixtures of increasing polarity and finally with mixtures of ethyl acetate and 
methanol. The column was allowed to dry completely between fractions to improve resolution 
and separation of compounds. Each fraction was collected, and evaporated to dryness at 40 ºC 
under vacuum using a rotary evaporator. The dried fractions were resuspended in dichlomethane 
and checked by TLC. Finally, they were pooled according to similar chemical profiles 
(Pattaraporn et al., 2014). 
 
2.4.3.5 Size exclusion chromatography 
 
For non-polar fractions, Sephadex® was soaked in a solution of 5% n-hexane in dichloromethane 
or 50% dichloromethane in methanol for several hours. The slurry was then poured and packed in 
a glass chromatography column of appropriated size containing about 10-15 mL of solvent 
allowed to freely drip in order to prevent air bubbles. Samples were dissolved in a small volume 
of the solvent used for the mobile phase. The concentrated sample was loaded at the top of the 
column. Elution was done with 5% n-hexane in dichloromethane or 50% dichloromethane in 
methanol. If needed, elution was continued with 100% dichloromethane or 100% methanol, 
respectively. For relatively polar fractions, Sephadex® was soaked in methanol and the column 
was then eluted with the same solvent. When the column had finish running, Sephadex® was 
washed with water then methanol and kept dried for re-use.  
 
2.4.3.6 Silica gel chromatography 
 
Open Column Chromatography was performed on silica gel 60 (mesh size 0.063-0.200 mm). The 
column was packed using the wet packing technique. Silica gel 60 was made into slurry using the 
least polar solvent of the eluting system and then poured and packed in a glass chromatography 
column of appropriate size. Air bubbles were eliminated by tapping and allowing the tap to run 
while packing. Excess solvent was allowed to run through and the column was left to settle down. 
Samples were dissolved in a suitable solvent and adsorbed on a small amount of silica gel 60 
(mesh size 0.063-0.200 mm), then loaded at the top of the column. Dry silica gel, or a cotton plug, 
or filter paper was applied over the sample to prevent any distortion when the solvent drops came 
from the solvent reservoir. Elution was carried out either isocratically (using a solvent system that 
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does not change composition during the run) or using a gradient. The collected fractions were 
analyzed by TLC and pooled according to similar chemical profiles. 
 
2.4.4 Compound identification by Nuclear Magnetic Resonance (NMR) and Mass 
spectrometric based techniques.  
 
1D and 2D 1H- and 13C-NMR experiments were carried out on a JEOL (JNM LA400) 400 MHz 
and a Bruker 500 or 400 MHz instruments. NMR tubes (5 mm) purchased from Wilmad-labglass 
were used for routine NMR experiments. Samples were dissolved in 0.6 mL of NMR grade 
deuterated chloroform and taken in NMR tubes. Before the tube was inserted into the spinner, it 
was thoroughly wiped with a clean wipe to remove any grease or solvent on the outside of the 
NMR tube which could contaminate the spinner and may cause the spinner to fail to grip the tube 
properly. The identification of pure compounds was first carried out by one dimensional 1H and 
13C NMR spectroscopy. Spectra obtained for known compounds were identified following 
comparison with published spectral data. Further 2D experiments were carried out when 
necessary to accurately assign proton and carbon chemical shifts and determine relative 
stereochemistry in some cases. 
2.4.4.1 1H-NMR 
 
1H-NMR experiments were carried out for all compounds isolated and were used as the primary 
means of structural identification. It provided information on the protons present in each 
molecule, their chemical shifts, multiplicity (coupling information) and estimated numbers from 
the integration. The spectra obtained were also used to assess the purity of any isolated 
compounds, and to determine the relative molar ratio of any components present as a mixture. 
 
2.4.4.2  13C NMR 
     
 
This gave information on the number and type of carbons present in a compound. The spectra 
obtained were either broad band-decoupled or J-modulated. In broad band-decoupled spectra, the 
1H nuclei are irradiated during the 13C acquisition so all protons were fully decoupled from the 
13C nuclei. When this was done each distinct 13C environment in the molecule gave rise to a 
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separate singlet signal. In the J-modulated experiment, the carbons were distinguished according 
to the extent of their proton attachments (C, CH, CH2 and CH3).  
 
2.4.4.3 Correlation spectroscopy (COSY) 
 
This 2D experiment gave 1H-1H coupling in the molecule and also revealed all coupling 
relationships in one experiment using a suitable pulse sequence. The proton shifts were plotted on 
both axes with the contour plotted along the diagonal of the square, and the correlations were 
shown as cross peaks with the diagonal corresponding to the ordinary 1H spectrum. Thus, the 
cross peaks refer to the spin-spin coupled protons.  
2.4.4.4 Nuclear Overhauser Enhancement spectroscopy (NOESY) 
 
The NOESY experiment was performed in order to determine compound structure and their 
relative stereochemistry. In this experiment, all correlations between protons showing Nuclear 
Overhauser Effect (NOE) were recorded two-dimensionally. The NOESY spectrum was used to 
measures 1H-1H interactions arising from (through space) dipolar coupling. The spectrum 
obtained was similar to the COSY spectrum (scalar through bonds coupling), but the NOESY 
spectrum showed cross-peaks representing NOE correlations.  
2.4.4.5 Heteronuclear Multiple Bond Correlation (HMBC) 
 
The spectra obtained from this experiment revealed heteronuclear shift correlations via long-range 
couplings. The proton spectrum was arranged on one axis while the carbon was on the other, and 
the correlations were displayed as cross peaks. Unless otherwise stated, the HMBC experiment 
carried out for different samples in the present study used a time delay of 0.00625 s (e.g. JCH = 8 
Hz). Since this pulse programme uses 1H-13C polarization transfer, the detection was about four 
times more sensitive than the 13C NMR experiment.  
2.4.4.6 Heteronuclear Single Quantum Correlation (HSQC)  
Heteronuclear Single Quantum Correlation (HSQC) is a 2D 1H-13C experiment which was carried 
out to shows one-bond (1J) direct correlations. The pulse sequence applied in this experiment uses 
a time delay set to 1/2J where J is the value similar to that of one-bond 1H-13C coupling. In the 
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HSQC spectrum, the 1H and 13C (also called DEPT) spectrum was plotted along the abscissa and 
ordinate respectively. The cross-peaks indicated proton and carbons that were directly connected 
to each other. 
 
2.4.4.7 Compound identification by Mass spectrometry 
 
Mass spectrometry was used to identify the amount and type of chemicals present in our sample 
by measuring the mass-to-charge ratio and abundance of gas-phase ions. High (and low) 
resolution electron impact mass spectra were recorded on a JEOL 505HA spectrometer using 
direct probe at elevated temperature (110-160 ℃) at 70 eV. Positive ion and negative ion mode 
Electrospray Ionisation (ESI) experiments were performed on a Thermo Finnigan LCQ-Deca 
Iontrap or Orbitrap HRESI mass spectrometer (mass analyser set up at 100,000 ppm, externally 
calibrated at 3 ppm). According to the polarity, samples were dissolved in acetonitrile, methanol 
or water (HPLC grade) or in a binary mixture of these solvents to get a concentration of 100 
µg/mL. Sample solution (10-20 µL) was injected along with a direct infusion of 0.1% formic acid 
in acetonitrile: water (90:10) at a flow rate of 200 µL/min.  
 
2.5 In vitro drug sensitivity assay using Resazurin (Alamar blue) dye 
  
The sensitivity of the various class of compounds tested in this work was carried out using the 
parasite viability dye, resazurin which in the presence of a viable cell is reduced to a pink 
fluorescent compound called resorufin. Alamar blue was used in various assays as reported 
below. 
 
2.5.1 Drug sensitivity using Alamar Blue in bloodstream forms of T. b. brucei 
 
The drug susceptibilities of bloodstream form trypanosomes T. brucei s427 and B48 were 
determined using the resazurin (Alamar blue) assay. This involves adjusting cell density to the 
desired concentration of 2 × 105 cells/mL of which 100 µL was added to all of the wells in the 
plate having a 100 µl serially diluted test compound (200 µM top concentration) in HMI-9 + 10% 
FBS, then incubating trypanosomes and test compound for a period of 48 hours followed by the 
addition of 20 µl filter-sterilised resazurin solution prepared by adding 25 mg resazurin sodium 
salt to 200 mL PBS. This was followed by further 24 hours incubation. Standard drugs including 
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pentamidine and diminazene aceturate were used as positive control. Fluorescence was measured 
in the 96-well plates with a FLUOstar Optima (BMG Labtech, Durham, NC, USA) at 
wavelengths of 544 nm for excitation, 590 for emission, and a gain of 1250. EC50 values were 
calculated by non-linear regression using an equation for a sigmoidal dose-response curve with 
variable slope (GraphPad Prism 5.0, GraphPad Software Inc., San Diego, CA, USA). 
 
  
                                                      
Figure 2.1 Drug dilution (doubly diluted) down two rows across the plate. The red well is 
the drug free well. 
  
2.5.2 Drug sensitivity using Alamar Blue in L. mexicana promastigotes    
 
The drug sensitivity assay in L. mexicana was carried out using a method similar to the one used 
for bloodstream form trypanosomes and was determined using the viability dye resazurin, which 
involves performing a serial dilution of drug such that there is 100 µL in each well as shown 
above (Figure 2.1). To each well, 100 µL of a 2×106 cells/mL suspension is to be added to give a 
final cell density of 1×105/well. Because of the difficulty associated with counting Leishmania on 
a haemocytometer, due to their rapid motility, the cells were fixed in 1% formaldehyde and this 
was achieved by taking 50 µl of culture and adding this to 400 µl of the media (HOMEM, pH 7.4) 
and 50 µl of 1% formaldehyde, making a 10% culture dilution after which the count was 
multiplied by the dilution factor of 10 to get the actual cell density. After adjustment of the cell 
density to exactly 2×106 cells/ml, 100 µl of the suspension was added to all wells in the plate, 
each already containing 100 µl of the serially diluted drugs (or medium in the no-drug controls). 
The plate was incubated for a period of 72 hours, at 25 ºC and 5% CO2 followed by the addition 
of 20 µl resazurin. This was followed by further 48 hours incubation. Pentamidine was used as a 
standard drug. Fluorescence was measured in the 96-well plates with a FLUOstar Optima (BMG 
Labtech, Durham, NC, USA) at wavelengths of 544 nm for excitation, 590 for emission, and a 
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gain of 1250. EC50 values were calculated by non-linear regression using an equation for a 
sigmoidal dose-response curve with variable slope (GraphPad Prism 5.0, GraphPad Software Inc., 
San Diego, CA, USA). 
 
2.5.3 Assessment of cytotoxicity of test compounds on Human Embryonic Kidney (HEK) 
293T cells or Human Foreskin Fibroblast (HFF) cells using an improved protocol 
 
Toxicity of drugs to mammalian cells was carried out using Human Embryonic Kidney (HEK) 
Cells (strain 293T) or Human Foreskin Fibroblast (HFF) cells according to our improved protocol 
(Rodenko, et al., 2015), with slight modifications. Briefly, HEK or HFF cells were grown in a 
culture containing 500 mL Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma), 50 mL 
New-born Calf Serum (NBCS) (Gibco), 5 mL Penicillin/Streptomycin (Gibco) and 5 mL L-
Glutamax (200 mM, Gibco). Mammalian cells were incubated at 37 ºC/5% CO2 and were 
passaged when they reached 80 - 85% confluence in vented flasks. For the assay, cells were 
suspended at a density of 3 × 105 cells/mL, of which 100 µL was added to each well of a 96-well 
plate. The plate was incubated at 37 ºC + 5% CO2 for 24 hours to allow cell adhesion. Serial drug 
dilutions were prepared in a separate sterile plate and 100 µL was transferred to the wells 
containing the cells; PAO was used as positive control. The plate was then incubated at 37 ºC/5% 
CO2 for an additional period of 30 h followed by the addition of 10 µL of resazurin solution (125 
mg/L in PBS) and a final incubation at 37 ºC/5% CO2 for 24 hours. The plate was read in a 
FLUOstar OPTIMA fluorimeter at wavelengths 530 nm for excitation and 590 nm for emission. 
The data were analysed using GraphPad Prism 5.0, and plotted to a sigmoid curve with variable 
slope to determine EC50 values. The selectivity index was calculated as EC50 (HEK)/EC50 
(trypanosomes).       
 
2.6 Drug sensitivity assay using cell counts  
 
Compounds of varying concentrations were tested on trypanosomes for determination of in vitro 
cell growth using cell counts. Trypanosomes at their mid logarithmic phase of growth were taken 
from cultures and cell density was determined using a haemocytometer. The cell density was 
adjusted to 2 x 105 with fresh HMI-9 medium. After predetermined periods of exposure to the test 
compound, cell counts were taken in triplicate, for each concentration of the compounds, typically 
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for up to 32 hrs. The experiment was repeated two more times and the average counts were used 
for plotting the growth curve against time in hours.  
 
2.7 Drug sensitivity assay using a Propidium Iodide (PI) 
 
This procedure was used to monitor the effects of the test compounds on trypanosome survival in 
real time (Rios Martinez et al., 2015). Trypanosomes become fluorescent when the plasma 
membrane is breached and PI enters the cell and binds to nucleic acids (Gould et al., 2008). In 
this method, 100 µL of HMI-9 was added to each well of a 96-well plate and 100 µL solution of 
test compounds at different concentrations, also in HMI-9, was added to the first column; wells 
receiving only media served as drug free controls. To each well was added 100 µL of HMI-9 
containing 1×107 trypanosomes and 18 µM of PI. Wells containing the same final concentration 
of PI (9 µM) in HMI-9 but no cells served to record background fluorescence. The plates were 
incubated in a FLUOstar OPTIMA fluorimeter (BMG Labtech) at 37 ºC with 5% CO2 
atmosphere, and the fluorescence was recorded at 544 nm excitation and 620 nm emission for 6 
hrs.  
 
2.8 Determination of oxygen consumption rate. 
 
The Oxygen Consumption Rate Assay Kit (Cayman chemicals, Ann Arbor MI, USA), designed to 
measure extracellular oxygen consumption in mammalian cells, was adapted to trypanosomes 
following the manufacturer’s protocol, but with substantial modifications. Cells were seeded in a 
sterile 96-well flat bottom tissue culture plate at a seeding density of 8×104 cells/well (i.e. 5×105 
cells/mL) in 150 µL of HMI-9 and test compounds were added in 10 µL to the appropriate wells, 
immediately prior to measurement; three blank wells received culture medium only. Glucose 
Oxidase Stock Solution (10 µL, provided by the kit), was added to a control well to deplete all 
oxygen from the medium, and 10 µL of SHAM was added to another control well (50 µM final 
concentration). Finally, 10 µL of the probe solution was added to every well except the blank 
wells; all reagents used had been freshly prepared. Using a repeating pipette, every well was 
gently overlaid with 100 µL of mineral oil (provided in the assay kit) pre-warmed to 37 ºC. The 
plate was immediately read kinetically for 120 minutes using a fluorimeter set at 37 ºC and at a 
wavelength of 380 nm for excitation and 650 nm for emission. Gain was adjusted so that the 
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fluorescent signal of probe in 21% O2 (air saturated) buffer was equal to 20% of the maximum 
measureable signal. 
 
2.9 Determination of mitochondrial membrane potential (Ψm) using flow 
cytometry 
 
Fluorescence Activated Cell Sorting technology (FACS) was employed in the determination of 
the change in mitochondrial membrane potential (MMP) due to exposure of trypanosomes to the 
test compounds by using tetramethylrhodamine ethyl ester (TMRE) (Denninger et al., 2007). The 
cell density was adjusted to 1×106 cells/mL with and without test compounds for the start of the 
experiment. 1 mL of sample was transferred at each time point into a microfuge tube and 
centrifuged at 4500 rpm for 10 min at 4 °C. The pellet was re-suspended in 1 mL PBS containing 
200 nM of TMRE, followed by incubation at 37 °C for 30 min. The suspension was placed on ice 
for at least 30 minutes before analysis by a Becton Dickinson FACS Calibur using a FL2-heigth 
detector and CellQuest and FlowJo software (Ibrahim et al., 2011). Valinomycin (100 nM) and 
troglitazone (10 µM) were employed as negative (mitochondrial membrane depolarisation) and 
positive (mitochondrial membrane hyperpolarisation) controls respectively (Denninger et al., 
2007). Mitochondrial membrane potential was determined at 0, 1, 4, 8 and 12 h. 
2.10 Assessment of cell cycle (DNA content assay) using flow cytometry 
 
Fluorescence Activated Cell Sorting Technology (FACS) was also used to study the effects of test 
compounds on DNA content in Trypanosoma brucei brucei s427 WT. Cell density was adjusted 
to 1×107 cells/mL with and without test compounds for the duration of the experiment. 1 mL of 
sample was transferred at each time point into microfuge tubes and centrifuged at 1620 × g for 10 
min at 4 °C, washed once in PBS containing 5 mM of EDTA and re-suspended and fixed in 1 mL 
of 70% methanol and 30% PBS/EDTA. The tube with the cells was left at 4 °C overnight in the 
dark, and the samples were subsequently washed once with 1 mL PBS/EDTA, re-suspended in 1 
mL PBS/EDTA containing 10 µg/mL propidium iodide and incubated at 37 °C for 45 minutes. 
RNase A (10 µg/mL) was added before the samples were analysed by a Becton Dickinson 
FACSCalibur using the FL2-Area detector and CellQuest software. The data obtained were 
analysed using FlowJo software (FlowJo LLC, Ashland, OR, USA). 
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2.11 Assessment of cell morphology and DNA configuration using fluorescence 
microscopy 
 
The configuration of nuclei and kinetoplast DNA of treated and untreated T. brucei was visualised 
using a vectashield mounting medium with the dye 4,6-diamidino-2-phenylindole (DAPI) (Vector 
Lab. CA, USA), which fluoresces when bound to DNA, while the mitochondrial integrity was 
examined using the Mito-Tracker Orange CMTMRos staining dye (ThermoFisher Scientific, 
UK), which is a cationic fluorophore that accumulates in the mitochondria due to the highly 
negative mitochondrial membrane (Gile et al., 2015).  
 
First, a stock solution of 100 µM was made by adding 10 µL of a 1 mM Mito-tracker stock to 90 
µL DMSO. From this solution, 1 µL was added to 1 mL of sample at each time point to make a 
final concentration of 100 nM of Mito-tracker. The sample was then incubated at 37 ºC and 5% 
CO2 for 5 minutes. The incubated sample was washed in filter-sterilized 1× PBS and spun at 
2,600 rpm for 10 minutes. After the final wash step, the sample was re-suspended in 1 mL of 1 x 
PBS. 50 µl of the re-suspended cells were spread onto a glass microscope slide, and were left to 
air dry, the cells were then fixed in methanol overnight at -20 ºC. The following day, the slides 
were rehydrated using 1 mL of PBS and allowed to rehydrate for 10 minutes after which it was 
then allowed to evaporate but not completely. A drop of Vectashield antifade mounting medium 
with DAPI (Vector Laboratories, USA) was added to the slides and spread by a coverslip; the 
coverslip was then applied and the edges were sealed with nail varnish.  
 
Slides were observed for cell morphology under the Delta Vision core microscope using 
softWoRx software, while DNA configuration was assessed using a Zeiss Axioplan microscope 
using Hamamatso digital camera and Openlab software. A total of 500 cells per slide were 
counted for each sample using a cell counter, and scores for DNA configuration were given 
following these groups: 1N1K, 1N2K, 2N2K (Early) and 2N2K (Late), where N is nuclear DNA; 
and K is kinetoplast DNA.  
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2.12 TUNEL assay 
 
Fragmentation of parasite DNA after exposure with various compounds was evaluated by TUNEL 
assay using the APO-BrdU TUNEL Assay Kit (Invitrogen) for the detection of DNA 
fragmentation, following the manufacturer’s protocol. The cell density of the parasites was 
adjusted to 1×106 cells/mL and the cells were incubated with or without the test compounds for 
the period of the experiment. After the incubation period the cells at first underwent fixation such 
that 1×107 cells were suspended in 500 µL of PBS, followed by the addition of 5 mL of 1% (w/v) 
paraformaldehyde in PBS to the sample and then placed on ice for 15 minutes. After this, the 
sample was centrifuged at 2000 rpm for 5 minutes, and then the cells were washed twice in 5 mL 
PBS, before re-suspending them finally in 500 µL PBS. Eventually, 5 mL of ethanol (70%) was 
added to the sample before storing at -20 ºC. Before analysis by flow cytometry, the sample was 
centrifuged for 5 minutes at 2000 rpm in order to remove the ethanol. The cells were re-
suspended in 1 mL of wash buffer, followed by centrifugation for 5 minutes at 2000 rpm; this step 
was repeated to remove any residual ethanol.  
 
Following the wash step, 50 µL of DNA-labelling solution (31.25 µL dH2O, 10 µL of the reaction 
buffer, 8 µL of BrdUTP, and 0.75 µL of Terminal deoxynucleotidyl transferase (TdT) enzyme 
were added and then incubated at 37 ºC for one hour (with an intermittent shaking of the sample 
every 15 min). At the end of the incubation period, 1 mL of the rinse buffer was added and the 
sample was spun for 5 minutes at 2000 rpm; this step was repeated, with the supernatants 
removed each time. After this, 100 µL of the antibody staining solution (95 µL of the rinse buffer 
and 5 µL of the Alexa Fluor 488 dye-labelled anti-BrdU antibody) was added to the sample and 
then incubated at room temperature for 30 minutes in the dark. Finally, 500 µL of propidium 
iodide/RNase (also provided by the kit) was added to the sample and the sample was then 
incubated for 30 minutes at room temperature with the sample protected from light. The sample 
was analysed by flow cytometry using both FL3- width and Anti-BrdU FITC detectors and cell 
Quest software. The data obtained were analysed with FlowJo (10) software. 
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2.13 ATP level determination 
 
Intracellular ATP was measured using an ATP Determination Kit (Invitrogen), which contains 
Luciferase (recombinant firefly) and Luciferin, following the manufacturer protocol. Briefly, 
culture containing 1×107 cells of both treated and untreated parasites were taken and centrifuged 
for 10 minute at 2800 rpm (4 ºC). The resulting pellets were washed twice in 200 µL of 50 mM 
Tris-HCl, pH 7.4, containing 0.1 mM Dithiothreitol (DTT). The cells were then lysed by 
sonication on ice (twice for 10 seconds separated by 30 seconds) using a Soniprep 150 with 
amplitude at 8 micron. After this, it was centrifuged at 14000 rpm for 10 min at 4 ºC. The 
resultant supernatant was frozen in liquid nitrogen and stored at -80 ºC. Cellular ATP levels were 
measured using the contents provided in the kit. The standard reaction solution was prepared for a 
10 mL volume master mix [8.9 mL dH2O, 0.5 mL 20× reaction buffer, 0.1 mL of 0.1 M DTT, and 
2.5 µL firefly luciferase (5 mg/mL), 0.5 mL of 10 mM D-luciferin]. After this, 90 µL reaction 
solution from the master mix was added to each well and the background luminescence was 
recorded using a FLUOstar OPTIMA fluorimeter; then 10 µL of each sample was added to the 
well and incubated for 15 min at 28 ºC and the luminescence was recorded. A standard curve was 
made using serial dilution of varying concentrations of ATP (0.5 µM – 500 pM) to calculate the 
ATP concentrations in the samples. 
 
2.14  Metabolomic assessments of T. b. brucei cells treated with natural 
compounds. 
 
Bloodstream form T. brucei was seeded at the same cell density (2×105/mL) in 75 cm2 flasks (one 
for the drug treatment, and another for the negative control) two days before the experiment in 
order to have a mid-log phase culture. The cells were treated with the appropriate compounds at 
concentration equal to half their EC50 for 10 h at 37 °C, and 5% CO2. Samples of 1×108 cells were 
taken at the end of the incubation period, transferred to a 50 mL falcon tube, and quenched by 
rapidly cooling the cells to 4 °C by submerging tube in a dry ice/ethanol bath. During the cooling 
process, the samples were continuously stirred to avoid freezing and cell lysis; the tubes were then 
wiped and placed on ice. Next, the samples were spun at 1250 ×g for 10 minutes at 4 °C, after 
which 10 µL of the supernatant was taken from each sample, transferred to a microfuge tube and 
kept in a freezer at -80°C. This supernatant sample was eventually mixed with 200 µL CMW for 
spent medium analysis. The supernatant having been mostly removed, (keeping the tube on ice) a 
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small volume was left in which the cells were re-suspended. This was transferred to a microfuge 
tube and centrifuged at 4500 rpm for 5 minutes at 4 °C, after which the last of the supernatant was 
carefully and completely removed. The pellet was washed in 1 mL PBS at 4 °C and centrifuged at 
4500 rpm, for 5 minutes at 4 °C and this step was repeated for 20 seconds in order to remove any 
PBS left. 
 
The pellet was then re-suspended in 200 µL of extraction solvent (Chloroform: Methanol: Water, 
CMW, 1:3:1) at 4 °C and was vigorously mixed in order to break up the pellet. The samples 
including the CMW solvent sample in microfuge tube (200 µL) and the fresh medium sample (10 
µL medium + 200 µL CMW) were left on the shaker in the cold room (4 °C) for 1 hour at 
maximum speed. After this period of shaking, the samples were centrifuged at 13,000 rpm, for 10 
min at 4 °C, and the supernatants (CMW extracts) were removed (180 µL) and transferred to MS 
vials, making sure no part of the pellet went into the sample. 
 
About 10 µL from each sample was collected (with the exception of the ‘no fresh medium’ and 
CMW solvent samples) into the same microfuge tube and was used as quality control (QC). 
Argon (Ar) was added to each sample before sealing and the samples were eventually stored at -
80°C until analysis by LCMS. 
 
2.15  TAO over-expression 
 
This was done with the aim of cloning the TAO gene into the pHD1336 plasmid in order to over-
express it in T. b s427 WT, creating a tool for the validation or otherwise of the proposed 
mechanism of action of the designed TAO inhibitors. 
 
2.15.1 Extraction of Genomic DNA 
 
Genomic DNA (gDNA) was obtained from T. b s427WT, and performed using standard gDNA 
extraction kit (NucleoSpin®) according to the method below.  
The trypanosome culture was spun at 2600 rpm for 10 minutes after which cell pellets were re-
suspended in PBS buffer in the wash step and spun at 2600 rpm for 10 minutes before re-
suspending the cell pellets in 500 µL of the NTE buffer (provided in the kit), 25 µL of 10% SDS, 
and 50 µL of 10 mg/mL RNase A. This mixture was then incubated at 37 ºC for 5 minutes after 
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which 25 µL of 20 mg/mL Pronase was added to the sample, which was then incubated overnight 
at 37 ºC.  
 
The next day, 600 µL of phenol: chloroform: isoamyl alcohol (25:24:1) was added to the sample. 
The tube was then spun at 12,000 rpm for 5 minutes and the clear supernatant was removed and 
dispensed into a separate sterile centrifuge tube, followed by the addition of the same volume of 
the same mixture and was centrifuged. Once more the upper phase was transferred to a new sterile 
tube and 600 µL of chloroform was added, and then centrifuged at 12,000 rpm for 5 minutes. The 
upper phase was then taken and transferred to a sterile polystyrene tube after which 2.5 mL of 
absolute ethanol was added to the sample in order to precipitate the DNA, the tube was 
centrifuged at 12,000 rpm for 5 minutes. The DNA obtained was washed with 70% ethanol. The 
tube was then centrifuged at a maximum speed and the DNA pellet was air-dried in the 
microbiological safety cabinet before it was resuspended in 50 µL TE buffer and the DNA sample 
was quantified with a nanoDrop then was stored until use at 4 °C. 
 
2.15.2 Primer design for Polymerase Chain Reaction (PCR) 
 
Primers were designed for 5′ and 3′ ends of the TbAOX gene with HindIII and BamHI as 
restriction sites: 
Forward- HDK560:  GCGC AAGCTT ATGTTTCGTAACCACG 
Reverse-HDK561:   GCGGATCC TACACATGTTTGTTTACATT 
 
2.15.3 Gradient PCR 
 
Gradient PCR was performed to determine the TAO primers’ annealing temperature (Tm). T. b 
427 WT genomic DNA (gDNA) was used as template. This involves the use of: 10 µL GC buffer, 
2 µL of 10 mM dNTPs, 2 µL forward primer, 2 µL reverse primer, 0.5 µL gDNA, 0.5 µL phusion 
polymerase, and 33 µL H2O. Next, 10 µL of the 150 µL master mix was added to 12 PCR tubes. 
Gene amplification was performed using a PCR machine. 
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2.15.4 Agarose Gel Electrophoresis of DNA  
 
Agarose gels were prepared for the analysis of PCR products. Briefly, 1% agarose was dissolved 
in 1 × TAE buffer and the solution was boiled until it became clear, signifying that the agar was 
dissolved in the TAE buffer. After cooling the solution until it became lukewarm, SYBR® safe 
was added. The gel was run at 110 Volts and the bands were observed under the UV 
transilluminator. The size of the TAO gene was noted. 
 
2.15.5 TAO gene amplification  
 
The TAO gene was amplified using PCR method similar to the one highlighted above, from T. b 
427 WT genomic DNA (gDNA) using a primer annealing temperature of 69.7 ºC. The PCR 
product was PCR-cleaned and DNA was quantified using a Thermo-Fisher Scientific NanoDrop - 
a spectrophotometer that calculates the absorbance of a very small sample across different 
wavelengths. Double digest for TAO and for the vector pHD1336 was performed using HindIII 
and BamHI as restriction endonucleases. This was followed by ligation of the TAO gene into the 
pHD1336 backbone. 
 
2.15.6 Transformation of XL1 Blue E.coli  
 
In order to transform ligations into XL1 blue E.coli, aliquot of competent XL1 blue cells were 
defrost on ice. Then, 10 µL of ligation product was put into a 1.5 mL microfuge tube followed by 
the addition of 50 µL of XL1 blue cells. It was incubated on ice for 30 minutes and then heat 
shocked at 42 ºC for 45 seconds after which it was put back on ice for 2 minutes. This was 
followed by the addition of 100 µL of LB broth, and incubated at 37 ºC for 1 hour with shaking. 
Cells were spread using a sterile spreader on pre-heated (at 37 ºC for 30 minutes) ampicillin 
containing Agar plates (100 µg/mL amp). It was then incubated at 37 ºC overnight. 
 
2.15.7 PCR screening of colonies 
 
Colonies on plate were screened the next day using PCR. Bacterial colonies from the agar plate 
were picked with a sterile 200 µL pipette tip, and were streaked onto a new LB agar plate 
(numbering each colony) and then using the residual bacteria for a PCR reaction, dipping the tip 
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into the reaction mix. The new agar plate was then put into an incubator set at 37 ºC while the 
PCR was carried out as follows: 
The lead was set to 112 ºC for a hot start PCR; the denaturation temperature step was set at 95 ºC 
for 3 minutes; start cycle: x35; annealing temperature step; Gradient step: 48.5 ºC for 30 seconds; 
extension step: 72 ºC for 1 min. 40 seconds; End cycle; A further extension step of 72 ºC for 5 
min.; Storage: 10 ºC.  
Samples were then run on 1% agarose gel to determine the positive and negative colonies. 
Overnight cultures of positive colonies were grown by adding 5 µL of 100 mg/mL ampicillin to 5 
mL LB broth, followed by the addition of a streak of the correct bacteria. These were kept in the 
shaker overnight. The following day, DNA was isolated from the colonies by miniprep, followed 
by a test digest to excise the insert from the vector. Samples yielding the correct sized dropout 
band were then sent for sequencing. Linearization of pHD1336 carrying the TAO insert was done 
using NotI incubated at 37 ºC for 4 hour after which the digest was purified using standard PCR 
cleanup kits (NucleoSpin®).  
 
2.15.8 Transfection of Bloodstream form (BSF) T. brucei with TAO inserted into pHD1336 
 
Transfection was carried out on 5×106 BSF T. brucei cells using cells with a density of around 
1×106 Cells/mL. The number of cells needed was worked out and the cells were spun at 1500×g 
for 10 minutes after which the supernatant was removed completely. Then, 10 µg of digested 
DNA was transferred to an electroporation cuvette. Cell pellets were resuspended in 100 µL T-
cell buffer and added to the cuvette with the DNA. It was zapped in the Amaxa electroporation 
machine using the X-001 programme on the machine, after which the electroporated parasites 
were transferred immediately into 10 mL pre-warmed HMI-9 medium where they were allowed to 
recover for 6-18 hours at 37 ºC, and 5% CO2. Three 50 mL tubes were then set up and labelled 
D1, D2, and D3 respectively. This was followed by the addition of 23 mL, 33 mL, and 12 mL of 
HMI-9 to D1, D2, and D3 respectively. Also, 23 µL, 33 µL, and 12 µL of blasticidin (5 µg/mL) 
was added to D1, D2, and D3 respectively. After this, 1 mL of culture was added to D1, 3 mL of 
D1 was transferred to D2 and 12 mL of D2 was transferred to D3. This ended up with a plate of: 
1/24 dilution, 1/288 dilution, and 1/576 dilution respectively. From each of D1, D2, and D3, 200 
µL was transferred into separate 96 well plates, which were labelled appropriately. After this, 10 
mL of fresh HMI-9 media was added to the remaining culture in the flask and 19 µL of blasticidin 
(5 mg/mL) was added. Both plates and culture flask were incubated at 37 ºC and 5% CO2. 
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2.15.9 Real Time-PCR 
 
This was performed on transfectants, empty vector and wild type controls using a method 
previously described (Ali et al., 2013). Briefly, complementary DNA (cDNA) for the TAO gene 
was synthesized using a Reverse Transcriptase (RT) kit (Primerdesign, UK). The cDNA for each 
of the samples was diluted 1:10 before using them for Real Time-PCR. Amplification of the 
cDNA was performed using a 7500 Real Time PCR System (Applied Biosystems). The 
dissociation curve was used to ensure the amplification of only one product, while samples 
without RT or cDNA were used as controls. The constitutively expressed gene GPI8 (Lillico et 
al., 2003; Capewell et al., 2011) was used as endogenous control. This uses primer sequences 
of 5′- TCTGAACCCGCGCACTTC and 5′-CCACTCACGGACTGCGTTT (Ali et al., 2013). For 
TAO, the ∆CT method was used for relative quantification (RQ) using WT cells in HMI-9 as an 
internal control or a calibrator. All data was analysed using Real-Time PCR systems software 
(Applied Biosystems 7500 SDS). Primers used for the amplification of TAO were 5′-
CGAAGTGGCTCGCGTGTA and 5′-TGATGAGGTCGCGGAATGT.The entire experiment was 
carried out on three independent occasions, beginning with cell culture and RNA isolation. 
 
2.16 Cloning, expression, and direct inhibitory studies of physiologic 
Trypanosome Alternative Oxidase (∆MTS-TAO) 
 
In this section the direct inhibitory studies of recombinant TAO (rTAO) using the novel designer 
TAO inhibitors is described. However, because the full length TAO (fl-TAO) doesn’t exist 
physiologically in trypanosomes, considering that the mitochondrial targeting signal (MTS) is 
cleaved upon transportation of TAO into the mitochondria, it was therefore imperative to target 
the physiological form of TAO (∆MTS-TAO) and carry out direct inhibitory studies with the 
potential inhibitors. Over-expression of N-His6 SUMO-TAO without mitochondrial targeting 
signal (∆MTS) was carried out in haem-deficient FN102 cells.   
 
2.16.1 Plasmid construction for recombinant TAO expression  
 
A previous plasmid construct, pTAO, which contains the cDNA for TAO from T. brucei brucei 
TC221 as previously described by Nihei et al. (2002; 2003), was used as template for the 
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amplification of TAO using 5′-AGCCGTAACCACGCATCGAGG-3′ and 5′-
CTTGTTGAAGCAGAGAATGAGCGC-3′ as sense and antisense cloning primers, respectively, 
for full length TAO, while 5′-AGCGACGCCAAAACACCTGTGTGGG-3′ and 5’-
CTTGTTGAAGCAGAGAATGAGCGC-3′ primer pair was used to amplify the gene segment 
lacking the MTS coding sequence (∆MTS-TAO). Pfu Ultra II Fusion HS DNA polymerase 
(Stratagene, Ca, USA) was used for the initial PCR amplifications followed by Taq DNA 
polymerase for the addition of 3′ A-overhangs. Following the manufacturer’s procedure, gel-
purified PCR product (TAO) containing the 3′ A-overhang was inserted into pET SUMO 
expression plasmid (Thermo-Fisher), and used for the chemical transformation of One Shot 
TOP10 E. coli cells. Colonies of transformants were grown on 50 µg/mL Kanamycin-
supplemented Luria-Broth (LB) plates. Construct-positive clones were confirmed by colony PCR 
and were then selected for liquid culture in LB media for the amplification of vector construct. 
TOYOBO Magnetic Extractor kit (Osaka, Japan) was used for plasmids extraction, and were 
subjected to further confirmation by sequence analyses. The NHis6SUMO-tagged TAO was 
further sub-cloned into pET101 (Invitrogen) which contained a carbenicillin resistance cassette. 
Following PCR and gene analyses, the correct construct was used to transform a haem-deficient 
FN102 protein expression E. coli host having a Kanamycin resistance gene. The construct-
positive colonies were selected under carbenicillin and Kanamycin pressure, and selected for 
storage and expression experiments.  
 
2.16.2 SDS-PAGE of purified rTAO 
 
SDS-PAGE was carried out following the method described in Balogun et al. 2013 with slight 
modifications. Bacterial lysate, membrane fractions, flow-through, and peak fractions from a 
TALON column were subjected to discontinuous SDS-PAGE. The stacking and separating gels 
were at 4% and 12% (w/v) acrylamide, respectively. Samples were mixed in a 1:1 (v:v) with 2× 
SDS PAGE loading buffer [4% (w/v) SDS, 125 mM TrisHCl, pH 6.8, 0.2% (w/v) bromophenol 
blue (Nacalai tesque), 15.8% (v/v) glycerol, and 10% (v/v) β-mercaptoethanol] and heated for 5 
min at 95 ºC. Protein preparations were then loaded into wells of a 1.0 mm thick gel and run 
alongside a lane containing broad-ranged Precision Plus Protein Standards (BIO-RAD, Hercules, 
CA, USA) in 1× Tris-glycine running buffer [0.1% (w/v) SDS, 14.3 g/L glycine, and 3.0 g/L 
Trizma-base]. The gel was run at 20 A per gel for about 90 min and stained for 25 minutes in 
GelCode Blue Safe Protein Stain (Thermo Fisher Scientific) and de-stained in milli-Q water on a 
77 
 
see-saw shaker with regular change of the milli-Q water after every 20 minutes until bands visibly 
appeared. Gel documentation was performed by scanning, using a colour imager (GT-7600U, 
Epson).  
 
2.16.3 Preparation of inner membrane-rich fraction 
 
Membrane samples were prepared following a method similar to the one described by Kido et al. 
(2010) with some modification. Briefly, glycerol stock of NHis6SUMO-TAO-pET101/FN102 was 
streaked onto an LB plate containing 100 µg/mL carbenicillin, 50 µg/mL Kanamycin, and 50 
µg/mL ALA (aminolevulinic acid) using a sterilized platinum rod spreader under sterile 
conditions. The plates were then incubated at 37 °C overnight. From the many colonies that 
appeared, a single colony of the strain (FN102) carrying the cDNA for T. b. brucei full-length or 
∆MTS TAO was used to prepare a pre-culture in 100 mL of Luria Broth medium containing 10 
mg carbenicillin, 5 mg kanamycin, and 5 mg 5-aminolevulinic acid (ALA) for 5 – 6 hours at 37 
°C in a shaking incubator at 250 rpm for maximum aeration.  
 
When the optical density (OD600) was about 0.6, the pre-culture was transferred to centrifuge 
tubes. The tubes were centrifuged at 8000 rpm for 3 minutes at 4 °C. The supernatant was 
discarded and the pellets were re-suspended with 20 mL of fresh culture media, and then 
centrifuged at 8000 rpm at 4 °C for 3 minutes. This wash process was repeated 2 more times to 
remove residual 5-aminolevulinic acid in the pellets. The pellets were aerobically grown on a 
larger scale at 30 °C in a total volume of 6 L of S-medium containing, 0.2% (w/v) glucose, 50 g 
tryptone peptone, 25 g casamino acid, 25 g yeast extract, 15 g KH2PO4, 52 g K2HPO4, 12.5 g 
(NH4)2SO4, 3.25 g trisodium-citrate.2H2O, 0.25 g MgSO4·7H2O, 0.125 g FeCl3, 0.125 g 
FeSO4·7H2O, 0.5 g carbenicillin, and 0.25 g Kanamycin. The 600 mL of the prepared culture was 
dispensed into 10 flasks for maximum aeration and growth. The initial OD600 of the culture was 
0.02.  
 
Expression of soluble and active TAO was made possible by induction with 25 µM of the 
inducer, isopropyl β-D-thiogalactopyranoside (IPTG) when optical density at 600 nm (OD600) 
reached 0.3, and post-induction growth was for 12 hours at 20 °C, after which the cells were 
harvested by centrifugation at 8000 rpm at 4 ºC for 5 minutes. Pellets were re-suspended in 50 
mM Tris–HCl (pH 7.5) containing 0.1 mM phenylmethane sulfonyl fluoride (PMSF), 40% (w/w) 
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sucrose, and protease inhibitor cocktail (Sigma). The cells were broken by a French press with a 
pressure of 150 - 200 megapascal. Unbroken cells were removed by centrifugation at 8000 ×g for 
10 minutes in a Beckman Optima, L-90K ultracentrifuge (USA). Inner membranes of 
NHis6SUMO-TAO-pET101/FN102 were fractionated in 40% sucrose after ultracentrifugation at 
200,000 ×g for 1 hour at 4 °C in a Beckman Optima, L-90K (30 mL of 20% sucrose lysate was 
overlaid on 30 mL of 50 mM Tris–HCl pH 7.5 containing 40% (w/w) sucrose per ultracentrifuge 
tube). The buoyant rich inner membranes were fractionated and the inner membrane pellets was 
separated by further ultracentrifugation at 200,000 ×g for 1 hour (Beckman Optima, L-90K, 
USA). The brown coloured inner membrane pellet was re-suspended in 50 mM Tris–HCl (pH 
7.5) containing 20% (w/w) sucrose. 
 
2.16.4 Membrane solubilisation 
 
The buoyant rich inner membranes were treated with solubilisation buffer (6 mg/mL protein in 50 
mM Tris-HCl, 14% (w/v) n-octyl-β-D-glucopyranoside (OG), 2 M MgSO4.7H2O, 20% (v/v) 
glycerol, pH 7.3) at 4 °C (in the cold room); the membrane sample was maintained at 4 ºC 
throughout the solubilisation process. The solubilized membranes were ultracentrifuged at 42,000 
rpm for 1 hour at 4 °C. The total protein content and the quinol oxidase activities of the samples 
were determined at various stages i.e. before centrifugation, in the supernatant, and in the pellet. 
 
2.16.5 Purification of recombinant TAO 
 
Purification of rTAO was done by means of a hybrid batch/column procedure using TALON 
metal affinity resin containing Co2+ metal ion which has a strong affinity for/interacts and binds to 
the histidine tag on SUMO-TAO. This was carried out according to the manufacturer's 
instruction. Briefly, 4 mL of TALON metal affinity resin was equilibrated in a batch set-up with 
100 mL of equilibration buffer (50 mM Tris–HCl containing 20% (v/v) glycerol, 1.4% (w/v) OG, 
0.1 mM MgSO4, pH 7.3). OG extract (20 ml) was mixed with the TALON resin for 20 minutes at 
4 °C. The resin was washed twice with 100 mL of wash buffer containing a low concentration of 
imidazole (0.1 mM imidazole , 20 mM Tris–HCl, 0.04% (w/v) n-dodecyl-β-D-maltopyranoside 
(DM), 20% (v/v) glycerol, 50 mM MgSO4, pH 7.3) and the resin-bound rTAO was transferred to 
a column for additional washing with 20 mL of second wash buffer (20 mM Tris–HCl, 0.1 mM 
imidazole, 0.04% (w/v) DM, 50 mM MgSO4, 20% (v/v) glycerol pH 7.3; flow rate 1 mL/min) and 
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protein elution. Finally, rTAO was eluted with elution buffer containing a higher amount of 
imidazole (80 mM imidazole, 20 mM Tris–HCl, 0.04% (w/v) DM, 160 mM NaCl, 50 mM 
MgSO4, 20% (v/v) glycerol pH 7.3; at a flow rate of 1 mL/min). Fractions (2 mL each) were 
collected in the cold room. 
 
2.16.6 Preparation of Ubiquinol-1 (UQ1H2) from Ubiquinone-1 (UQ1) 
 
The quality of Ubiquinol-1 [2,3-Dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinol] is 
critical to the overall study of TAO kinetics. This is due to the ability of ubiquinol-1 to quickly re-
oxidize to either the partially reduced (semiquinone or ubisemiquinone) form, or the fully 
oxidized (ubiquinone) in the presence of molecular oxygen. Because of this, the following 
procedure was carefully followed with all precautions duly observed. 
 
Three bottles of UQ1 [2,3-Dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone] 
corresponding to 10 mg/bottle were emptied into 3 mL of absolute ethanol, then transferred to a 
separating funnel containing 15 mL of a 0.25 M sucrose, 0.1 M sodium phosphate buffer (pH 
7.5). This was followed by the addition of 2 mL of the first separating solvent, cyclohexane, the 
mixture was subjected to N2 (g) bubbling. An equal volume of the second separating solvent, 
ethanol (2 mL) was added to the mixture and transferred to a clamped separating funnel. This was 
followed by the addition of 1 spatula of the reducing agent Dithionite, and the separating funnel 
with its content was subjected to N2 flushing. The mixture was vigorously mixed until the hexane 
part became clear, and a phase separation appeared in ~ 2 – 3 minutes. After the lower phase 
(ethanol phase) had been let down the funnel, the upper phase (hexane phase) was collected with 
a Pasteur pipette into a pre-weighed (W1) clean 20 mL Pyrex Eggplant type flask. 
 
Because the ubiquinol (UQ1H2) produced would still be trapped in the aqueous phase, and to 
exhaustibly extract the UQ1H2, the ethanol phase was returned to the separating funnel after 
which 2 mL of fresh hexane was added to it, and it was mixed vigorously and left until a phase 
separation appeared. The hexane phase was collected and added to that previously collected in the 
pre-weighed (W1) clean 20 mL Pyrex Eggplant type flask followed by N2 flushing. This process 
was repeated three more times to exhaustibly extract the trapped UQ1H2. The content of the Pyrex 
Eggplant type flask (UQ1H2 in hexane) was vacuum dried in a rotary evaporator set at 40 °C until 
the content became syrupy and there was no more hexane left. The flask was re-weighed (W2) 
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and the weight of UQ1H2 was calculated as W2 – W1. This was followed by the addition of 2 mL 
acidified ethanol (1% hydrochloric acid in ethanol) to recover the ubiquinol from the flask. The 
concentration was determined spectrophotometrically at 290 nM after which the 
spectrophotometric values were fitted to Beer-Lambert’s law using an extinction coefficient of 5.0 
mM-1.cm-1. 
Aliquots were made in 5 mL amber bottles, and were deoxygenated with N2 flushing and were 
stored at -20 °C until required. 
 
2.16.7 Ubiquinol oxidase/TAO inhibitory assay 
 
The Ubiquinol oxidase activity of purified TAO was measured by recording the absorbance 
change of ubiquinol-1 at 278 nm on a double beam-dual wavelength spectrophotometer 
(Shimadzu spectrophotometer UV-3000, Japan) over 2 minutes. Reactions were initiated by the 
addition of ubiquinol-1 (ε278=15,000 M−1 cm−1) after 2 min of pre-incubation at 25 °C in the 
presence of rTAO and 50 mM Tris–HCl (pH 7.4) in a total reaction volume of 1 mL. For TAO 
kinetics/inhibitor assays, the reaction was initiated by the addition of varying concentration of 
ubiquinol-1 after 2 min pre-incubation at 25 °C in the presence of fixed amounts of rTAO and 
varying concentrations of Ubiquinol-1 and the inhibitor, all in a 50 mM Tris–HCl (pH 7.4) buffer 
containing 0.05%(w/v) octaethylene glycol-monododecylether detergent. 
 
2.17 Surface Plasmon Resonance binding analysis of enzyme-inhibitor complex 
 
Surface plasmon resonance (SPR) binding experiments were performed in order to study the 
molecular interactions between the inhibitors and the TAO enzyme, according to the method 
described by Drescher et al. 2009. Briefly, the test compounds were in the mobile phase and the 
recombinant TAO was fixed on a thin gold film. In the experiment, recombinant TAO was 
immobilized by an amine-coupling reaction onto a sensor chip (Biacore, Piscataway, NJ, USA) 
and was inserted into the flow chamber of the Biacore T200 (Biacore, Uppsala, Sweden). 
Addition of the flow-through analyte (the test compound) to the chamber resulted in the binding 
of the compound to the immobilized recombinant TAO, thereby producing a change in refractive 
index at the gold surface which was then quantified with precision. The sensorgram obtained was 
fitted to a 1:1 binding model, and the binding affinities were obtained from the ratio of rate 
constants, producing a rather straightforward characterization of the rTAO-inhibitor interaction. 
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Chapter 3: Isolation of anti-parasitic compounds from 
Nigerian medicinal plants. 
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3.1 Introduction  
 
African trypanosomiasis and Leishmaniasis as a global health challenge is compounded by the 
lack of vaccines, making chemotherapy the only suitable alternative at the moment (La Greca and 
Magez, 2011). In addition, existing antiparasitic drugs are hampered by toxic side effects and the 
emergence of resistance (Delespaux and De Koning, 2007; Fairlamb et al., 2016). However, 
natural products have been identified as highly promising starting points for the discovery of anti-
protozoan agents (e.g. Salem and Werbovetz, 2006; Omar et al., 2016; Siheri et al., 2016; Dike et 
al., 2016), and indeed have a long and distinguished history as essential drugs in the fight against 
tropical disease (e. g. Tu  2011). Indeed, over the period 1981-2002, 61% of all new chemical 
entities approved for infectious diseases were natural compounds or directly derived thereof 
(Newman et al., 2003).  
 
Natural products derived from plants have played an important role in the control of diseases 
caused by the protozoal parasites, a classical example is malaria caused by Plasmodium 
falciparum. Current malaria treatment relies heavily on plant-derived products, including the 
sesquiterpene lactone artemisinin (Wells, 2011), and the alkaloid quinine (Moyo et al., 2016). The 
success stories of artemisinin, isolated from the Chinese wormwood plant (Artemisia annua) and 
of quinine, isolated from the bark of cinchona trees (Cinchona officinalis), both used traditionally 
as antimalarial therapies, justify drug discovery based on ethnopharmacological usage, as these 
drugs were discovered following an intensive screening of hundreds of plants traditionally used 
for treating malaria (Tu, 2011).These achievements notwithstanding, unfortunately, fewer efforts 
have been put into investigating extracts from various plants traditionally used for treating the 
kinetoplastid diseases like trypanosomiasis and leishmaniasis despite the undesirable side effects 
and effectiveness of the currently available drugs.  
 
Centrosema pubescens, Moringa oleifera, Tridax procumbens, Polyalthia longifolia, Newbouldia 
laevis, and Eucalyptus maculata (Appendix A) thrive well in Nigeria where they grow in the wild 
except for Moringa oleifera, which is cultivated for food and for medicinal use. Newbouldia 
laevis is mostly used in northern Nigeria for boundary demarcation, while Polyalthia longifolia 
commonly called ‘‘mast tree’’ is used as an ornamental plant. These plants (studied in this work) 
are highly valued and are also used for treating various infections caused by the protozoan 
parasites including species of Trypanosoma, Leishmania, and Plasmodium, especially the strains 
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that resists existing chemotypes (Alli et al., 2011; Abubakar et al., 2012; Nwodo et al., 2015; 
Bankole et al., 2016). Because these plants grow on many soil types, are abundant in the wild, and 
only their leaves are used, their utilization as herbal remedies pose no danger to biodiversity. 
 
The development of an effective chemotherapy based on a local resource will ensure new drugs 
that will combat existing problems of drug resistance and toxicity and provide additional 
economic driver for famers, thus increasing economic activity and contributing to a reduction in 
poverty in resource poor communities where these diseases affect man and livestock. Hence, in 
this study, we investigate the potentials of selected herbs traditionally used for treating infections 
caused by trypanosomatid parasites in northern Nigeria. 
 
Although leaves from the various plant species studied herein are traditionally used in northern 
Nigeria against various protozoan infections, but unfortunately none of the herbal preparations 
from these plants have been standardized for use, nor extensively investigated for their toxicity on 
mammalian cells, and their activity against protozoan parasites has not been scientifically 
validated. In search of improved and non-toxic active antiprotozoal principles that are not cross-
resistant with current anti-parasitics, the results of the in vitro screening of extracts from seven 
selected medicinal plant species used traditionally to treat kinetoplastid infections in Nigeria, and 
the isolation of their bioactive principles is reported, with the aim of investigating the efficacies of 
the medicinal plant extracts, and of compounds isolated therefrom, against kinetoplastid parasites, 
assess cross-resistance to existing chemotherapy, and assay their toxicity against mammalian cells 
in vitro. 
In order to achieve this aim, plants used locally to treat trypanosomiasis and other tropical fevers 
were obtained and extracted with hexane, ethyl acetate and methanol. Active principles were 
isolated by bioassay-led fractionation, testing for trypanocidal activity, and identified using NMR 
and mass spectrometry. EC50 values for their activity against wild-type and multi-drug resistant 
Trypanosoma brucei were obtained using the fluorescent viability indicator dye resazurin. The 
results are presented below. 
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3.2 Results  
 
3.2.1 Antitrypanocidal activity and cross resistance studies of extracts using wild type and 
the multi-drug resistant strains of T. brucei. 
 
A total of 21 dried extracts from the leaves of the seven plants studied in this work were screened 
against protozoan parasites. Extracts were selected for further purification according to a slightly 
modified version of the protocol of Dua et al. 2011. The trypanocidal activity of the primary 
extracts was tested at a starting concentration of 400 µg/mL. None of the methanol fractions 
showed measureable activity, probably because all the active ingredients had already been 
extracted by the earlier hexane and ethyl acetate washes. Another notable observation was that 
most of the extracts did not show reduced activity against the multi-drug resistant strain B48, and 
are therefore not cross-resistant with first-line trypanosomiasis drugs such as pentamidine, 
melarsoprol, diminazene and Cymelarsan. The one exception was the hexane extract of plant A, 
which was in fact significantly more active against B48 (P<0.001; Fig. 3.1). 
 
The trypanocidal activities of the hexane (H) and ethyl acetate (E) extracts with EC50 values <100 
µM are depicted in Figure 3.1, and a full list is given in Table 3. 1. Of particular interest were 
those with an EC50 value below 15 µg/mL, being the hexane extract of plant D (HDK-DH, 2.4 ± 
0.1 µg/mL), and the ethyl acetate extracts of plants E (HDK-EE. 4.2 ± 0.7 µg/mL) and F (HDK-
FE, 12.3 ± 0.3 µg/mL); these were selected for further purification.  
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Figure 3.1 Drug sensitivity assays with medicinal plant extracts against T. brucei s427WT and B48 
cell lines following 72 hours of exposures to extracts. The figure shows all the EC50 values from 
hexane (H), ethyl acetate (E) and methanol (M) extracts that could be obtained using the protocol 
described in the Methods section. When not shown the EC50 value was >400 µg/mL, which is equal to the 
highest concentration on the plate. The hexane fraction of Centrosema pubescens (HDK-AH) was more 
active against multi-drug resistant strain B48 than against wild type s427; no other significant differences 
(p<0.05) between the two strains were observed. Bars represent the average EC50 values and SEM of at 
least three independent determinations. *** P<0.001 by Student’s unpaired t-test. The dotted line identifies 
the fractions with EC50 values ≤15 µg/ml. 
 
3.2.2 In vitro selectivity of extracts: therapeutic index relative to Human Embryonic Kidney 
cells  
 
All 21 crude extracts from the seven medicinal plants were tested on Human Embryonic Kidney 
(HEK) 293-T cells in vitro, using a modified, and more sensitive, resazurin assay, involving a 
total incubation period of 78 hours. The result showed that at high doses extracts HDK-CH, 
HDK-DH, HDK-EE, and HDK-FH displayed a cytostatic, rather than cytotoxic, activity against 
HEK cells (EC50 <100 µg/ml), whereas other extracts displayed less toxicity (Table 3.1). Indeed, 
no EC50 value could be obtained for 11 out of 21 extracts, using a top concentration of 400 
µg/mL. The selectivity index (SI), defined as the in vitro EC50 value of the extract against the host 
cell divided by the EC50 value against the target cell, reached >20 but could not be determined 
where either EC50 value could not be obtained due to either low efficacy or low toxicity.  
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Table 3.1 EC50 value, Resistance Factor (RF) and Selectivity Index (SI) of crude ethyl acetate (E), Hexane 
(H), and methanol (M) extracts from seven Nigerian medicinal plants. 
Fractions T. b. s427 WT  
       (µg/mL) 
T. b. B48 
(µg/mL) 
   RF HEK (293T) 
cells (µg/mL) 
SI 
HDK-AE 92.2 ± 2.1 ND ND       >500 >5.4 
HDK-AH 74.3 ± 4.2 40.3 ± 2.1 0.543 386 ± 24 5.2 
HDK-AM 233 ± 11 ND ND       >500 >2 
HDK-BE 71.5 ± 8.0 67.3 ± 2.4 0.94 492 ± 37 6.9 
HDK-BH 41.0 ± 1.9 42.6 ± 6.2 1.04        >500 >12 
HDK-BM        >250 ND ND        >500 ≥2 
HDK-CE 50.1 ± 5.2 60.8 ± 0.5 1.22 198 ± 12 4.0 
HDK-CH 22.0 ± 2.6 27.1 ± 0.8 1.23 80.0 ± 17 3.6 
HDK-CM      222 ± 5 ND ND        >500 >2 
HDK-DE 15.2 ± 1.0 16.9 ± 0.2 1.11      114 ± 3 7.5 
HDK-DH 2.4 ± 0.1 6.8 ± 0.1 2.93 50.9 ± 2.2 21.6 
HDK-DM 129 ± 18 ND ND >500 >3.9 
HDK-EE 4.2 ± 0.7 5.4 ± 0.1 1.28 56.2 ± 1.9 13.3 
HDK-EH 98.5 ± 1.1 ND ND >500 >5 
HDK-EM 150 ± 10 ND ND >500 >3.3 
HDK-FE 12.3 ± 0.3 12.0 ± 0.1 0.98 246 ± 17 20.1 
HDK-FH 18.4 ± 0.1 25.4 ± 0.5 1.383 86.9 ± 9.9 4.7 
HDK-FM 141 ± 16 ND ND >500 >2.8 
HDK-GE >500 ND ND 378 ± 17 <1 
HDK-GH >500 ND ND         >500 ND 
HDK-GM >500 ND ND         >500 ND 
Pentamidine 3.4 ± 0.51 1040 ±1801 305 ND ND 
PAO2 ND ND ND     118 ± 61 ND 
 
Results were expressed as average EC50 of at least three independent determinations. Extracts 
HDK-CH, HDK-DH, HDK-EE, and HDK-FH were cytostatic rather than cytotoxic at high doses on HEK 
cells. Values are average of EC50 values of 4 independent determinations, expressed in µg/mL. 1EC50 
values for pentamidine and PAO are given in nM. 2PAO, phenylarsine oxide. 3P<0.001, Student’s unpaired 
t-test, comparing WT and B48. ND, not determined. 
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3.2.3 Anti-Leishmanial activity of the primary plant extracts  
 
In order to determine the in vitro anti-leishmania activity of extracts from the selected plants, the 
extracts were tested on Leishmanial mexicana (M379) promastigotes (Fig. 3.2). The result 
revealed that hexane extracts from Tridax procumbens and Polyalthia longifolia (HDK-CH and 
HDK-DH) gave the best activity against L. mexicana in vitro (EC50 values of 16.8 and 17.2 
µg/mL respectively), while hexane extracts from Moringa oleifera (HDK-BH), Newbouldia laevis 
(HDK-EH), Eucalyptus maculata (HDK-FH), and ethyl acetate fractions of Tridax procumbens 
(HDK-CH) and Polyalthia longifolia (HDK-DH) all displayed moderate anti-leishmanial activity 
in vitro (EC50 50-70 µg/mL). Extracts not included in figure 3.2 were inactive against L. mexicana 
under our experimental condition. There is only moderate correlation between the antileishmanial 
and antitrypanosomal activities of these extracts, but, importantly, extract HDK-DH displayed the 
strongest activity against both of the parasites.  
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Figure 3.2 Effect of Nigerian plant extracts on L. mexicana promastigotes using a top/starting 
concentration of 400 µg/ml. The data shown are the average EC50 ± SEM of three separate experiments. 
Inset:  pentamidine (PMD), a standard drug, was used as internal control. 
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3.2.4 Bioactivity-guided isolation of the active constituents from extracts 
 
Between 150 - 200 fractions were collected from the column for each extract selected for 
fractionation, and the isolation of active compound was guided by the activity of each fraction. 
Progress of purification was monitored with NMR and mass spectrometric techniques. 
After column chromatography the HDK-DH crude extracts yielded a fraction that was very active 
against trypanosomes. This was followed by further purification on a Sephadex column, which 
gave a pure and active compound, analyzed by 1H and 13C-NMR (Appendix B). Nuclear 
Overhauser Experiments, HMBC, HQSC, and COSY were then carried out to determine the exact 
structure and relative stereoisomer. Mass spectrometry was also performed to confirm the 
structure and its purity. The result was a clerodane-type diterpenoid with an alpha,beta-
unsaturated lactone ring in the side chain identified as clerodane (16-α-hydroxy-cleroda-3-13(-
14)-Z-dien-15,16-olide; HDK-20). 
In addition, polyalthialdioc acid (HDK-79) and Kolavenic acid (HDK-52) were also isolated pure 
from other fractions of the crude hexane extract of plant D, Polyalthia longifolia  (Figure 3.3). 
 
 
HDK-20                         HDK- 79                           HDK-52                                HDK-40 
 
Figure 3.3 Anti-kinetoplastid compounds isolated from Polyalthia longifolia (HDK - 20, 79 and 52) 
and Eucalyptus maculata (HDK-40). HDK-20 is 16-α-hyroxy-cleroda-3-13(-14)Z-dien-15,16-olide; HDK-
79 is kolavenic acid; HDK-52 is polyalthiadioc acid; and HDK-40 is 3β,13β-dihydroxy-urs-11-en-28-oic acid. 
 
Fractionation of extract HDK-FE yielded a series of compounds, including triterpenes, aromatics 
(xanthones), cinnamate/chalcone types, aliphatics, and triterpenoids. Some of these were found in 
combination in the fractions, or with other impurities. However, the active fraction on 
trypanosomes was, after chemical analyses, identified as an ursane type triterpenoid (C30H48O4; 
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HDK-40) with a molecular weight of 472.36 g/mol. Signals for seven skeletal methyl groups, of 
which two were doublets and five were singlets, were contained in the 1H-NMR spectrum. The 
presence of 30 carbon atoms in its 13C-NMR, coupled with the signal from the 1H-NMR spectrum 
was suggestive of the fact that this compound was an ursane-type triterpenoid. Furthermore, 
analyses of the 1H-NMR spectrum of this compound revealed two olefinic protons and a 
secondary hydroxyl group whose splitting pattern and chemical shift were characteristic of a 3β-
equatorial hydroxy in the nucleus of a typical ursane-type triterpenoid. 
In addition, two active compounds were identified from the crude extract of HDK-EE. The NMR 
and mass spectrometry analyses revealed them to be pheophytin A and B (HDK-28 and HDK-23 
respectively) with molecular formula C55H74O5N4 and C55H72N4O6 and molecular masses of 870 
and 885.18 g/mol respectively. 
 
3.2.5 Trypanocidal activity of the purified active compounds 
 
The isolated natural compounds were tested on wild-type s427 trypanosomes as well as a panel of 
s427-derived cell lines adapted to high levels of resistance of current and experimental classes of 
trypanocides. B48 is highly resistant to virtually all diamidines and melaminophenyl arsenicals; 
AQP2/3-KO lacks the AQP2/AQP3 genetic locus and is moderately resistant to pentamidine and 
melarsoprol; TbAT1-KO is somewhat resistant to pentamidine and highly resistant to diminazene; 
R0.8 is highly resistant to inhibitors of cAMP phosphodiesterases TbrPDEB1 and B2 (Gould et 
al., 2013), an important class of new therapeutic leads against trypanosomiasis (Shakur et al., 
2011; Gould et al., 2011). The results are presented in the table below. 
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Table 3.2 Comparing the EC50 values of purified natural compounds for the different trypanosomes strains (s427 WT, B48, AQP2/3KO, AQP1-3-KO, 
TbAT1-KO, and R0.8) used in this study. 
Compounds 
s427 WT  B48  AQP2/3-KO 
AQP1-3-KO 
TbAT1-KO 
R0.8 
EC50 
(µg/ml)  
 EC50 
(µg/ml)  RF  t-test 
EC50 
(µg/ml)  RF t-test 
EC50 
(µg/ml)  RF t-test 
EC50 
(µg/ml)  RF t-test 
EC50 
(µg/ml)  RF t-test 
HDK-20 0.38 ± 0.05 0.40 ± 0.005 1.1 0.76 0.42 ± 0.02 1.1 0.53 
0.46 ± 0.02 1.2 
0.23 0.37 ± 0.009 1.0 0.82 0.48 ± 0.01 1.2 0.069 
HDK-23 1.58 ± 0.09 1.86 ± 0.092 1.2 0.092 2.70 ± 0.08 1.7 0.0006 
3.32 ± 0.04 2.1 
2.3E-5 2.43 ± 0.071 1.5 0.0040 2.13 ± 0.24 1.3 0.044 
HDK-28 25.0 ± 2.8 28.8 ± 4.2 1.2 0.46 22.8 ± 0.4 0.9 0.55 
21.59 ± 0.41 0.9 
0.35 26.9 ± 0.71 1.1 0.58 24.3 ± 0.7 0.9 0.70 
HDK-40 1.58 ± 0.03 1.55 ± 0.012 1.0 0.40 1.39 ± 0.16 0.9 0.0046 
1.194 ± 0.11 0.8 
0.024 1.75 ± 0.022 1.1 0.020 1.68 ± 0.01 1.06 0.020 
HDK-52 12.3 ± 0.5 10.1 ± 0.5 0.8 0.026 6.86 ± 0.04 0.6 0.0002 
3.40 ± 0.21 0.3 
1.0E-4 9.64 ± 0.78 0.8 0.029 14.2 ± 0.4 1.1 0.007 
HDK-79 3.57 ± 0.16 5.2 ± 0.4 1.5 0.0059 5.54 ± 0.18 1.6 0.0011 
6.29 ± 0.32 1.8 
0.0024 4.81 ± 0.19 1.3 0.015 4.4 ± 0.3 1.2 0.019 
1PMD (µM) 0.003 ± 0.0004 0.77 ± 0.013 232 1.3E-8 0.046 ± 0.02 15.5 7.8E-6 
0.072 ± 0.0029 24.2 
1.1E-6 0.0074±0.001 2.5 0.0021 0.0072 ± 0.0001 2.3 0.0019 
2DA (µM) 0.23 ± 0.04 2.14 ± 0.24 9.3 4.5E-6 ND -- -- ND -- -- 2.06 ± 0.74 9.0 3.8E-5 ND -- -- 
3NPD-001  
(µM) 
0.029 ± 0.005 ND -- -- ND -- -- ND -- -- ND -- -- 3.53 ± 0.16 122 1.6E-6 
 
Multi-drug resistant strains of T. b. brucei are not cross-resistant with the purified compounds.1PMD = Pentamidine, a known trypanocidal agent; 2DA, diminazene 
aceturate; 3NPD-001 is a trypanocidal phosphodiesterase inhibitor. RF = Resistance factor. An RF value of ~ 1 indicates no prospect for cross resistance; RF value 
well above one indicates possibility of cross resistance; RF value below 1 indicates increased sensitivity. P-values (p<0.05) were calculated using the unpaired 
Student’s t-test. ND, not determined.  
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Compound HDK-20 displayed the highest activity against s427-WT trypanosomes, with an EC50 
value of 0.38 ± 0.05, corresponding to approximately 1 µM. HDK-23, HDK-40 and HDK-79 also 
displayed activity below 5 µg/mL, but the activity of HDK-52 was rather disappointing at 12.3 
µg/mL. HDK20, HDK-79 and HDK-52 are closely related compounds from the same plant, 
Polyalthia longifolia, and most likely metabolites of each other. Clearly, the sidechain appears to 
have a large impact on the trypanocidal activity with the closed β-lactone highly effective; this 
gives a potential starting point for derivatization towards even higher anti-parasitic activity. 
Testing of all purified compounds on our panel of drug resistant trypanosome lines identified only 
minor variations in sensitivity, which although statistically significant in some cases, were always 
well below even a 2-fold difference from EC50 value against the wild-type control (Table 3.2), in 
contrast to very high levels of resistance to the control drugs. As the resistance mechanisms for 
these drug classes are now well understood both in the lab strains here and in field isolates (Graf et 
al., 2003) we can conclude with confidence that the natural compounds reported here are not cross-
resistant with key trypanocide classes such as the diamidines, melaminophenyl arsenicals and PDE 
inhibitors. Indeed, HDK-52 was significantly more active against all the resistant strains of T. 
brucei than the wild type.  
 
3.2.6 Cytotoxicity of the purified compounds 
 
The purified compounds were tested for their effects on human embryonic kidney (HEK) cells, 
using the same protocol as used for the crude extracts, so as to determine whether the antiprotozoal 
activity is the result of general toxicity or is more specifically antiprotozoal. The toxicity assays 
showed that the natural compounds that have an effect on T. brucei have almost no inhibitory 
activity on HEK cell growth and viability. Selectivity indices (SI, EC50 of HEK cells / EC50 of 
parasites) for trypanosomes are not shown as none of the compounds tested were toxic to HEK 
cells at the highest concentration tested (200 µg/mL) (Fig. 4). However, this means that SI values 
range between >8 for HDK-28 and >526 for HDK-20. We conclude that the purification increased 
not only the activity of the plant extracts but also dramatically improved the selectivity of the 
product. 
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Figure 3.4 Cytotoxicity assay of natural compounds on HEK 293-T cells, with 24 h cyto-adherence, 30 
h incubation with drugs, and 24 h with sodium resazurin (alamar blue). None of the isolated 
compounds displayed sigmoidal curves, showing that they were not toxic to mammalian cells at 
concentrations >200 mg/mL after 78 hours of incubation with the test compounds. The experiment shown 
was representative of three independent repeats with identical outcomes. 
 
3.2.7 Activity of Purified compounds against Trypanosoma congolense and Leishmania 
mexicana. 
 
The purified compounds were next tested against T. congolense in order to determine their 
prospects of being developed and used as veterinary drugs to treat animal African trypanosomiasis 
(AAT or nagana), a condition that causes billions of dollars in economic losses in sub-Sharan 
Africa (Giordani et al., 2016). Most of the compounds were somewhat less potent against T. 
congolense than against T. brucei under the assay conditions, but displayed a similar order of 
potency: HDK-20 >> HDK-40 > HDK-52 = HDK-79. In addition, the compounds were tested 
against L. mexicana promastigotes. As for the other two protozoan species, HDK-20 was the most 
potent of the compounds tested, and the order against L. mexicana was HDK-20 >> HDK-52 > 
HDK-40 > HDK-79. Figure 3.5 displays the EC50 values against all three pathogens side-by-side. 
The level of anti-parasite activity for HDK-20 makes this a promising lead compound against 
kinetoplastid pathogens. 
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Figure 3.5 Effects of purified natural compounds against three pathogenic protozoa: bloodstream 
forms of T. brucei s427 and T. congolense strain IL3000, and promastigotes of L. mexicana strain 
M379, using a top/starting concentrations of 200 µg/ml. EC50 values shown are the average and SEM of 
4 independent determinations. 
 
3.3 Discussion 
 
There is an increased interest in the antiprotozoal screening of plant extracts related to traditional 
therapy (Ndjakou Lenta et al., 2007; Osorio et al., 2007) apparently due to their very low toxicity, 
the stability of natural compounds, and their reported reduced prospects for resistance or cross 
resistance to existing drugs (Nour et al., 2009). We report here on the antiprotozoal activity of the 
extracts of seven Nigerian medicinal plants.  
 
Several of the crude ethyl acetate and hexane extracts displayed promising activity, whereas the 
methanol extracts were markedly less active. The low activity of the methanol extracts may simply 
be the result of the plants material already having been extracted with hexane and ethyl acetate, or 
genuinely indicate that the less polar solutes from these plants have the best anti-protozoal activity. 
The polar compounds extracted by methanol generally display less cellular penetration than 
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hydrophobic ones (Orsi and Essex, 2010), and this may contribute to the lack of in vitro anti-
parasite activity.  
 
The extracts of C. pubescens, M. oleifera, T. procumbens and J. tanjorensis (plants A, B, C and G, 
respectively) did not display any significant in vitro anti-trypanosomal activity under our 
experimental design. However, these plants may contain compounds with other anti-protozoal or 
antibacterial activities, for which we did not test in the current study. Furthermore, the plants may 
in fact contain anti-trypanosomal compounds, but perhaps only in low amounts at the time of 
gathering the material. It must also be remembered that in the traditional usage the plant 
preparations are taken orally and may be activated in vivo.  
 
It has previously been reported that Nigerian medicinal plants contain active anti-parasite 
constituents (Ene et al., 2014; Igoli et al., 2011). However, the plants that we report on here have 
not previously been investigated for their anti-kinetoplastid activities, nor have their active 
compounds been identified before now. The only exception is a report that methanol extracts of P. 
longifolia leaves (our plant D) inhibit the growth of L. donovani promastigotes, with an IC50 value 
of 4.18 µg/mL (Pal et al., 2011). In our screens, too, P. longifolia displayed the most promising 
anti-leishmanial activity, with the crude hexane extract displaying a similar IC50 against L. 
mexicana promastigotes. P. longifolia leaf extracts have also been reported to possess activity 
against pathogenic fungi such as Candida albicans, and against gram-positive bacteria, particularly 
Staphylococcus aureus, but not against gram-negative strains (Chanda and Nair, 2010).  
 
The second-most promising medicinal plant in our study was E. maculata (plant F), with both the 
ethyl acetate and hexane extracts displaying anti-trypanosomal EC50 values below 20 µg/mL; this 
was apparently attributable to the presence of the ursane type triterpene HDK-40, isolated from the 
ethyl acetate extract. Several previous studies reported anti-infectious activities of Eucalyptus 
species. Extracts of E. maculata leaves with methanol-dichloromethane were previously shown to 
have activity against gram-positive bacteria (Takahashi et al., 2004). Extracts from E. sideroxylon 
and E. torquata similarly displayed activity against gram-positive bacteria, and some fungi 
(Ashour, 2008), and, the ethyl acetate fraction from E. camaldulensis displayed a 100% growth 
inhibition against the protozoan Trichomonas vaginalis in vitro at a concentration of 12.5 mg/mL 
(Hassani et al., 2013).  
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Extracts of N. laevis (plant E) have been reported to exercise anti-diabetic (ethanolic extract of 
leaves; Kolawole and Akanji, 2013), bactericidal (methanolic leaf extract; Usman and Osuji, 2007), 
analgesic and anti-inflammatory (ethanolic flower extract; Usman et al., 2008) activities but we are 
not aware of any studies regarding their anti-protozoan activities. Here, we report the anti-
kinetoplastid activity of N. laevis and attribute its activities to the presence of pheophytin, a 
compound that was previously isolated from Loniera hypoglauca in a screen for activity against 
hepatitis C virus, and was shown to inhibit its NC3 serine protease (Wang et al., 2009). We found 
both pheophytin A and B to exhibit a good level of anti-trypanosomal activity, but pheophytin B 
was approximately 15-fold more potent than pheophytin A.  
 
Our initial NMR data revealed the presence of some common classes of active compounds in these 
plants under study, including terpenoids, aromatics, and pheophytins (Salem and Werbovetz, 2006; 
Wink, 2012). We attribute the remarkable anti-kinetoplastid activity of Polyalthia longifolia 
extracts and their isolated compounds observed in this study to the presence of clerodane 
diterpenes, of which the closed lactone form, HDK-20, was more active against the kinetoplastids 
than the aldehyde or carboxylic acid moieties on the scaffold. HDK-20 and HDK-79 have 
previously been described in extracts of P. longifolia, with antifeedant (Phadnis et al., 1988) and 
anti-inflammatory properties (inhibition of NO production by macrophages; Wu et al., 2014). 
 
Wink (2008) reported that lipophilic secondary metabolites like the terpenoids have detergent-like 
properties which can disrupt biological membranes, alter their fluidity and inhibit the function of 
membrane proteins, including those involved in cellular signaling and transport. Although, we 
observed no major differences in activity against our cell lines with altered drug transport (B48, 
AQP2/3-KO, AT1-KO) or cAMP signaling (R0.8), HDK-52 consistently displayed a significantly 
higher activity against transporter mutants than against the wild-type, a situation that was reversed 
for HDK-79, and both were somewhat less effective against clone R0.8 as well. However, we do 
not propose that chemical disruption of the lipid bilayer can be the main mode of action of these 
compounds, as this would fail to explain the considerable selectivity vis-à-vis the Leishmania 
mexicana or human cells. 
 
The active principles isolated in this work could be potentially developed to treat either human or 
animal African trypanosomiasis (HAT and AAT, respectively). Whereas HAT, commonly known 
as sleeping sickness, is a devastating, fatal disease, its disease burden is steadily declining (Simarro 
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et al., 2015) while AAT continues to cause huge economic losses, and places serious limitations on 
agriculture in sub-Saharan Africa – not just for cattle rearing (beef, dairy) but also for draught 
power for ploughs, carts, etc. The main AAT pathogens are Trypanosoma congolense and 
Trypanosoma vivax (Giordani et al., 2016), and we therefore also tested some of the active 
principles on in vitro cultures of T. congolense. Interestingly, the same order of potency for these 
compounds applied for both T. brucei and T. congolense, with HDK-20 again being by far the most 
active agent. Together with the similarly potent activities against multi-drug resistant trypanosome 
lines, this appears to indicate that the clerodane diterpenes may have general utility against African 
trypanosomes. This is important, as African livestock may be infected by any of several 
Trypanosoma species and any drug must be able to act on all of them, as identification of (sub)-
species for individual animals is currently impracticable. Although the bio-assay fractionation was 
guided by activity against T. brucei, the extracts and their isolated compounds were also tested on 
L. mexicana, as the plants are considered to have broad activity against protozoan infections. The 
anti-Leishmania efficacy of some of these plants (hexane extracts of T. procumbens and P. 
longifolia) and their purified compounds (HDK-20), affirms their continuous use in folkloric 
medicine, and we propose that at least some of the plants are good prospects for new drugs against 
kinetoplastid diseases. 
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    Chapter 4: Investigations into the mode of action of natural     
     compounds against T. brucei. 
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4.1 Introduction 
 
Medicinal chemists have been able to synthesize a good number of synthetic chemo-types, which 
are being used for treating many but by no means all protozoan parasites. A particular problem 
remains with drugs against parasites causing the ‘neglected tropical diseases’. One of the major 
problems is that the most of these drugs are old, causing parasitic strains to become resistant to 
these drugs (Rodenko et al., 2015). Unfortunately, the development of new and efficient anti-
protozoan drugs has not received much attention or funding from the pharmaceutical industry for 
the reason that most of these diseases occur in resource-poor communities where the people 
suffering from these diseases cannot afford to pay for the high price of the drugs, but rely heavily 
on subsidized or donated drugs (Wink, 2012). Consequently, investing in drug development against 
especially tropical parasitic diseases is rather a risky venture. The search for anti-parasitics from 
natural sources especially from secondary metabolites derived from plants is a good alternative to 
synthetic drugs considering that medicinal plants have been used for centuries for treating 
infectious diseases.  
 
Medicinal plants are a rich source of drug candidates and leads, and like synthetic compounds, 
could be exploited as anti-protozoan agents that could solve the present problem of drugs’ 
inefficiencies (Schmidt et al., 2012; Wink, 2012). Some of the drugs in use today for tropical 
infections were originally from plant materials previously used for treating these same infections, 
which account for their long usage as traditional herbal remedies (Maya et al., 2007). The success 
story of the alkaloid artemisinin, isolated from the Chinese anti-malarial wormwood plant 
(Artemisia annua), and quinine from the bark of cinchona trees (Cinchona officinalis) are classic 
examples (Willcox, 2011). Several plant-derived natural products from diverse structural classes 
including various flavonoids, alkaloids, quinonoids and terpenoids have been studied as anti-
kinetoplastid candidates against some parasite, sometimes targeting specific metabolic pathways 
such as nucleic acid biosynthesis, biomembranes, and cytoskeletal proteins and enzymes (Wink, 
2007). 
 
Natural products have played a significant role in the development of new chemotherapies. For 
instance in the years 1981 to 2006, 1,184 new drugs were developed and registered for use, out of 
which 28% were of natural origin. Another 24% of all the new drugs registered within this period 
had functional groups with pharmacological activity (pharmacophores) derived from natural 
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products (Newman and Cragg, 2007). Therefore, a good starting point  for drug discovery, and in 
particular to find anti-parasitic natural lead compounds would be traditional medicinal plants, such 
as those from Nigeria, that have been used to treat various types of infectious diseases. Although 
there have been many promising developments to identify leads against tropical protozoan parasites 
using various plant extracts the translation of these results into actual drug candidates has not 
occurred. In most cases the active principles of these plant extracts remain unknown due to a lack 
of research facilities and funding. Moreover, the specific mechanism of action of these reported 
bioactive extracts or bioactive principle is rarely determined if at all [e.g., triptolide; curcumin 
(Corson and Crews, 2007)]. However, a comprehensive understanding of the interaction of a drug 
lead with its molecular target is especially helpful for the process of drug development, for the 
reason that it allows the use of medicinal chemistry approaches for optimization, and in some cases 
a more suitable clinical trial design. This is crucial to the development of new and efficient 
chemotherapy that will replace the current inefficient ones.  
 
Using in vitro models of Trypanosoma brucei, ethnopharmacological/bioassay guided fractionation 
approach was used towards the identification of new lead compounds and evaluate their potency, 
based on extracts from traditional medicinal plants from Nigeria. We have shown (see chapter 
three) that neither the crude extracts, nor the active compounds isolated from them, are toxic to 
human cells. However, promising activity was found against a drug sensitive wild type strain of 
Trypanosoma brucei (s427-WT) and a multi-drug resistant strain, B48, which lacks both the 
TbAT1/P2 transporter and the high affinity pentamidine transporter (HAPT). Therefore this chapter 
reports the mode-of-action of two of the most promising isolated compounds (16α-hydroxycleroda-
3,13(14)Z-dien-15,16-olide [HDK20; figure 4.1(A)], and 3β,13β-dihydroxy-urs-11-en-28-oic acid 
[HDK40; figure 4.1(B)] on T. brucei.  
                                  
                 EC50 = 0.38 µg/mL                                                    EC50 = 1.58 µg/mL 
 
 Figure 4.1 Structure of 16α-hydroxycleroda-3,13(14)Z-dien-15,16-olide, HDK20 (A), and 3β,13β-            
dihydroxy-urs-11-en-28-oic acid, HDK40 (B), and their in vitro EC50 against trypomastigotes of T.  b. brucei. 
B A 
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4.2 Results 
 
4.2.1 Effect of different concentrations of HDK20 and HDK40 on the growth of bloodstream 
form T. brucei brucei WT following long and limited exposures. 
 
The effect of test compounds HDK20 and HDK40 on trypanosome (s427 WT) proliferation was 
studied after exposure of a limited duration. For some drugs like the diamidines (i.e. pentamidine) 
trypanosomes need only to be exposed for a short period (1-3 hours); although this drug acts very 
slowly, cell death does occur hours after the exposure would have ceased (Barrett et al., 2007). This 
means that its early effects are irreversible and trypanosomes will not recover once this effect is 
initiated. For the translation into in vivo activity, a short minimum exposure time for a drug is 
desirable and may reduce potential toxic effects associated with keeping compounds at peak 
circulation levels for longer. Obviously pharmacological data is crucial in the assessment of 
potential trypanocides, with key implications for any course of therapy. 
Consequently, the effects of limited exposure of trypanosomes to the test compounds were carried 
out. 
The initial seeding density was 2 × 105 cells/mL, the cells were treated with the appropriate test 
compound concentrations (Figure 4.2 panel B and D) except for the drug-free control. The cultures 
were first incubated at 37 ºC and 5% CO2 for a brief period of 1 hour, after which the cells were 
washed with fresh media by centrifuging at 2400 rpm, re-seeded (2 × 105 cells/mL) in fresh HMI-9 
media, and samples were taken and counted at each time point. The counting was performed in 
triplicate and the average values obtained were plotted against time using GraphPad prism 5 
software. 
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Figure 4.2 Growth curve assays of HDK20 and HDK40 treated cells: Growth curve of T. brucei wild-type 
s427 grown in the continuous presence of HDK20 or HDK40 at indicated concentrations, or untreated (no 
drug) (panels A and C respectively); and growth curve showing the effect of test compounds on 
trypanosome proliferation after a limited exposure (1 hour) to the same concentrations of HDK20 and 
HDK40 (Panels B and D respectively). Seeding density was 2 x 105 cells/mL, incubations were at 37 ºC and 
5% CO2. In panels B and D, the cells were treated with the appropriate concentrations, the cells were 
washed with fresh media by centrifuging at 2400 rpm after 1 hours of exposure and were re-seeded at 2 x 
105 cells/mL in fresh HMI-9 media, and samples were taken and counted at each time point. Microscopic cell 
counts were performed in triplicate using a haemocytometer, and the values obtained were plotted against 
time using GraphPad Prism 5 software. 
 
The result shows that the growth pattern of cells with long time exposure were similar to those with 
limited exposure to HDK20 (Fig. 4.2). However, the time to achieve a complete clearance of 
trypanosomes from the culture was somewhat extended for this test compound at 0.8 µg/mL. For 
HDK40, the compound seemed rapidly trypanocidal in the continuous presence of the two higher 
concentrations, but following the wash after 1 h, the effect appeared to be a long-term growth 
arrest. 
These results show that, over the duration of this experiment, the effects of HDK20 and HDK40 on 
trypanosomes are irreversible after a limited exposure time (1 h).  
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4.2.2 Monitoring the speed of action (Time to kill) of HDK20 and HDK40 on Trypanosomes 
by using a propidium iodide based assay. 
 
The rationale for this assay is to examine the speed of action of the test compounds (HDK20 and 
HDK40) on wild type trypanosomes in real time. The principle of the assay is that cells become 
fluorescent as propidium iodide (PI) begins to enter them and become bound to nucleic acids. As PI 
is not taken up by intact T. brucei, this can only occur when the plasma membrane is breached as a 
result of loss of cellular integrity. Correspondingly, the effects of varying concentrations of the test 
compounds on the cell viability or membrane permeabilization were monitored over a 6-hour 
period. 
 
The parasites were incubated with and without the test compounds in HMI-9 medium, which has 
10% FBS, at 37 ºC with 5% CO2. Propidium iodide concentration was at 9 µM, and the 
fluorescence was measured over 6 hours at 544 nm for excitation and 620 nm for emission. 
Separate traces (background fluorescence were recorded in the absence of cells and these were 
subtracted from those presented herein.  
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Figure 4.3 Results showing the speed of action of test compounds, HDK20 (panel A) and HDK40 
(panel B) on trypanosomes. The result presented here shows Propidium Iodide (PI) permeabilization of 
cells caused by the two test compounds on the bloodstream form of T. b. brucei in a dose dependent 
fashion. The parasites were incubated with and without the test compounds in HMI-9 medium, which has 
10% FBS at 37 ºC with 5% CO2. Propidium iodide concentration was at 9 µM, and the fluorescence was 
measured over 6 hours at 544 nm for excitation and 620 nm for emission. Digitonin, a compound known to 
cause rapid cell permeabilisation was used as positive control. Separate traces (background fluorescence 
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were recorded in the absence of cells and these were subtracted from those presented herein. a = 
digitonin treated cells; b = 4 ˣ EC50; c = 2 ˣ EC50; d = cells + PI (untreated); e = media + PI (no cells). Note 
that the experiments with HDK20 and HDK40 were performed at the same time, allowing the positive 
(digitonin) and negative control traces to be used in both panels. 
 
Figure 4.3 shows that both compounds disrupted the plasma membrane architecture leading to 
loss of membrane integrity, consequently affecting cellular viability during 6 hours of incubation 
at concentrations of 2× and 4×  their EC50 values, and there is a significant difference  between 
treated and untreated trypanosomes (0.4 µg/mL and 1.0 µg/mL for HDK20 and HDK40, 
respectively).  
Trypanosomes treated with 0.8 µg/mL of HDK20 started becoming significantly fluorescent after 
approximately 2-3 hours of incubation; however, when this concentration was doubled (1.6 
µg/mL), the cells became significantly fluorescent as early as 1-2 hours after the start of the 
incubation. 
This period of increasing fluorescence was also similar for the HDK40 treated cells. None of the 
treated groups reached the maximum fluorescence as does the digitonin treated cells, reflecting a 
slow entry of PI into cells - either only part of the population became permeable to PI or the cells 
became increasingly permeable over the course of the experiment. 
 
This result showed that HDK20 and HDK40 at concentrations above their EC50 cause a 
permeabilisation of the plasma membrane of trypanosomes leading to lose of membrane integrity. 
This experiment does not elucidate whether the cell membranes become permeable as a result of a 
loss of viability, or the other way around, where the perturbation of the cell membrane causes the 
cell death.  
 
4.2.3 Natural products cause cell cycle arrest in trypanosomes  
 
Some compounds purified from natural sources elicit their activity by inhibiting progression of 
the cell cycle, for instance by binding to a protein required for cell division, or by intercalating 
with DNA. Thus, an understanding of cell cycle events may help in deciphering the mode of 
action for anti-parasite compounds. Consequently, in this study, and following on from the cell 
viability (alamar blue) assay reported in chapter three, an attempt was made to study the effect of 
these test compounds on cell cycle progression in trypanosomes using a wild-type strain of 
Trypanosoma brucei s427 (1×107 cells/mL). Cells were stained with DAPI following incubation 
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with the test compounds at a concentration close to its EC50, and viewed under a fluorescent 
microscope at various time points within the incubation period and the result was presented as 
percentage of 500 cells, and scores for DNA configuration given as 1N1K, 1N2K, 2N2K (Early: 
no cell division furrow) and 2N2K (Late, cell division furrow apparent), where N is nucleus; and 
K is kinetoplast.  
 
The result showed that upon fluorescence microscopic examination of DNA configuration, cell 
cycle defects were noticed after 8 hours of incubation with the natural compounds: DNA 
synthesis could not be initiated, leading to a dramatic increase in the percentage of cells with just 
1 nucleus and 1 kinetoplast, with a concomitant decrease in cells in all stages of the cell division 
process (see fig. 4.4). 
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Figure 4.4 Cell cycle determination in T. b. s427 WT using DAPI. Fixed cells prepared on slides were 
viewed under a fluorescence microscope after 32 hours of incubation with 0.2 µg/mL (HDK20) or 0.5 
µg/mL (HDK40) and the untreated control (ND, no drug) were incubated without the test compounds. 
Values were expressed as percentage of 500 counted cells. N = nuclear DNA; K = kinetoplast DNA; e = 
early stage; L = late stage. Open symbols represents treated cells while filled symbols represent untreated 
cells. Note that because the incubations with both compounds were performed in parallel, the same control 
cell population was used in both panels. 
 
HDK20 and HDK40 exhibited similar effects on the cell cycle of T. brucei, although at the 
concentrations chosen, the effect of HDK20 developed somewhat faster than that exhibited by 
HDK40. Both compounds caused the near-disappearance of the 2N2K-early and 2N2K-late cell 
cycle stages from the cell population after 28 hours of incubation. On the other hand, there was a 
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corresponding steady increase in the population of cells with 1N1K for the HDK20 treated cells 
from 8 hours of incubation and from 10 hours of incubation for the HDK40 treated cells (Fig. 
4.4). 
 
This result showed that the cell cycle might be a target for the trypanocidal activity of the test 
compounds or at least may be contributing to the efficacies of these compounds. The apparent cell 
cycle arrests induced by the continuous exposure to low concentrations of the compounds for up 
to 32 h are consistent with the growth inhibition depicted in Figure 4.2. 
 
4.2.4 Microscopical investigation of cellular morphology of T. brucei treated with 
purified natural compounds 
 
Microscopical investigation of cellular morphology of T. brucei treated with purified natural 
compounds was carried out after the cells were incubated with the purified compound and sample 
were taken at various time points, then incubating the samples at each time point with 
mitotracker,® and then staining the prepared slide with DAPI. Viewing was with the aid of a 
fluorescence microscope.  
 
The result revealed that the cell population incubated with HDK-20 (0.4 µg/mL) had one nucleus 
and one kinetoplast (1N1K) DNA after 8 hours of incubation; however, DNA fragmentation 
became evident after 10 hours of incubation with compound HDK-20 (0.4 µg/mL). Although the 
mitochondrion of the cells remained normal throughout the experiment, cells treated with HDK 
20 appear swollen after 12 hours of incubation, and in some cells the nucleus appeared to have 
fragmented.  
The Untreated (control) cells remained normal throughout the period of the experiment as shown 
in figure 4.5. The kinetoplast DNA also appears to be normal in both the treated and control 
groups, and there were no monster cells found in the population to the extent that would suggest 
inhibition of cytokinesis. 
 
 
 
 
 
106 
 
 
POL DAPI Mitotracker POL/DAPI/Mito- 
Tracker 
1N1K 
 
ND 
    
1N2K 
 
ND 
 
  
 
2N2K-E 
 
ND 
 
  
 
2N2K-L 
 
ND 
    
HDK20-
treated cells. 
(8 h) 
1N1K. 
   
 
HDK20-
treated cells 
(10 h) 
DNA breaks? 
    
 
 
Figure 4.5 DNA contents and mitochondrial examination of treated and untreated (ND) cells.     
Images of T. brucei s427 wild type showing DNA breaks following 10 hours of incubation with or without the 
test compound (HDK20, 0.4 µg/mL), and these images were taken with the aid of a fluorescent microscope. 
Treated cell population had 1N1K after 8 hours of incubation, and nuclear DNA fragmentation was noticed 
after 10 hours of incubation. N = nuclear DNA; K = kinetoplast DNA; e = early stage; L = late stage; ND = 
untreated control. DAPI = 4',6-diamidino-2-phenylindole; POL = Polarized light or bright field. 
 
4.2.5 Assessment of DNA breaks using TUNEL assay 
 
Cell cycle defects may lead to apoptosis or programmed cell death, and the latter is known to be 
linked with DNA fragmentation. The microscopic examination of cells treated with HDK 20 
revealed cell cycle defect after 8 hours of incubation: DNA synthesis could not be initiated, leading 
to a dramatic reduction of cells with more than 1 nucleus or kinetoplast, and DNA fragmentation 
became evident after 10 hours of incubation with compound HDK-20 (0.4 µg/mL). Consequently, a 
TUNEL assay was used to study DNA fragmentation upon incubation with 0.3 µg/mL HDK20 or 1 
µg/mL HDK40, and phleomycin (2 µg/mL) was used as a positive control (Sleigh, 1976), while the 
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negative control was drug free. Phleomycin, which is a mixture of copper-containing glycopeptides 
first isolated from Streptomyces verticillus, is known to bind to DNA where it induces DNA 
breakage either via enzymatic or non-enzymatic mechanisms (Sleigh, 1976). 
Fragmentation of parasites DNA after exposure with the aforementioned compounds was evaluated 
by TUNEL assay using the APO-BrdU TUNEL Assay Kit (Invitrogen) for the detection of DNA 
fragmentation following the manufacturer protocol. The cell density of the parasites was adjusted to 
1×106 cells/mL, the suspension was incubated with or without the test compounds for 12 h, and the 
results show that the drug-free culture was significantly different (p<0.05) from the cells treated 
with HDK20 and HDK40 (Figure 4.6).  
 
 
Figure 4.6 DNA fragmentation of treated and untreated T. b s427 cells following 12 hours of 
incubation with the test compounds (HDK20 and HDK40) or without the test compounds (untreated 
cells). Phleomycin (2 µg/ml) was used as a positive control. **p<0.01; *p<0.05, and the result represent an 
average of three independent determinations using a flow cytometer and flowJo 10.0 software. The result 
revealed increase of cells with high fluorescence (Br-dU incorportation) after 12 hours incubation with 
HDK20 and up to 70% with such levels of fluorescence in HDK40 treated cells, which was similar to that 
observed with the phleomycin-treated control. The dot plot and histograms are presented in appendix D and 
E respectively. 
 
The result showed a strong increase in Br-dU fluorescence in cells after 12 hours incubation with 
HDK20 and a slightly lower increase in cells treated with HDK40. Although the positive control 
(Phleomycin treated) exhibited a strong effect on the cell population, the cells treated with 0.3 
µg/mL HDK20 appeared to have undergone an even more marked DNA fragmentation after 12 h 
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(Figure 4.6, also see appendix D and E) at the concentrations used, whereas there was no 
significant difference (p<0.05) between the phleomycin treated and the HDK40 treated cells. 
 
4.2.6 Effects of purified natural compounds on mitochondrial membrane potential of T. b. 
brucei treated cells. 
 
HDK20 and HDK40 affected the cell cycle progression of T. brucei cells in this study leading to an 
apparent accumulation of cells in the G1 phase of cell cycle and accumulation of 1N1K cells. A 
direct causal effect has been previously reported between the mitochondria membrane potential and 
cell cycle progression in T. brucei cells (Alkhaldi et al., 2016). Consequently, we examined 
whether these compounds affect the mitochondrial function in T. brucei and whether this is 
connected with the cell cycle defects observed earlier. 
 
In this study, Fluorescence Activated Cell Sorting (FACS) was employed for the determination of 
the change in mitochondrial membrane potential (MMP) due to exposure of trypanosomes to the 
test compounds using tetramethylrhodamine ethyl ester (TMRE) (Denninger et al., 2007). A cell 
density of 1×106 cells/mL with and without test compounds was used for the start of the 
experiment, and 1 mL of sample was transferred at each time point into a microfuge tube and 
centrifuged at 4500 rpm for 10 min at 4 °C. The pellet was re-suspended in 1 mL PBS containing 
200 nM of TMRE, followed by incubation at 37 °C for 30 min. The suspension was placed on ice 
for at least 30 minutes before analysis by a Becton Dickinson FACS Calibur using a FL2-heigth 
detector and CellQuest and FlowJo software (Ibrahim et al., 2011). Valinomycin (100 nM) and 
troglitazone (10 µM) were employed as negative (mitochondrial membrane depolarisation) and 
positive (mitochondrial membrane hyperpolarisation) controls respectively (Denninger et al., 
2007). Mitochondrial membrane potential was determined at 0, 1, 4, 8 and 12 h. 
The values given are the percentage of cells having fluorescence greater than 100 arbitrary units 
(AU), a value set to approximately 50% for the untreated cells, so that a shift to a higher 
fluorescence indicates hyperpolarisation (increased Ψm), while a shift to a lower fluorescence is 
indicative of a decreased  Ψm (depolarization) (Denninger et al., 2007; Alkhaldi et al., 2016). The 
result was presented as histograms of TMRE fluorescence (See Appendix F). 
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Figure 4.7 Mitochondrial membrane potential (%ψm) of treated and untreated T. b. s427 WT cells. 
The analysis was measured with a flow cytometer using T. b. b. (bloodstream-form) incubated with 200 nM 
tetra-methylrhodamine (TMRE). Troglitazone (10 µM) was used as mitochondrial membrane 
hyperpolarization control, while valinomycin (100 µM) was used as mitochondrial membrane depolarization 
control. The results shown here are the averages of three independent experiments; and the error bars 
represent standard errors. A shift to a higher fluorescence indicates hyperpolarisation (increased Ψm), while 
a shift to a lower fluorescence is indicative of a decreased Ψm (depolarization)  
 
The result shown above is a summary of the mitochondrial potential (Ψm) following 12 hours of 
incubation with or without the test compounds and read at 0, 1, 4, 8 and 12 h. As expected, there 
was no change in the mitochondrial potential for untreated cells for the duration of the experiment 
(12 h). However, valinomycin induced a very rapid and strong depolarisation of the mitochondrial 
membrane after just 1 hour of incubation, whereas troglitazone caused a clear hyperpolarisation of 
the mitochondrial membrane (Fig. 4.7). 
 
Compounds HDK-20 and HDK-40, even at relatively low concentrations (0.3 µg/mL and 1.0 
µg/mL, respectively) induced a fast and profound depolarisation of the parasites’ mitochondrial 
membrane potential after 1 hour of incubation and continued until a near complete depolarization 
was achieved after 12 hours. 
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These results indicate that both HDK20 and HDK40 induced a depolarisation of mitochondrial 
membrane potential as an early effect on the parasites. 
 
4.2.7 Effects of purified natural compounds on ATP levels in T. b. brucei 
 
The previous section described that HDK20 and HDK40 caused depolarisation of the 
mitochondrial membrane potential of T. brucei s427 WT and it is well understood that the 
oligomycin-sensitive ATP synthase present in the mitochondrial membrane of bloodstream form 
(BSF) T. b. brucei is responsible for the maintenance of its mitochondrial membrane potential 
(Brown et al., 2006). It is conceivable that a reduction in cellular ATP levels leads to the reduced 
mitochondrial membrane potential by denying the F0F1 ATPase the ATP it needs to pump H+ 
across the inner mitochondrial membrane. Consequently, these compounds were tested at the same 
concentrations as that of the mitochondrial membrane potential above in order to study their effect 
on ATP production. 
 
Intracellular ATP level was measured using an ATP Determination Kit (Invitrogen) following the 
manufacturer protocol. ATP was determined using recombinant firefly luciferase and alongside its 
substrate D-luciferin in the cell. This assay is based on luciferase activity which requires ATP as a 
co-enzyme in an enzymatic reaction to produce a luminescent light (emission maximum was 
approximately 560 nm at pH 7.8). The luciferase assay was found to be very sensitive (the 
luminometer could detect as little as 0.1 picomole of ATP). Known amounts of an ATP standard 
(provided by the kit), prepared as a serial dilution were made and used to plot a standard curve 
which was eventually used to quantify in vivo ATP levels. 
 
Accordingly, Trypanosoma brucei cultures containing 1×107 cells of both treated and untreated 
parasites were taken at each time points and centrifuged for 10 minute at 2800 rpm (4 ºC) and the 
pellets was used for the assay using the assay kits and following the manufactures manual. 
 
A standard curve was prepared using different concentrations of ATP (10 nM – 1 µM) to calculate 
the ATP concentrations in the samples by imputing the luminescence obtained from the test well in 
the straight line equation generated from the standard curve shown in Fig 4.5A. 
The result showed that intracellular ATP levels of the T. brucei treated with HDK20 and HDK40 
were found to be severely depleted (Fig. 4.8 B). Although the intracellular ATP level in the HDK20 
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and HDK40 treated cells trended down after just one hour of incubation, this became statistically 
significant after 2 hours of incubation with both test compounds.  
Oligomycin is a well-known inhibitor of ATP synthase. It was used in this study as a positive 
control to prevent phosphorylating respiration of trypanosomes by inhibiting the trypanosomes 
ATP synthase thereby blocking its proton channel (Fo subunit), which in most mitochondria is 
essential for the phosphorylation of ADP to ATP (energy generation) (Brown et al., 2006), but in 
BSF generates the mitochondrial membrane potential. As the oligomycin treated (control) cells had 
the lowest ATP content it shows that the membrane potential is essential for ATP production. The 
fact that oligomycin induced a much more rapid depletion of ATP, compared to that exhibited by 
HDK20 and HDK40, seems to indicate that these test compounds do not directly inhibit the FoF1 
ATPase.  
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Figure 4.8 Determination of ATP levels in trypanosomes. (Panel-A) ATP standard curve determined in 
parallel and under the same assay condition as that of the test samples, the luminescence gotten 
expressed as artificial units were plotted against ATP concentrations (10 nM – 1 µM) to generate an 
equation for a straight line from which the ATP concentrations in the test samples were extrapolated by 
fitting their luminescence to this equation; (Panel-B) ATP concentrations in treated and untreated 107 T. b. 
brucei cells using 50 mL extraction buffer. Incubation was for a period of 12 hours with samples taken at 
each time point. The results shown here are the averages of four independent experiments; and the error 
bars represent standard errors. 
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ATP concentration in the oligomycin treated control was reduced to 8 nM after 1 hours of 
incubation compared to HDK20 and HDK40 treated cells which had an intracellular ATP 
concentration of 16 nM under our experimental conditions (Fig. 4.8 B). However the ATP 
concentration in the oligomycin treated cells then remained steady until after 8 hours of 
incubation before it fell further to a concentration of 6 nM. Meanwhile the HDK20 and HDK40 
treated cells exhibited a steady decline in ATP concentration for the duration of the experiment, 
but had the lowest value of intracellular ATP levels of 10 nM and 13 nM respectively. The 
untreated cells had a rather steady intracellular ATP concentration throughout the experiment. 
 
This result show that HDK20 and HDK40 deplete the T. brucei intracellular ATP concentration 
corresponding to their effect on mitochondria membrane potential described in the previous 
section. From the timelines of the two sets of experiments it appears that the loss of mitochondrial 
membrane potential precedes the reduction in ATP levels, and thus, like oligomycin causes the 
low ATP levels. Much less clear is how these two (unrelated) compounds cause such a dramatic 
collapse of Ψm. Usually, compounds with such effects are cationic and accumulate in the 
mitochondrion, but it is unlikely that either HDK20 or HDK40 are charged. 
 
 
4.2.8 Metabolomic assessments of T. b. brucei cells treated with sub-lethal doses of 
purified compounds. 
 
The biochemical investigation into the mode of action of a biologically active compound has in 
the past involved time-consuming assays on single enzyme activities. However, the use of a 
modern metabolomics platform can rapidly give insight into a multitude of biochemical pathways 
that could potentially be involved in the cellular perturbations induced by the test compound.  
 
Metabolomics is a comparatively new technology that allows for the identification of hundreds of 
metabolites from a single sample, usually a cell extract or a sample of growth medium. In 
principle, if a drug inhibits an enzyme then it is expected that the substrate of this enzyme should 
build-up and its concentration should rise within the system, while the concentration of the 
product of the enzymatic reaction should fall. Also, if the drug perturbs the cell membrane by 
altering its integrity, then it is expected that this loss of plasma membrane integrity would result 
in build up of intracellular metabolites within the culture media relative to the untreated culture. 
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Also if the compound inhibits the utilization of any component of the media, such component will 
show as elevated (less depleted) in the metabolomic analysis compared with the untreated groups. 
Various authors have recently used metabolomics approaches to investigate metabolism in 
trypanosomes (Creek et al., 2011 and 2012; Barrett et al., 2010; Kamleh et al., 2008; Burgess et 
al., 2011; Vincent et al., 2012; Alkhaldi et al., 2015; Ali et al., 2013). 
 
This section therefore utilises untargeted metabolomics to assess the impact of in vitro treatments 
with HDK20 and HDK40 on T. brucei. In untargeted metabolomics there is no prior supposition 
on a mode of action and the whole metabolome is studied to the limit of the technology. We 
directly compared the metabolic changes between the untreated control group and trypanosomes 
incubated with the test compounds. The software SIMCA was used for multivariate analysis such 
as CV-ANOVA, while the false discovery rate (FDR) and p-values were taken from the Meta-  
Boanalyst website (http://www.metaboanalyst.ca/). MZMatch (http://mzmatch.sourceforge.net/) 
was used to extract metabolites and their masses, retention times (RTs) and intensities. It was 
immediately obvious from a global overview of data visualization of the principal component 
analysis (PCA) of intracellular metabolome that there is a clear-cut separation of the treated 
replicates from that of untreated ones (Fig. 4.9). 
 
 
Figure 4.9 Data visualization of the Principal Component Analysis (PCA) of the intracellular 
metabolome of HDK20 (3C, A-D) (panel A), and HDK40 (4C, A-C) (panel B) following 10 hours of 
incubation of the cells with the respective compounds at concentration equal to half their EC50. The 
untreated cells (5C, A-D) were used as control and were incubated and subjected to the same 
experimental condition as the treated cells. The visualization shows clear separation between the treated 
and untreated controls. The data presented here is that of four biological repeats, the experiment was 
conducted using LC-MS, and the data generated were analysed using SIMCA software.  
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We also analysed the spent media, and directly compared the metabolite changes between the 
untreated control group and trypanosomes incubated with the test compounds (HDK20 and 
HDK40), as indicators for metabolic changes that cause perturbations in nutrient uptake or 
metabolite efflux (Fig 4.10). It was obvious from a global overview of data visualization of the 
principal component analysis (PCA) of the extracellular metabolome that there is a clear-cut 
separation of the treated replicates from that of untreated ones, and most of the replicates except 
3SA and 4SC clustered together. 
                  
 
 
Figure 4.10 Data visualization of the Principal component analysis (PCA) of extracellular 
metabolome of HDK20 (3S, A-D) (Panel-A), and HDK40 (4S, A-D) (Panel-B) following 10 hours of 
incubation of the cells with the respective compounds at concentration equal to half their EC50. The 
untreated cells (5S, A-C) were used as control and were incubated and subjected to the same 
experimental condition as the treated cells.  The analysis shows clear separation between the treated and 
untreated controls. The data presented here is that of four biological repeats, the experiment was 
conducted using LC-MS, and the data generated were analysed using SIMCA software.  
 
A general overview of the metabolome of the cells at the multivariate level revealed the 
identification of 422 metabolites (Table 4.1). Based on the number of significant metabolites, the 
effect of the two compounds on the extracellular metabolome was more pronounced than that on 
the intracellular composition. In terms of multivariate analysis, HDK20 had a stronger 
extracellular effect on the whole metabolome (422 metabolites) of treated trypanosomes 
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compared to its intracellular effect with predictive variability (0.443) higher than its orthogonal 
effect (0.35). HDK20 significantly altered 14 extracellular metabolites with highest predictive 
effect (0.862) and very low orthogonal variability (0.092) compared to HDK40. The effect of 
HDK20 and HDK40 appear to be weak intracellular compared to their extracellular effect. 
 
The predictive variation in table 4.1 refers to between-groups variation, which is caused by the 
effect of the intervention (treatments) on the metabolites, while the orthogonal variation refers to 
variations within the group, caused by systematic effect on metabolites.  Other statistical analyses 
used include the PCV ANOVA which is the p-value of cross validated analysis of variance 
between the two groups. From these analyses a good outcome will be having a higher predictive 
and a lower orthogonal variation and a significant CV ANOVA (<0.05). Hence, a model having 
an insignificant p-value and/or low predictive variation with a high orthogonal variation was 
regarded to be insignificant at multivariate level; however this would not be the case at the 
univariate level. 
  
Table 4.1 General overview of the metabolome of treated cells at multivariate level. 
  whole metabolome Selected metabolites 
Cellular 
part 
No. of 
metabolites 
Comparison Pred. 
var. 
Ortho. 
var. 
PCV-
ANOVA 
No. of 
metabolites 
Pred. 
var. 
Ortho. 
var. 
PCV-ANOVA 
  Intra 422 (whole 
metabolome) 
3C vs 5C 0.20 0.655 1.0 4 0.861 0.051 0.082 
4C vs 5C 0.13 0.766 0.945 7 0.779 0.028 0.033 
Extra 3S vs 5S 0.357 0.485 0.949 14 0.862 0.092 0.0038 
4S vs 5S 0.443 0.35 0.952 15 0.751 0.186 0.043 
 
Pred. var. = predictive variation = between groups variation, caused by the effect of intervention on 
metabolites; Ortho. Var. = orthogonal variation = within group variation, caused by systematic effect on 
metabolites; PCV ANOVA = p-value of cross validated Analysis of Variance between the two groups; the 
good model = higher predictive and lower orthogonal variation + significant CV ANOVA (<0.05). 
Insignificant p-value and/or low pred. var. and high Ortho. Var. = the model is insignificant at multivariate 
level, but this is not the case at univariate level. 
  
An overview of the intracellular metabolome at the univariate level for the HDK20 (3C) treated 
cells compared to the intracellular metabolome of the untreated cells revealed the perturbation of 
four metabolites: Choline, and 3-(4-Hydroxyphenyl) lactate were slightly elevated, while L-
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Tryptophan, and 2-oxobut-3-enanoate were moderately reduced in the intracellular extract (see 
table 4.2). 
 
Table 4.2 Overview of differences in the intracellular metabolome after HDK20 or HDK40 
treatment - univariate level 
 
Putative 
 Metabolite 
Mass *RT 3C/5C p-
value 
**FDR Putative 
Metabolite 
Mass RT 4C/5C p-
value 
FDR 
2-oxobut-3- 
Enanoate 
100.0 14.4 0.54 0.04 0.67 (R)-2-
Hydroxystearate 
300.3 3.814 2.33 0.030 0.75 
Choline 103.1 20.39 3.04 0.03 0.67 N3-
hydroxyethylcyto
sine 
155.1 17.51 0.53 0.041 0.77 
L-Tryptophan 204.1 11.53 0.43 0.03 0.67 3-(4-
Hydroxyphenyl)la
ctate 
182.0 8.582 3.68 0.036 0.80 
3-(4-
Hydroxyphenyl) 
Lactate 
182.1 8.582 1.91 0.03 0.67 N-Acetyl-beta-
alanine 
131.1 14.28 0.50 0.002 0.79 
      L-Tryptophan 204.1 11.53 0.50 0.028 0.76 
      Choline 103.0 20.39 3.17 0.043 0.78 
      L-Histidine 155.0 14.77 0.47 0.019 0.80 
 
3C and 4C are the intracellular metabolome of HDK20 or HDK40 treated trypanosomes respectively and it 
is here compared with 5C which is the intracellular metabolome of drug-free control cells in order to identify 
any changes in intracellular metabolism. *Retention time; **False discovery rate. 
 
An overview of the intracellular metabolome at the univariate level for HDK40 (4C) compared to 
the intracellular metabolome of the untreated trypanosomes shows the perturbation of 7 
metabolites namely: (R)-2-Hydroxystearate, 3-(4-Hydroxyphenyl) lactate, and Choline, all of 
which were moderately elevated in the extracellular medium, while N3-hydroxyethylcytosine, N-
Acetyl-beta-alanine, L-Tryptophan, and L-Histidine were slightly depleated. Most of these are 
from the amino acid metabolic pool (see table 4.2). 
 
An overview of the extracellular metabolome at the univariate level for the HDK20 and 40 treated 
trypanosomes (3S and 4S respectively) compared to the untreated control cells (5S) reveal the 
perturbation of 12 metabolites in the spent medium of the HDK20 treated cells (Table 4.3) while 
a total of 15 metabolites were observed to have changed in the extracellular metabolome (spent 
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medium) after HDK40 treatment, compared to that of the untreated trypanosomes (5S) (Table 
4.4).  
 
Table 4.3 Overview of the extracellular metabolome - univariate level (HDK20 treated cells) 
 
Putative metabolite      Mass      *RT     3S/5S     p.value    **FDR 
3-Oxo-5beta-cholanate 374.28 3.612 27.0912 0.010704 0.26991 
Cholesterolsulfate 466.31 3.565 3.814068 0.002192 0.070549 
Glycine 75.032 15.46 1.400403 0.038769 0.26991 
Docosahexaenoicacid 328.24 3.698 1.288593 0.024936 0.26991 
2-Oxoglutarate 146.02 14.96 1.668769 5.57E-04 0.019716 
5S-hydroxy-12-keto-
6Z,8E,10E,14Z-eicosatetraenoic 
acid 
334.21 4.165 494.5669 1.88E-06 1.33E-04 
13E-docosenoic acid 338.32 3.676 1.586402 0.023889 0.26991 
1-octadecanoyl-2-
nonadecanoyl-sn-glycero-3-
phosphoserine 
805.58 3.914 3.404562 0.011189 0.26991 
AMP 347.06 13.31 387.5218 3.89E-07 3.44E-05 
Adenine 135.05 9.549 2.405145 0.003438 0.10141 
2-Methyl-3-oxopropanoate 102.03 14.84 1.582258 5.55E-04 0.019716 
 
This table shows the result of the extracellular metabolomic perturbation of 3S - which is the average of 4 
separate determinations of the spent medium of HDK20 treated trypanosomes, compared with the average 
of 4 separate determinations of 5S - which is the spent medium of the drug free control cells in order to see 
whether there is any changes in the extracellular metabolome. The sample preparation and analysis for the 
3S and 5s samples were performed in parallel. *Retension time; **FDR = False discovery rate. 
 
It could be clearly observed for both the HDK20 and HDK40 treated cells that all the metabolic 
changes observed in the extracellular medium (spent medium) i.e. 3S/5S and 4S/5S reflected 
elevated metabolite levels, largely from the glycerophospholipid metabolism (Tables 4.3 and 4.4).  
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Table 4.4 Overview of the extracellular metabolome - univariate level (HDK40 treated cells) 
 
Putative metabolite  Mass   *RT   4S/5S  p.value **FDR 
1-Palmitoylglycerophosphocholine 495.33 4.604 843.4975 0.007954 0.23872 
1-Oleoylglycerophosphocholine 521.35 4.495 5787.07 4.80E-06 5.34E-04 
Ethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate 332.27 3.706 1.721136 0.015041 0.23872 
Ethyl (5Z,8Z,11Z,14Z)-5,8,11,14-icosatetraenoate 434.24 4.55 186.0807 0.032151 0.23872 
1-Oleoyl-glycero-3-phosphate 436.26 4.518 1821.768 2.74E-05 0.001584 
1-Stearoyl-2-meadoyl-sn-glycero-3-phosphocholine 811.61 3.835 3.064126 0.040941 0.23872 
(2R)-2-Acetoxy-3-(hexadecyloxy)propyl 2-
(trimethylammonio)ethyl phosphate 
523.36 4.461 10063.61 1.25E-06 4.34E-04 
1-Stearoyl-2-arachidonoyl phosphatidylinositol 886.56 3.623 8.814194 0.043642 0.23872 
1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-
phospho-1'-myo-inositol. 
836.54 3.629 8.640292 0.02004 0.23872 
1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-
phosphoserine 
773.56 3.626 12.35933 0.043039 0.23872 
1-octadecyl-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-
3-phosphoserine 
771.54 3.622 12.65741 0.043017 0.23872 
Adenine 135.05 9.549 1.48833 0.009708 0.23872 
[ST dimethyl(5:0/3:0)] (5Z,7E,22E,24E)-(1S,3R)-
26,27-dimethyl-24a-homo-9,10-seco-
5,7,10(19),22,24-cholestapentaene-1,3,25-triol 
454.34 3.887 3962.885 3.69E-05 0.00183 
Reduced Vitamin K (phylloquinone) 470.38 3.966 441.9501 0.027529 0.23872 
 
This table shows the result of the extracellular metabolomic perturbation of group 4S - which is the 
average of 4 separate determinations of the spent medium of HDK40 treated trypanosomes, compared 
with the average of 4 separate determinations of 5S - which is the spent medium of the drug free control 
cells in order to see whether there are any changes in the extracellular metabolome. The sample 
preparation and analysis for the 4S and 5S samples were performed in parallel. *Retension time; **FDR = 
False discovery rate. 
 
 
4.3 Discusion 
 
The structural diversity of natural compounds and the fact that they usually possess highly 
specific and selective biological activities based on their mode of action are the two main 
reasons why natural products are of immense interest to drug development. Two classical 
examples of these are the tubulin-assembly promotion activity of paclitaxel, and the HMG-
CoA reductase inhibition displayed by statins such as lovastatin, neither of which would have 
been discovered and developed without the natural product leads and investigating their 
mode of action (Cragg and Newman, 2013). A complete knowledge of the interaction of a 
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drug lead with its biological target is particularly helpful for the process of drug 
development, because it allows the use of medicinal chemistry strategies for optimization of 
the compounds drug-like properties, and in some cases a more suitable design of clinical 
trial. This is crucial to the development of new and efficient chemotherapy that will replace 
the current inefficient ones. 
 
It is very rare nowadays for a new chemotherapeutic agent to be licensed without prior 
knowledge of its MOA, hence understanding drug mode of action is of fundamental 
importance. Yet, of the five drugs currently in use against human African trypanosomiasis 
(HAT), convincing evidence on a specific mode of action has only been proposed for the 
polyamine pathway inhibitor eflornithine - which also is the most recently developed. 
Knowledge of the MOA of a novel anti-parasite inhibitor reduces the risk of unexpected 
toxicity and also allows synergism and resistance mechanisms to be predicted (Vincent et al., 
2012). Accordingly, the mode of action was studied for two of our purified compounds and 
the findings are discussed here. 
 
Although the two purified compounds studied in this work were obtained from two distinct 
plants and these compounds belong to different class of compounds i.e. diterpenes (HDK20) 
and triterpenes (HDK40), they, surprisingly, displayed similar mode of action, however they 
both differ slightly in the extent to which they elicit their trypanocidal activity. Previously, 
the trypanocidal (mode of) action of some diterpenoids and triterpenoids has been studied 
and reported in the literature. For instance, Eleganolone, a diterpene isolated from the ethyl 
acetate extract of the marine alga Bifurcaria bifurcata, was reported to inhibit the growth of 
Trypanosoma brucei rhodesiense in vitro with an IC50 of 45.0 µM (Galle et al., 2013). The 
diterpene HDK20 reported in this work also induced a rapid, irreversible growth arrest of 
Trypanosoma brucei (Fig. 4.1), probably by inhibiting mitochondrial DNA replication, 
thereby preventing the initiation of the S-phase of the cell cycle and leading to accumulation 
of cells with 1 nucleus and 1 kinetoplast. 
It follows also that the diterpene tested here is targeting a significant part of the trypanosome 
that once initiated, the trypanosomes lacks the machinery of reversing it, at least not within a 
short period of time following exposure.   
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A clerodane 16α-hydroxycleroda-3,13(14)Z-dien-15,16-olide (i.e. HDK20), was previously 
purified from the ethanolic extract of the leaves of Polyalthia longifolia var. pendula 
(Annonaceae),  and was tested against Leishmania donovani where it was reported to be 
potent, safe, and orally active (Misra et al., 2010). This diterpene was active against the 
amastigote forms of the parasite in vitro (IC50= 5.79 µg/mL). The in vivo anti-leishmanial 
studies of this compound were performed in hamsters infected with L. donovani, at oral 
doses of 25, 50, 100 and 250 mg/kg/day (n= 6) for 5 consecutive days, showing potency from 
50 mg/kg/day. In vivo survival studies of up to 6 months as well as in vitro cytotoxicity 
studies on macrophages indicated that this compound is safe (Misra et al., 2010). This is 
consistent with our own finding that the clerodane, was not toxic to Human Embryonic 
Kidney cells at concentrations >400 µg/mL (see section 3.2.6 of chapter 3). These findings 
present this clerodane as a potential lead for the discovery of a safe trypanocide that will 
replace the existing toxic ones. 
  
It has previously been reported that clerodane selectively targets topoisomerase and thereby 
the DNA of pathogens including Leishmania. For instance, it has been shown that the 
clerodane 16α-hydroxycleroda-3,13(14)Z-dien-15,16-olide (HDK20) inhibits DNA 
topoisomerases I of L. donovani (Misra et al., 2010). It is thought that topoisomerase 
inhibitors block the ligation step of DNA replication, thereby generating single and double 
stranded breaks that eventually harm the integrity of the genome. Introduction of these breaks 
would subsequently lead to apoptosis and, inevitably, cell death. HDK20 was also shown to 
affect cell cycle progression in the work here presented (Fig. 4.4), and induced significant 
DNA breaks in trypanosomes after 12 hours of incubation (Fig. 4.6), a phenomenon that was 
also noticed with the DAPI microscopy (Fig. 4.5). Hence, the mechanism of DNA breaks 
observed in this work may be similar to the one that occurs through inhibition of DNA 
topoisomerases 1 reported in literature for this clerodane; this, however, was not directly 
confirmed with our data. 
 
Triterpenes are C-30 terpenoids broadly distributed all over the plant kingdom. These 
compounds, have been reported to show a wide range of biological properties, and can be 
seen in their free form in so many cyclic skeletal types, or sometimes linked to sugar moieties 
(triterpene saponins). Triterpenes can also exist in modified forms owing to ring cleavage, 
oxidations and loss of carbon atoms (limonoids, nortriterpenoids, quassinoids). These latter 
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classes are often of particular interest with respect to their biological activity, and are limited 
to some families of plants, mostly of the order Sapindales, such as Simaroubaceae, Rutaceae, 
Cneoraceae or Meliaceae (Schmidt et al., 2012). The most wide spread triterpenes 
commonly found in plant species are the oleanolic and ursolic acids, which have been 
reported as been active against various Leishmania species (Peixoto et al., 2011; Schmidt et 
al., 2012). 
 
It was also observed in this work that both HDK20 and HDK40 depleted the mitochondrial 
membrane potential of trypanosomes and depleted their ATP concentration (Fig 4.7). From 
the timeline observed, it appears that the depolarisation of the mitochondrial membrane 
potential may occur first, and that ATP depletion is subsequently reduced as a result thereof. 
Such a link is consistent with current models of the functioning of the mitochondrion of BSF 
T. brucei (Alkhaldi et al., 2016). 
 
The kDNA of trypanosomatids is a structure that is highly organised, and is made up of tens 
of maxicircles and thousands of minicircles (Liu et al., 2015, Alkhaldi et al., 2016). To 
ensure that T. brucei daughter cells receive identical kDNA networks, the process of 
replication is highly synchronized with replication of the nuclear materials, prior to cell 
division; thus, the mitochondrial S phase for kDNA replication is initiated before the longer 
nuclear S-phase (Mckean, 2003; Jensen and England, 2012). Indeed, the initiation of 
mitochondrial division appears to be an essential checkpoint that must precede nuclear 
division, leading necessarily to the creation of 1N2K cells before the onset of mitosis and 
nuclear division (Chanez et al., 2006). The here observed accumulation of 1N1K cells thus 
appears to indicate a failure either to initiate mitochondrial S-phase, or a failure of the 
mitochondrial S-phase, i.e. of kDNA replication. With the mitochondrial S-phase not being 
concluded, the nuclear S-phase would not commence, resulting in cell cycle arrest at 1N1K. 
 
Replication of the kDNA is dependent on intracellular ATP and hundreds of mitochondrial 
proteins (Beck et al., 2013), that are mobilized to the mitochondria (Schneider et al., 2007) in 
what is, in BSF, is also an ATP-dependent process (Williams et al., 2008). Thus it is 
reasonable to conjecture that the severe depletion of ATP and the decrease of the parasites’ 
mitochondrial membrane potential interfered with the successful initiation or conclusion of 
kDNA replication, resulting in cell cycle arrest due to the failure of cells to progress from the 
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G1 phase, hence the reason why the cell population as observed in this study universally 
contain only a single nucleus and kinetoplast. Similar observations were also reported 
following RNAi knockdown of ATP/ADP carrier in procyclic forms of T. brucei cells, in 
which failure of the overall cell division machinery was linked to reduced cytosolic ATP 
levels (Gnipova et al., 2015). 
 
The above investigation thus gives rise to a model by which HDK20 and HDK40 rapidly 
depolarise the mitochondrial membrane, leading to a much-reduced cellular level of ATP, 
which in turn leads to cell cycle arrest at the stage of the mitochondrial S-phase. What 
remains unclear is what the primary target(s) might be, that by binding of either natural 
compound causes the collapse of Ψm. We considered that an analysis of biochemical 
pathways by metabolomics might give an indication as which protein(s) is/are targeted by the 
test compounds. There are two approaches to studying metabolomics-based mode of drug 
action; firstly, the alterations that ensued after drug induction are observed using a metabolic 
fingerprint, after which the metabolome is then compared with drugs whose mode-of-action 
is already known by using a multivariate statistical analysis (Yi et al., 2007). Unfortunately, 
there are only a few trypanocides whose mode-of-action is known, even though examples 
subsist, such as the new N-myristoyltransferase (NMT) inhibitors and Eflornithine (Vincent 
et al., 2012). However, it is unlikely that a novel compound with an unknown anti-
trypanosome mode of action would precisely mimic the effects of either the NMT inhibitors 
or eflornithine. A higher probability of success would come with an unbiased approach, 
focusing on individual metabolite abundance changes that take place after addition of the 
drug (Le Roch et al., 2008); this facilitates the discovery of new modes of action. 
Correspondingly a non-targeted metabolomic-based approach was used in this work to enable 
us to study pathways in response to the action of the isolated compounds with the aim of 
defining the mode of action of these trypanocides. 
 
Metabolomic profiling of the effect of HDK20 and HDK40 on Trypanosoma brucei resulted 
in the identification of 422 metabolites using LC-MS. Based on the number of significantly 
changed metabolite levels, the effect of the two compounds on the extracellular medium (by 
modulation of export and/or import rates) was higher compared to their effects on the  
intracellular metabolite pools. In terms of multivariate analysis, HDK20 had better 
extracellular effect on the whole metabolome (422 metabolites) of treated trypanosomes 
124 
 
compared to its intracellular effect with predictive variability (0.443) higher than its 
orthogonal effect (0.35). HDK20 significantly altered 14 extracellular metabolites with 
highest predictive effect (0.862) and very low orthogonal variability (0.092) compared to 
HDK40. The effect of HDK20 and HDK40 appear to be weak intracellular compared to their 
extracellular effect.  
 
Although the metabolomic assessments of T. brucei cells did not clearly reveal the targeting 
of any specific metabolic pathway, it appeared that these compounds may have some effects 
on the plasma membrane following 8 hours of incubation at concentrations around their 
EC50. The results of the metabolomic profile of the extracellular metabolome may support 
this speculation as most of the few metabolites with increased concentration compared to the 
untreated control were found to be associated with glycerophospholipids metabolism. The 
perturbation of the plasma membrane integrity following hours of incubation which led to 
permeabilization of trypanosomes’ plasma membrane and the corresponding increase in 
fluorescence brought about by the entry of propidium Iodide into the cells may also support 
the suspicion that loss of plasma membrane integrity may be a contributing factor. However 
this finding needs to be interpreted with caution as a total loss of cell membrane integrity 
would result in the wholesale release of cellular contents into the culture media, and this was 
certainly not observed. Any serious effects on plasma membrane integrity would therefore 
occur much later than the observed biochemical changes on Ψm and ATP levels, and even 
cell division.  
 
In summary, the mode-of action of HDK20 and HDK40 appear to be similar and only differ 
in the extent of damage they inflict on trypanosomes, and in their metabolomic profile, 
although the interpretation of the metabolomic data is by no means straightforward. Hence 
their activity timeline can be summarised thus:  (1) a fast and profound depolarisation of the 
parasites’ mitochondrial membrane potential after 1 hour of incubation and this continued 
until a near complete depolarization was achieved after 12 hours. The mechanism causing 
this might be irreversible as shown by the experiment showing irreversibility of growth arrest 
after 1 h. (2) Intracellular ATP levels of the T. brucei were found to be depleted on a 
timescale closely following the loss of mitochondrial membrane potential. (3) Fluorescence 
microscopic assessment of DNA configuration revealed cell cycle defects after 8 hours of 
incubation with the natural compounds: DNA synthesis could not be initiated, leading to a 
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dramatic reduction of cells in the S phase. (4) DNA fragmentation became evident after 10 
hours of incubation with compound HDK-20, visualised by flow cytometry and Terminal 
deoxynucleotidyl transferase dUTP Nick-End Labelling (TUNEL) assay, which revealed 
significant DNA fragmentation after 12 hours.  
 
Further mode-of-action studies, Structure Activity Relationship (SAR) analysis of related 
compound libraries could improve the efficacies of these compounds, which would enable in 
vivo animal work to confirm their in vivo anti-parasite activity.   
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Chapter 5: Evaluation of mitochondrion-targeting lipophilic cation 
conjugates of Salicylhydroxamate and 2,4-Dihydroxybenzoate as 
potential drugs against African trypanosomes. 
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5.1 Introduction  
 
In contrast to mammalian cells, which contain hundreds of mitochondria per cell, trypanosomes 
possess a single mitochondrion that is involved in vital cellular functions including maintenance 
and expression of genetic information, energy metabolism, RNA editing, Fe-S cluster biogenesis, 
etc, yet is biochemically very different from mitochondria in human cells (Verner et al., 2016). 
Hence, this essential organelle represents a good chemotherapeutic target for the development of 
trypanocidal drugs (Lanteri et al., 2008; Cortes et al., 2015; Alkhaldi et al., 2016).  Among the 
many validated mitochondrial targets of T. brucei (e.g. kDNA and topoisomerases, tRNA import, 
fatty acid biosynthesis) (Fidalgo et al., 2011), the mitochondrial respiration of the parasite is a 
particularly attractive target. In effect, during their life-cycle, trypanosomes adapt their energy 
metabolism to the availability of nutrients in their environment (Tielens and Van Hellemond, 
1998). Hence, procyclic forms of T. brucei have a fully functional respiratory chain and 
synthesize ATP by oxidative phosphorylation in the mitochondrion. In contrast, bloodstream 
trypomastigotes of T. brucei (i.e. the human-infective form) rely exclusively on glycolysis for 
energy production as they have no oxidative phosphorylation, no cytochrome-mediated electron 
transport systems, and no tricarboxylic acid cycle (Verner et al., 2016). Clarkson et al have 
shown that respiration of T. b. brucei trypomastigotes is dependent on a plant-like alternative 
oxidase known as the trypanosome alternative oxidase (TAO), which is localized in the inner 
mitochondrial membrane (Clarkson et al., 1989). Because it is essential to the viability of 
bloodstream trypanosomes, and because it has no counterpart in the mammalian host, TAO is 
considered an excellent target for chemotherapy (Nihei et al., 2002; Yabu et al., 2006; Chaudhuri 
et al., 2006; Nakamura et al., 2010).  
 
Earlier reports in the literature have shown that very simple chemical structures containing the 
2,4-dihydroxybenzoate (2,4-DHB) and salicylhydroxamate (SHAM) scaffolds (Fig. 5.1) did 
inhibit TAO (Clarkson et al., 1976; Grady et al., 1986; Ott et al., 2006) however, their 
trypanocidal activity proved disappointing because the inhibitors did not effectively cross the 
inner mitochondrial membrane to reach their target. 
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Figure 5.1 Examples of 2,4-dihydroxybenzoate and salicylhydroxamate derivatives showing low 
micromolar activity against T. brucei. 
 
In the present chapter, a strategy to enhance the antitrypanosomal potency of this class of 
compounds based on the conjugation of these trypanocides with a mitochondrion-targeting 
lipophilic cation (LC) (See Appendix C) (Madak and Neamati, 2015) was investigated. The 
triphenylphosphonium (TPP) cation is one of the most successful LC for mitochondria targeting 
(Smith et al., 2003; 2008; 2011), and the use of the “TPP strategy” to deliver trypanocidal drugs 
to the mitochondrion of trypanosomes has recently been demonstrated (Long et al., 2012; Cortes 
et al., 2015). Lipophilic cations can cross lipid bilayers by non-carrier mediated transport and 
accumulate specifically into mitochondria driven by the plasma and mitochondrial 
transmembrane potentials (Ross et al., 2006; Luque-Ortega et al., 2010; Taladriz et al., 2012; 
Dardonville et al., 2015). The strong accumulation of dications by the charged mitochondria 
allows the inhibition of various essential functions with relatively low extracellular drug 
concentrations (Wilkes et al., 1997; Ibrahim et al., 2011; Alkhaldi et al., 2016). In addition, LCs 
can cross the blood–brain barrier (BBB) and generate therapeutically effective concentrations in 
the brain (Smith et al., 2003), which is particularly relevant for the treatment of late-stage 
sleeping sickness.  
 
Accordingly, the activity of 3 series of LC conjugates based on the 2,4-DHB and SHAM 
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scaffolds (Figure 5.2) is been reported here. The compounds were evaluated in vitro against 
African trypanosome species (T. b. brucei, T. congolense), including wild-type and multi-drug 
resistant strains in order to assess their effects on the parasite’s viability, their  toxicity on 
mammalian cells, and to evaluate their structure activity relationship. 
 
 
 
Figure 5.2 Design and general structure of the SHAM and 2,4-DHB conjugates. 
 
5.2 Results 
 
5.2.1 Assessment of trypanocidal activity of mitochondrion-targeting lipophilic cations on 
wild-type and multi-drug resistant trypanosome lines; determination of in vitro selectivity 
index.  
 
Two different cationic groups were tested as mitochondrion targeting moieties: the bulky TPP 
cation and the flat heteroaromatic 1-quinolinium cation. Methylene spacers from 4 to 16 units 
were tested to find the optimal length between the LC carrier moieties and the trypanocidal 
scaffold. 
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As TAO is essential for parasite viability, inhibition of TAO should have a deleterious effect on 
parasite growth. Also the test compounds were tested on an in vitro culture of mammalian cell 
[Human Embrayonic Kidney (HEK) cells, or Human Foreskin Fibroblast (HFF) cells], and the 
trypanocidal effect (EC50 T. brucei) was compared with the cytotoxicity effect on human cells 
(CC50 HEK or HFF) in order to determine the in vitro selectivity index of the test compounds. 
 
5.2.1.1 In vitro activity of lipophilic cation–TAO inhibitors on T. brucei (Lister s427) and T. 
congolense (strain IL3000) bloodstream forms 
 
In order to assess the trypanocidal activity of these mitochondrion-targeting lipophilic cations, 
drug-sensitive wild-type strains of T. brucei (Lister s427, and T. congolense (strain IL3000) were 
used, and this was done in parallel with the multi-drug resistant T. b. brucei line B48 which lacks 
both the TbAT1/P2 transporter and the high affinity pentamidine transporter (HAPT), hence 
became highly resistance (>200 fold) to pentamidine, melarsoprol and diminazene. These 
experiments were performed in vitro using an Alamar blue-based assay (Table 5.1). The 
structures of all the TAO inhibitors can be found in Appendix C. 
 
The result showed that SHAM and 2,4-DHB, the scaffolds used in the design of the new inhibitor 
series, were active in the micromolar range against bloodstream trypomastigotes of T. b. brucei 
s427 (WT). The cationic inhibitors were the most effective against T. brucei WT with EC50 values 
ranging from the outstanding 0.6 nM (TAO52) to 1.75 µM (TAO46). The SHAM–TPP 
conjugates (i.e. TAO4, 5, and 6) and the 2,4-DHB-quinolinium conjugates (TAO - 23, 24, and 
28) displayed submicromolar EC50 values (0.1 to 0.4 µM) against this trypanosome strain. 
However, the 2,4-DHB-TPP derivatives (i.e. TAO – 7, 8, 9, 10, 25, and 27) were 10- to 66-times 
more active with low to mid-nanomolar EC50 values (0.0012 to 0.073 µM) - in the same range as 
the reference drugs pentamidine and diminazene (Table 5.1). However, the TPP derivatives 
(TAO49, TAO47, TAO45) were >24-fold more potent than their respective quinolinium 
counterparts (TAO50, TAO48, TAO46), displaying single-digit nanomolar EC50 values. The 4-
formyl-3-hydroxyphenoxy-based inhibitors (TAO45, TAO46) were the least active of these 
series, with EC50 values of 0.133 and 1.75 µM, respectively.  
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Table 5.1 EC50 values (µM) against Wild Type and Resistant Strains of T. b. brucei, T. congolense, 
and Cytotoxicity against Human Cells (CC50, µM).  
Cmpd T. brucei WTa SIb T. brucei B48c RFd T. 
congolense 
WTe 
SIf Human 
cellsg,h 
TAO 1 2.92 ± 0.70 46.92 Ndi  15.28 ± 2.23 8.97 137 
TAO 2 
       0.30  ± 0.09 4396.7 Nd  4.62 ± 0.38 285.50 1319 
TAO 3 2.42 ± 0.61 68.18 Nd  16.69 ± 2.29 9.89 165 
TAO 4 0.40 ± 0.14 >1000 Nd  27.20  >14.7 >400g 
TAO 5 0.20 ± 0.04 >2043 Nd  Nd  >400g 
TAO 6 0.14 ± 0.01 >2857 Nd  46.40 8.6 >400g 
TAO 7 0.073 ± 0.003 106 0.359 ± 0.004 0.94 3.9 ± 2.7 2 7.73 ± 0.79g 
TAO 8 0.0059 ± 0.0025 789 0.056 ± 0.004 1.24 0.21 ± 0.16 21.9 4.68 ± 1.26g 
TAO 9 0.0013 ± 0.0010 1768 0.019 ± 0.002 0.86 0.19 ± 0.03 12.2 2.33 ± 0.53g 
TAO 10 0.0012 ± 0.0012 1334 0.021 ± 0.003 0.96 0.03±0.02 5.5 1.65 ± 0.42g 
TAO 16 135 ± 35 >3 Nd  >100 >4 >400g 
TAO 17 30.7 ± 3.8 >13 Nd  >100 >4 >400g 
TAO 18 > 100 >4 Nd  >100 >4 >400f 
TAO 19 32.72 ± 9.79 >12 Nd  55.48 >7 > 400g 
TAO 20 0.0018 ± 0.0004 3433 0.015 ± 0.001 0.7 0.95 ± 0.05 180 6.01 ± 1.47g 
TAO 21 
       0.06 ± 0.01 1966 0.19 ± 0.02 3 1.50 ± 0.29 59 118 
TAO 22 
     32.94 ± 0.88 >63 33.63 ± 1.03 1.0 >100 >2 > 200h 
TAO 23 0.33 ± 0.01 609 0.347 ± 0.002 1.05 7.3 ± 0.3 34.1 202 ± 7h 
TAO 24 0.10 ± 0.01 1657 0.125 ± 0.015 1.21 3.6 ± 0.1 95.8 172 ± 14h 
TAO 25 0.0015 ± 0.0003 23378 0.0012±0.0001 0.78 Nd  59.7± 6.4h 
TAO 26 
      31.82 ± 0.93 869 22.11 ± 4.09 0.69 >100  26964 
TAO27 0.009 ± 0.001 27714 0.008 ± 0.001 0.91 0.118 ± 0.007 >3384 249 ± 66h 
TAO28 0.14 ± 0.01 2410 0.14 ± 0.01 1.01 3.0 ± 0.2 >132 345 ± 24h 
TAO29 49.04 ± 7.79 >4 41.58 ± 5.51 0.85 >100 >2 > 200h 
TAO30 42.12 ± 2.85 >5 36.55 ± 0.88 0.87 >100 >2 > 200h 
TAO31 14.54 ± 0.97 >13 14.90 ± 1.02 0.98 52.09 ± 3.70 >4 > 200h 
TAO32 26.71 ± 5.52 >7 31.94 ± 7.99 1.19 >100 >2 > 200h 
TAO33 11.88 ± 1.60 >10 12.95 ± 3.71 1.09 >100 >2 > 200h 
TAO34 45.68 ± 1.52 >4 48.96 ± 0.64 1.07 >100 >2 > 200h 
TAO35 17.59 ± 0.55 >11 15.50 ± 0.78 0.88 42.62 ± 6.32 >5 > 200h 
TAO36 >400 
 >400  >400  > 200h 
TAO37 3.77 ± 0.12 >68 3.63 ± 0.18 1.0 >400  > 200h 
132 
 
TAO38 14.40 ± 0.067 >15 14.40 ± 0.23 1.0 >400  > 200 h 
TAO39 4.06 ± 0.091 >50 4.44 ± 0.02 1.1 >400  > 200 h 
TAO40 >400 
 >400  >400  > 200 h 
TAO41 17.70 ± 0.48 >11 20.50 ± 1.78 1.15 72.85 ±22.49 >2.7 > 200 h 
TAO42 >400 
 >400  51.58 ± 1.84 >4 > 200 h 
TAO43 14.58 ± 0.22 >15 15.62 ± 0.21 1.07 >100 >2 > 200 h 
TAO44 >400 
 >400  Nd  > 200 h 
TAO45 0.13 ± 0.0033 1538 0.11 ± 0.02 0.9 0.27 ± 0.12 >740 > 200 h 
TAO46 1.75 ± 0.013 >100 2.35 ± 0.15 1.3 2.11 ± 0.70 >100 > 200 h 
TAO47 0.0024 ± 0.00080 
 
0.0022 ± 1.2E-4 1.0 0.039 ±0.015 >5128 > 200 h 
TAO48 0.21 ± 0.023 >1000 0.30 ± 0.026 1.4 1.82 ± 0.45 >100 > 200 h 
TAO49 0.0016 ± 0.00047 
 
0.0019 ± 3.2E-4 0.9 0.005 ±0.001 >40000 > 200 h 
TAO50 0.032 ± 0.00058 >6666 0.089 ± 0.0010 2.7 Nd  > 200 h 
TAO51 14.72 ± 0.14 >15 17.30 ± 0.19 1.17 >50 >4 > 200 h 
TAO52 0.00058 ± 0.00001 
 
0.00075 ± 4E-5 1.2 0.018 ±0.005 >11111 > 200 h 
TAO53 >400 
 >400  >400  > 200 h 
DHBj 17.1 ± 1.0  Nd  Nd 
 
Nd 
PMD 0.0028 ± 0.0003  0.94 ± 0.03 98 Nd 
 
Nd 
SHAMk 38.7 ± 4.8  Nd  Nd  Nd 
PAOl 0.0011 ± 0.00003  Nd  Nd  0.036 ±0.004g 
0.29 ± 0.02h 
DMZ 0.065 ± 0.007  0.78 ± 0.04  0.15 ±0.002  Nd 
 
aTrypomastigotes of T. b. brucei s427 (n ≥ 4). bSelectivity index (SI) = CC50/EC50 (T.brucei. WT). cT. b. 
brucei strain resistant to pentamidine, diminazene, and melaminophenyl arsenicals. dResistance 
factor relative to WT. eTrypomastigotes of T. congolense IL3000. fSelectivity index (SI) = CC50/EC50 
(T. congolense WT). gActivity on human embryonic kidney cells; hActivity on Human Foreskin 
Fibroblast (HFF) cells. iNot determined. j2,4-Dihydroxybenzoate. kSalicylhydroxamate. lPhenylarsine 
oxide. 
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Figure 5.3 comparing the trypanocidal efficacies of the 2,4-DHB based inhibitors. This figure shows 
an abridged structure of the test compounds and their corresponding EC50, as well as comparative 
analyses of the trypanosomal activity of the structures with regards to their trypanocidal activity. The 
direction of the arrow shows a decrease in activity from right to left for each series. The complete 
structures can be found in appendix C. 
 
The non-cationic TAO inhibitors displayed much reduced activity against T. brucei with EC50 
values in the micromolar range (Figure 5.3). However, the formiate derivatives (TAO33, TAO39, 
TAO37) were approximately 3-times more potent than the bromo analogues (TAO34, TAO38, 
TAO35 respectively), whereas the dimer compounds (TAO22, TAO29, TAO30, TAO32, TAO36, 
TAO42, TAO44, TAO40) displayed very weak activity against T. brucei (IC50 >25 µM). This 
result was not unexpected as these compounds do not have the lipocation mitochondrion-
targeting group and the observed low activity probably results from poor uptake into the 
mitochondrion of the parasite.  
There was no clear trend as regards to the influence of the spacer length on the activity against T. 
brucei but spacers with more than 8 methylene units seemed to be favoured: 12 > 10 > 8 
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methylene units for TAO – 4, 5, and 6 respectively; then 10 > 14 > 12 ≈ 9 > 16 >> 8 methylene 
units for TAO - 7, 8, 9, 10, 25, and 27 respectively. Also, 14 > 16 > 12 methylene units for TAO 
– 23, 24, and 28 respectively (See Table 5.1 and Appendix C). TAO18 and TAO16, lacking the 
TPP or 1-quinolinium cations, were mostly inactive showing that the LC-carrier moiety 
effectively enhances the trypanocidal activity of the compounds. Another interesting finding was 
the low activity displayed by the methyl ester analogue TAO17 (30.7 µM) compared to its 
benzoate counterpart TAO9 (0.0013 µM). This finding illustrates the importance of the 4-OH for 
higher activity in this series.  
 
The compounds were generally less active against T. congolense strain IL3000 grown in culture 
(from 20- to 250-fold). However, with EC50 values for the best compounds (TAO- 8, 9, 10, 27, 
45, 47, 49 and 52) in the submicromolar range (Table 5. 1), close to or better than that of the 
widely used (Giordani et al., 2016) reference drug diminazene (EC50 = 0.15 µM), several 
compounds showed significant potential for use against this species.  
 
5.2.1.2 Assessment of cross-resistance with current anti-trypanosome drugs 
 
Strains that are resistant to current chemotherapies can be used as a model to study the possibility 
of cross-resistance between the existing chemotherapies, as already exists in the field, and any 
potential new trypanocides. Considering the current threat of trypanosomes’ drug resistance, it is 
important that a potential trypanocide, whether for human or veterinary use, be tested for cross 
resistance, and this treatment should at least not be cross-resistant with the diamidine and arsenic-
based drugs currently in use. Besides, the development of new drugs became a high priority 
exactly because of the high levels of resistance to these classes of drugs. It is for this reason that 
the compounds tested here were evaluated whether they would be effective against a well-
characterised multi-resistant laboratory strain of T. b. brucei, which is resistant to the diamidines 
and melaminophenyl arsenicals. 
In the present study, all experiments were carried out at least three times for each compound 
tested and each of these experiments included a positive control, pentamidine, and diminazene; 
drug-free incubations were used as negative controls. The fluorescence intensities obtained were 
analysed using the GraphPad Prism 5 software, and these data were plotted by non-linear 
regression to a sigmoid curve with variable slopes, in order to determine the EC50 values (The 
Effective Concentration that inhibits 50% of the maximal growth of trypanosomes). 
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The result showed that a very little difference in activity was observed between WT and B48 cell 
lines, with resistance factors (RF) consistently close to 1 (Table 5.1), showing that the known 
drug transporters TbAT1 and HAPT1 are not involved in their uptake. 
Normally, a resistance factor >1 signifies cross resistance, while a resistance factor of <1 signifies 
increased sensitivity of the resistant strain to the test compound.  
However a resistance factor of approximately 1 was observed for the majority of the test 
compounds reported in this assay (Table 5.1) and this signifies no in vitro cross resistance of 
these test compounds with the current diamidine and arsenical trypanocides. 
 
5.2.1.3 Cytotoxic activity of lipophilic cation–TAO inhibitors on human cells and 
therapeutic index values  
 
The high level of toxicity in the current sleeping sickness therapies is one of the main reasons for 
the efforts to develop a new trypanocide. Hence, the test compounds studied here were tested 
using the cell viability dye, Alamar blue, for their effects on human embrayonic (HEK 293-T) 
cells or Human Foreskin Fibroblast (HFF) cells in order to assess whether the highly impressive 
anti-trypanosome activity of these test compounds (as listed in Table 5.1), is the result of a 
general toxicity or is selectively targeting trypanosomes.   
 
The experiments were carried out at least three times for each compound tested and each of these 
experiments included a positive control, phenylarsine oxide – a known cytotoxic agent (Alkhaldi 
et al., 2016), drug-free incubations were used as negative controls. The fluorescence intensities 
obtained were analysed using the GraphPad Prism 5 software, and these data were plotted by non-
linear regression to a sigmoid curve with variable slopes, in order to determine the CC50 values 
(the cytotoxic concentration that inhibits 50% of the maximal growth of HEK or HFF cells). 
 
The results of the toxicity assays against the mammalian cells revealed that the test compounds 
that displayed the anti-trypanosome activity have a much lower activity, or in some cases, no 
effect on the growth and viability of these cells. The therapeutic index rates calculated as CC50 of 
HEK or HFF cells / EC50 of wild-type T. b. brucei are shown in Table 5.1. 
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In general, the compounds’ cytotoxicity was low (>200 µM), except for TAO – 7, 8, 9, 10, and 25 
which displayed a cytostatic (as opposed to cytotoxic) effect in the low micromolar range. In most 
cases the selectivity indices (SI) were >200, and TAO27 reached SI >27,000. 
 
It is however worth mentioning here that in this experiment, the higher limit of the therapeutic 
index was not achieved as the highest concentration of the test compounds on HEK or HFF cells 
were 400 µM and a large percentage of the test compounds did not affect the growth of these 
mammalian cells at this concentration. Whereas the results presented here appear to be highly 
promising, it is however acknowledged that the low in vitro toxicity may not necessarily translate 
to a low in vivo toxicity, given the complexity of whole organisms and the many varied tissues. 
Hence, a far more toxicological and pharmacological analyses of this test compounds need to be 
performed if this series of inhibitors are to be developed into genuine lead compounds for anti-
trypanosomal drug development. 
  
5.2.2 Analysis of structural determinants of the mitochondrial-targeting inhibitors 
contributing to their trypanocidal activity  
 
The structural determinants for activity of the test compounds against TAO are similar to those 
previously found to be essential for anti-trypanosome activity of some trypanocides. For instance 
the presence of the 4-hydroxyl on the scaffold of the SHAM derivatives and the 2,4-
dihydroxybenzoate derivatives were found to be a significant requirement for improved anti-
trypanosome activity of these classes of inhibitors (See also Fig. 5.4). A hydroxyl substituted 
benzoate moiety was previously reported to be the basic structural requirement needed to inhibit 
the alternative oxidase activity in plants and trypanosomes as reported for Ascofuranone (AF) and 
its derivatives (Saimoto et al., 2013). Saimoto and his fellow workers also identified the 
pharmacophore of ascofuranone that interacts with TAO base on structure-activity relationship. 
The comprehensive inhibitory profiles of these analogues implicated the 1-formyl and 6-hydroxyl 
groups on AF, as contributing to intramolecular hydrogen bonding and/or serving as donor for 
hydrogen-bonding, and that these were responsible for the direct interaction with TAO (Saimoto 
et al., 2013).  
Because the compounds tested in the present work are targeted at TAO, and the protein is located 
in the mitochondria, the hydroxyl requirement for increased activity may be similar to that already 
reported for SHAM and ascofuranone. 
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Another very important groups on the scaffolds that clearly contributed to the anti-trypanosome 
activity of these classes of inhibitor as observed in this assay is the presence of the lipophilic 
triphosphonium or a 1-quinolinium cations (Figure 5.4). For instance, TAO18 and TAO16, 
lacking the TPP or 1-quinolinium cations (See Table 1 and Appendix C), were mostly inactive 
showing that the LC-carrier moiety effectively enhances the trypanocidal activity of the 
compounds. This same observation has been reported for some tripanocidal triphosphonium salts 
(Alkhaldi et al., 2016). 
 
Another requirement for antitrypanosomal activity of this series of compounds is the number of 
methylene units (n). It was clearly observed that the trypanocidal activity decreases when the 
methylene units is less than 10 but increases when the number of methylene units is more than 10, 
up to when the number of methylene units is 12 for the SHAM derivatives. A similar observation 
was also made for the anti-trypanosomal effect of ascofuranone derivatives, where it was reported 
that the methylene group is contributory to the conformation of the TAO enzyme-bound molecule 
(Saimoto et al., 2013).  
 
 
Figure 5.4 Summary SAR of DHA-based trypanocides with triphenylphosphonium or quinolinium 
lipophilic cations (LC); or its dimer, highlighting the unique structures on the scaffold that is 
responsible for the trypanocidal activity on wild-type s427 BSF trypanosomes.  
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Finally, the strategy that involves the use of triphenylphosphonium lipophilic cation conjugate is 
more effective at killing the parasites than that involving the use of quinolinium lipophilic cation. 
 
5.2.3 Monitoring the rate of trypanosome lysis induced by test compounds, using propidium 
iodide 
 
The purpose of this experiment was to monitor the speed of action of the test compounds, in order 
words, how fast these compounds act on trypanosomes in real time, and whether they also cause 
loss of membrane integrity, becoming permeable to propidium iodide across the cell membrane. 
The principle behind this assay is that trypanosomes become fluorescent when there is a breach in 
the plasma membrane integrity (i.e., loss of cellular integrity), allowing propidium iodide to enter 
the cell and bind to nucleic acids.  
Various dilutions of the test compounds were used to study the dose dependence effect of the test 
compounds on cell viability during 6 hours of exposures. Digitonin was used as positive control, 
while untreated wells served as negative controls. The effects of two representative LC 
conjugates (i.e. TPP and quinolinium derivatives with the same linker and high activity/selectivity 
profile) were tested on T. b. brucei in real time. The effects of TAO25 and TAO24 on T. brucei 
s427 trypomastigotes was dose-dependent; at doses near their EC50 values the compounds 
induced increased rate of PI influx only marginally compared with untreated control cells, over 
the 6 hours of the experiments. For both compounds, at ~3-fold of their EC50 values (1.5 nM and 
100 nM, respectively), killing of the trypanosomes was complete in approximately 4 hours 
(Figure 5.5). These results show that there is no immediate disruption of the plasma membrane 
from the administration of these nanomolar concentrations of LC conjugates. 
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Figure 5.5 Viability assay for TAO24 and TAO25. Left panel: cells were incubated with 10 µM digitonin (a) 
or with test compound TAO24 at 6× (b), 4× (c) or 2× EC50 (d), or no test compound (e) in the presence of 9 
µM propidium iodide. Background fluorescence was recorded for wells containing media only (f). Right 
panel: parallel experiment with compound TAO25, at 3× (b), 2× (c) and 1× Ec50 (d). An increase in 
fluorescence recorded as arbitrary units (A.U.) correlates with increased permeability to propidium iodide, 
reflecting membrane integrity. 
 
 
5.3 Discussion 
 
The chemotherapy of HAT is still deficient despite recent efforts to discover new treatments 
effective for both stages of the illness (Eperon et al., 2014). Besides, drugs against animal African 
trypanosomiasis (AAT, or nagana) are even more urgently needed than for the corresponding 
human condition (Giordani et al., 2016). As current drugs are becoming ineffective due to drug 
resistance, cross-resistance between existing drugs and new ones is one of the most important 
issues that must be tackled early in the search for new antitrypanosomal agents (Rodenko et al., 
2013).  
 
In this work, two trypanocidal scaffolds (i.e. 2,4-dihydroxybenzoate and salicylhydroxamate) 
known to interact with mitochondrial targets were conjugated with a mitochondrion-targeting 
lipophilic cation in order to boost their potency against trypanosomes. Their activities against WT 
and resistant T. brucei, and against a drug-sensitive T. congolense strain, were studied in vitro.  
 
The first important result came from the low nanomolar range activities displayed by the 2,4-
DHB–TPP derivatives (TAO- 7, 8, 9, 10, 25, and 27, 47, 49 and 52), and the submicromolar 
activities of the 2,4-DHB–quinolinium derivatives (TAO- 23, 24, and 28, 48 and 50), as 
compared with the mid-micromolar EC50 values of the parent compound. In contrast, the SHAM–
TPP derivatives displayed somewhat lower activities, even though this still represented an 
approximately 100-fold improvement in potency relative to SHAM. The superior 
antitrypanosomal activities observed with the TPP vs quinolinium conjugates is consistent with 
earlier studies on diphenyl cationic trypanocides (Dardonville et al., 2015). It probably reflects 
the higher lipophilicity and charge dispersion around the phosphorus atom in the TPP cation, 
which is optimal for membrane permeation and accumulation in the mitochondrion.  
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Secondly, the insignificant differences in susceptibility between the WT and the multi-drug 
resistant B48 cell lines means that cross-resistance with existing first line HAT and AAT drugs, 
including pentamidine, diminazene, cymelarsan and melarsoprol, is highly unlikely to appear 
with these compounds, despite the diamidines, at least, also having mitochondrial targets (Lanteri 
et al., 2008; de Macêdo et al., 2015). Indeed, some compounds (e.g. TAO25) were, if anything, 
slightly more effective against the T. brucei B48 resistant line compared to WT, although this did 
not reach statistical significance. The lack of cross-resistance of 2,4-DHB and SHAM–LC 
conjugates with diamidines can be attributed to the fact that diamidine resistance in T. brucei is 
associated with loss of specific cell surface transporters (Baker et al., 2013; Munday et al., 2014), 
whereas the lipophilic LC conjugates are likely to diffuse across biological membranes.  
Also noteworthy is the submicromolar to nanomolar activity displayed by compounds TAO- 8, 9, 
10 and 27, 45, 47, 49, and 50 against T. congolense, the principal etiological agent of AAT. Their 
EC50 values are similar to, and in one case (i.e. TAO49), 30-fold more effective than the 
veterinary drug diminazene and their utility against AAT should be investigated further, as drugs 
against this condition are even more urgently needed than for the corresponding human condition 
(Giordani et al., 2016).  
 
In conclusion, in this chapter, several highly potent trypanocidal agents against T. brucei and T. 
congolense with very high selectivity indices up to >23,000 and no cross resistance with existing 
trypanocidal drugs were synthesized. We showed that the linking of a lipophilic cation to the 2,4-
DHB or SHAM scaffold drastically improved the activity against trypanosomes in vitro. The 2,4-
DHB scaffold gave the most potent compounds and the 14-methylene linker seemed optimal for 
trypanocidal action. Since the compounds described here were designed as potential 
mitochondrion-targeted molecules, more so that SHAM and 2,4-DHB are previously known to 
target TAO, the mechanism of their derivatives studied here might also be via inhibition of TAO. 
Hence their effects on parasite respiration need to be further investigated in order to know 
whether TAO might be involved in the observed antitrypanosomal activity. 
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Chapter 6: Investigation into the mode of action of mitochondria 
targeting lipophilic cations against T. b. brucei bloodstream form 
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6.1 Introduction 
 
Respiration of bloodstream trypomastigotes of Trypanosoma brucei relies on a plant-like 
alternative oxidase known as the trypanosome alternative oxidase (TAO) (Nihei, et al., 2002; 
Chaudhuri et al., 2006; Yabu et al., 2006; Nakamura et al., 2010). This mitochondrial enzyme, 
which is essential to the viability of trypomastigotes and has no counterpart in the mammalian 
host, is a validated target for chemotherapy (Nihei, et al., 2002; Ott et al., 2006; Nakamura et al., 
2010). To boost the activity of a TAO inhibitor, 2,4-dihydroxybenzoate (DHB), and 
salicylhydroxamate (SHAM), which were hitherto fairly active against T. brucei in a whole cell 
assay, we investigated a chemical strategy consisting of the conjugation of these fairly active 
TAO inhibitors with lipophilic cations (LCs) that can cross lipid bilayers by non-carrier mediated 
transport, and thus accumulate specifically into mitochondria, driven by the plasma and 
mitochondrial transmembrane potentials. In chapter five it was reported that this design afforded 
three series of LC–TAO inhibitor conjugates active in the submicromolar (i.e. TAO- 4, 5, 6, 23, 
24, and 28) to low nanomolar (i.e. TAO- 7, 8, 9, 10, 25, 28, 47, 49, and 52) range against wild 
type and resistant strains of African trypanosomes (T. brucei brucei, T. congolense). Selectivity 
over human cells was >200 and reached >23,000 for TAO25.  
We therefore speculated in chapter 5 that the mechanism of their anti-parasitic effect is most 
likely via the intended target (TAO). 
 
However, how easily enzyme inhibitors reach their target in vivo is determined by the 
accessibility of the enzyme (either intra- or extracellular) and the pharmacokinetics of the 
inhibitor. It is not uncommon that excellent enzyme inhibitors designed for intracellular targets 
are inactive when tested in whole cell assays because the compounds  simply do not reach the 
requisite concentration at the target location (Gilbert et al., 2013). In the case of antiparasitic 
compounds whose target is located inside the mitochondrion of the parasite, the compound must 
at a minimum cross the plasma and mitochondrial membranes to reach the enzyme target 
(Delespaux et al., 2013); additional membranes will have to be crossed for intracellular parasites. 
Consequently, effective delivery strategies that exist to ensure proper access of a drug to its 
cellular target must be validated.  
 
Hence, in this chapter, an attempt was made to study the effect of the compound series on some 
biochemical parameters including parasite respiration, mitochondrial membrane potential (Ψm) 
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and the cell cycle, in order to understand whether these compounds do indeed, as designed, 
effectively target TAO in vitro. We also aim to investigate whether the LC-carrier strategy 
developed herein had successfully delivered the specific antiparasitic agents to their 
mitochondrial target. 
 
6.2 Results 
 
6.2.1 Effects of TAO over-expression and aquaporin knockout in TAO activity against T. b. 
brucei bloodstream forms 
 
TAO was over-expressed in wild type trypanosomes using pHD1336 as expression vector (Fig. 
6.1A). The purpose was to study the effect of the over-expressed TAO gene on the tolerance of 
trypanosomes to the test inhibitors. Hence, we should be able to know whether these classes of 
inhibitors inhibit TAO activity in the mitochondria of trypanosomes. 
 
The result of over expression of the TAO gene in the wild type trypomastigotes of T. brucei s427 
is shown in Fig. 6.1B. Expression in clone 3 was approximately 80% higher than in the s427 WT 
and empty vector (controls), while expression in clone 2 was 60% higher than in the control cells. 
As expected, the expression levels in the two control strains (s427 WT vs Empty vector) were 
identical. 
Thus, the introduction of the construct resulted in a moderate increase in the expression of the 
mRNA (Figure 6.1C). 
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Figure 6.1 Expression of TAO in T. b. brucei trypomastigotes. Panel A: pHD1336 plasmid map 
showing strategy for TAO over-expression. Panel B: PCR confirmation/Agarose gel electrophoresis of 
TAO insert in BSF T. brucei, L=1kb DNA ladder (ThermoFisher Scientific), lanes 1-3 = TAO over-
expressor clones 1-3, lane 4 = wild type T. brucei, lane 5 = water.  Panel C: Relative levels of TAO 
expression were determined by qPCR in wild-type Lister 427, in the same cell line transfected with the 
‘empty vector’ pHD1336 (no insert) and with the TAO open reading frame in pHD1336. HDK0429 and 
MB0035 are primers. Error bars are average and SEM of 6 determinations. 
 
The T. brucei cell line over-expressing TAO (TbTAOoe) was used in parallel with other strains to 
determine the EC50 of the test series and compared with the EC50 values of the wild type control. 
It was anticipated that genuine TAO inhibitors, acting principally on this protein, would display 
reduced activity against TbTAOoe, whereas compounds that predominantly acted by another 
mechanism against the parasite, would display an unchanged activity against this strain. 
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Hence, some of the compounds were tested on a T. b. brucei cell line overexpressing TAO, as a 
further test for activity through inhibition of TAO, as it is not possible to delete the TAO gene, or 
even reduce its expression by RNAi (Helfert et al., 2001; Schnaufera et al., 2002). 
 
The aquaporins are known to be directly involved in the export of glycerol, H2O, urea, and other 
small molecules across the T. brucei cell membrane (Munday et al., 2015). We therefore 
hypothesised that the export of glycerol would become essential for the survival of BSF T. brucei 
especially when there is a blockade of the aerobic respiration via TAO, with the attendant build-
up of glycerol in the cell. Trypanosomes lacking the aquaglyceroporin (aquaporin) should die due 
to mass action of glycerol which builds up inside the cell and inhibits the anaerobic pathway of 
glycolysis that is the cell’s only pathway to ATP when TAO is inhibited. Similarly this mass 
action effect should play-out if there is also glycerol build-up in the media in the presence of 
TAO inhibition (Yabu et al., 1998). Accordingly, two strains: one lacking the aquaporin 2 and 
aquaporin 3 genes (aqp2/3 null) and the other lacking all three aquaporin genes (aqp1-3 null) 
were tested. Also, the compounds were tested against the wild type T. brucei BSF in the presence 
of 5 mM glycerol.   
 
 
The result showed that there was no significant difference between the wild type and the TAO 
over-expressor lines, only a few of the inhibitors tested were only slightly less active against the 
TbTAOoe line. However, TAO25 and SHAM were significantly less effective against this cell line 
than against the wild-type control, by 2.6 (P=0.0001) and 1.6-fold (P<0.01), respectively, 
indicating a possible involvement of TAO in the MOA of both compounds (table 6.1) but, the 
level of overexpression was really modest, as established by qPCR (Figure 6.1), owing to the 
already very high expression level of TAO in T. brucei trypomastigotes. 
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Table 6.1 EC50 values (µM) of LC TAO inhibitors against BSF T. b. b. cell line over-expressing TAO, and glycerol (5 mM) potentiating effect on Wild 
type BSF T. b. b. 
s427 WT 
a
 TAO-over-expressor 
b
 
TAO inhibitor +  5 mM glycerol on T. b. b s427 
WT 
c
 
COMPD 
AVG 
d
 
(µM) 
SEM 
e
 
(µM) AVR (µM) SEM  RF 
f
 t-test 
g
 AVG (µM) SEM  RF t-test 
TAO 7 0.073 3.28E-03 0.081 2.20E-04 1.12 0.12 0.08 0.01 1.16 0.33 
TAO 8 0.0059 2.50E-03 0.0062 1.99E-04 1.05 0.94 0.01 0.002 0.88 0.86 
TAO 9 0.0013 1.03E-03 0.0012 2.19E-05 0.95 0.96 0.0017 1.1E-04 1.26 0.83 
TAO 10 0.0012 1.17E-03 0.0012 3.58E-05 0.93 0.96 0.0012 3.4E-05 1.01 1.00 
TAO 20 0.0018 3.55E-04 0.0019 1.23E-04 1.09 0.79  - -  -  -  
TAO 21 0.062 0.0054 0.061 0.0020 0.97 0.87  - -  -  -  
TAO 22 32.94 0.88 33.047 5.65 1.00 0.98 13.62 1.18 0.41 4.0E-05 
TAO 23 0.33 0.014 0.37 0.024 1.11 0.21 0.23 0.01 0.69 2.7E-03 
TAO 24 0.10 0.012 0.11 0.0021 1.07 0.63 0.08 0.01 0.75 0.19 
TAO 25 0.0015 0.0002 0.0039 0.00014 2.60 1.35E-04 0.0008 6.7E-05 0.56 0.05 
TAO 26 31.82 0.93 35.00 0.60 1.10 0.05 17.48 0.88 0.55 1.E-04 
TAO 27 0.0092 0.0007 0.0077 1.05E-04 0.83 0.12 0.005 4.2E-05 0.54 3.7E-03 
TAO 28 0.143 0.014 0.15 0.0041 1.07 0.59 0.09 0.003 0.62 0.02 
TAO 29 49.04 7.79 44.64 1.12 0.91 0.71 12.25 0.61 0.25 0.01 
TAO 30 42.12 2.85 50.88 2.24 1.21 0.07 15.88 1.48 0.38 7.5E-04 
TAO 31 14.54 0.97 14.89 0.94 1.02 0.81 6.16 0.30 0.42 8.6E-04 
TAO 32 26.71 5.52 32.18 0.34 1.21 0.44 12.41 0.30 0.46 0.08 
TAO 33 11.88 1.60 10.92 0.53 0.92 0.70 5.14 0.52 0.43 0.02 
TAO 34 45.68 1.52 50.70 1.96 1.11 0.09 11.08 0.65 0.24 8.6E-06 
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TAO 35 17.59 0.55 15.83 0.30 0.90 0.05 10.746 0.540 0.61 8.79E-04 
TAO 37 3.77 0.12 4.17 0.087 1.11 0.05 1.798 0.011 0.48 7.19E-05 
TAO 38 14.40 0.07 14.26 0.062 0.99 0.21 7.498 0.120 0.52 9.48E-07 
TAO 39 4.06 0.09 4.17 0.054 1.03 0.36 7.800 0.392 1.92 7.50E-04 
TAO 41 17.70 0.48 21.58 0.60 1.22 0.01 12.093 0.538 0.68 0.001 
TAO 43 14.58 0.22 13.97 0.098 0.96 0.06 7.707 0.027 0.53 6.29E-06 
TAO 45 0.13 0.003 0.075 0.0072 0.56 0.002 0.067 0.005 0.51 4.84E-04 
TAO 46 1.75 0.01 1.36 0.18 0.78 0.09 1.229 0.077 0.70 0.003 
TAO 47 0.0024 7.97E-04 0.0038 5.03E-04 1.56 0.22 0.003 0.0005 1.32 0.44 
TAO 48 0.21 0.02 0.16 0.017 0.78 0.18 0.145 0.007 0.69 0.06 
TAO 49 0.0016 4.70E-04 0.0023 8.82E-05 1.45 0.22 0.001 0.0001 0.92 0.81 
TAO 50 0.03 0.001 0.056 0.010 1.76 0.07 0.071 0.002 2.22 2.07E-05 
TAO 51 14.72 0.14 13.57 0.052 0.92 0.002 7.185 0.067 0.49 1.13E-06 
TAO 52 0.001 1.20E-05 6.9E-04 1.22E-04 1.19 0.41 0.00039 0.00003 0.66 0.01 
DHB
 h
 17.06 1.08  nd  Nd  Nd Nd 19.00 1.02 1.11 0.26 
SHAM 
i
 38.73 4.78 60.31 4.97 1.56 0.01 7.01 0.31 0.18 1.3E-11 
PDM 
j
 0.0028 2.70E-04 0.0031 2.88E-04 1.08 0.57 0.0037 5.6E-04 1.32 0.13 
DMZ
 k
 0.065 0.01 nd 
l
 nd nd nd 0.06 2.1E-03 0.97 0.84 
PAO 
m
 0.0012 2.89E-05 0.0013 7.7E-05 1.14 0.12 nd nd nd nd 
 
aTrypomastigotes of T. b. brucei s427 (n ≥ 4). bT. brucei over-expressing TAO. CT. b. b incubated with TAO inhibitors in the presence of 5mM glycerol. 
dAverage of at least 4 independent determinations. eStandard error of mean of all determinations. fResistance factor. gUnpaired Student’s t-test comparing 
EC50 value of WT against the various cell lines or determinations. h2,4-Dihydroxybenzoate. iSalicylhydroxamate. jPentamidine and kdiminazene aceturate, both 
are known trypanocides. lNot determined. mPhenylarsine oxide, a known cytotoxic agent. 
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Table 6.2 EC50 values (µM) of LC TAO inhibitors against BSF T. b. b. cell line with double or triple knockouts of the aquaporin genes. 
 
 
s427 WT 
a
  aqp2/3-double null 
b
.  aqp1-3 triple null 
c
. 
COMPD AVG 
d
 (µM) SEM 
e
  (µM) 
AVG 
(µM) SEM  
f 
RF 
g 
t-test AVG (µM) SEM  RF t-test 
TAO 7 0.073 3.28E-03 0.073 0.0013 1.00 0.99 0.08 0.002 1.16 0.06 
TAO 8 0.0059 2.50E-03 0.0044 8.6E-04 0.75 0.70 0.01 2.2E-04 1.06 0.92 
TAO 9 0.0013 1.03E-03 0.0013 3.7E-05 0.98 0.99 0.001 4.5E-05 0.87 0.91 
TAO 10 0.0012 1.17E-03 0.0016 2.0E-04 1.27 0.84 0.001 2.7E-05 0.86 0.91 
TAO 20 0.0018 3.55E-04 0.0015 1.2E-04 0.87 0.70 0.0013 9.8E-05 0.76 0.49 
TAO 21 0.062 0.0054 0.056 6.2E-04 0.89 0.47 0.06 2.2E-03 0.93 0.66 
TAO 22 32.94 0.88 26.68 1.80 0.81 0.02 8.94 0.60 0.27 4.73E-06 
TAO 23 0.33 0.014 0.26 0.021 0.78 0.03 0.12 0.01 0.38 8.13E-05 
TAO 24 0.10 0.012 0.09 0.0012 0.89 0.44 0.04 0.01 0.37 0.01 
TAO 25 0.0015 0.0002 0.0020 1.9E-05 1.36 0.09 0.0009 1.2E-05 0.61 0.06 
TAO 26 31.82 0.93 27.43 0.67 0.86 0.02 15.64 0.38 0.49 3.26E-05 
TAO 27 0.0092 0.0007 0.01 5.5E-04 0.92 0.49 0.01 1.5E-04 0.77 0.06 
TAO 28 0.143 0.014 0.25 0.02 1.74 0.005 0.06 0.01 0.44 0.01 
TAO 29 49.04 7.79 24.59 0.57 0.50 0.07 7.09 0.78 0.14 0.01 
TAO 30 42.12 2.85 28.22 1.20 0.67 0.01 14.77 0.24 0.35 4.63E-04 
TAO 31 14.54 0.97 10.04 0.09 0.69 0.01 4.69 0.33 0.32 4.14E-04 
TAO 32 26.71 5.52 14.31 0.78 0.54 0.12 9.28 0.30 0.35 0.04 
TAO 33 11.88 1.60 4.99 0.12 0.42 0.02 1.27 0.07 0.11 2.74E-03 
TAO 34 45.68 1.52 14.52 0.72 0.32 1.52E-05 5.07 0.24 0.11 3.24E-06 
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TAO 35 17.59 0.55 8.397 0.24450 0.48 0.000085 7.8700 0.39793 0.45 0.000136 
TAO 37 3.77 0.12 1.426 0.09300 0.38 0.000056 1.8170 0.02515 0.48 0.000080 
TAO 38 14.40 0.07 7.084 0.20000 0.49 0.000001 7.1617 0.55037 0.50 0.000199 
TAO 39 4.06 0.09 1.396 0.04350 0.34 0.000014 1.8463 0.16086 0.45 0.000284 
TAO 41 17.70 0.48 11.550 0.62000 0.65 0.000919 12.0700 0.14364 0.68 0.000367 
TAO 43 14.58 0.22 7.302 0.00800 0.50 0.000005 6.7843 0.27070 0.47 0.000023 
TAO 45 0.13 0.003 0.042 0.00549 0.32 0.000612 0.0531 0.00635 0.40 0.000364 
TAO 46 1.75 0.01 0.954 0.02885 0.54 0.000474 1.0843 0.02700 0.62 0.000024 
TAO 47 0.0024 7.97E-04 0.002 0.00012 0.92 0.835686 0.0049 0.00308 2.01 0.483710 
TAO 48 0.21 0.02 0.098 0.01064 0.47 0.017224 0.0861 0.00472 0.41 0.006264 
TAO 49 0.0016 4.70E-04 0.001 0.00016 0.51 0.259280 0.0014 0.00013 0.89 0.744033 
TAO 50 0.03 0.001 0.035 0.00258 1.11 0.116814 0.0277 0.01012 0.87 0.693984 
TAO 51 14.72 0.14 6.752 0.07900 0.46 0.000001 6.9927 0.19160 0.48 0.000005 
TAO 52 0.001 1.20E-05 0.0002 0.00013 0.43 0.011882 0.00037 0.00005 0.64 0.016516 
DHB
 h
 17.06 1.08 nd nd nd nd 16.59 0.88 0.96 0.44 
SHAM 
i
 38.73 4.78 31.86 0.95 0.82 0.36 8.91 0.35 0.23 0.0043 
PDM 
j
 0.0028 2.70E-04 0.049 0.004 17.34 8.54E-08 0.07 5.6E-04 26.04 5.5E-16 
DMZ
 k
 0.065 0.01 nd 
l
 nd nd nd nd nd nd nd 
PAO 
m
 0.0012 2.89E-05 0.0013 4.2E-05 1.17 0.02 0.0013 3.1E-05 1.11 0.04 
 
aTrypomastigotes of T. b. brucei s427 (n ≥ 4). bAquaporin2/3 double knockout and caquaporin1-3 triple knockout BSF T. brucei. dAverage of at least 4 
independent determinations. eStandard error of mean of all determinations. fResistance factor. gUnpaired Student’s t-test comparing EC50 value of WT against 
the various cell lines or determinations. h2,4-Dihydroxybenzoate. iSalicylhydroxamate. jPentamidine and kdiminazene aceturate, both are known trypanocides. 
lNot determined. mPhenylarsine oxide, a known cytotoxic agent. It should be noted that the experiments reported in tables 6.1 and 6.2 were performed in 
parallel, there have the same controls and experimental conditions. 
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Co-incubation with glycerol, which inhibits the T. brucei anaerobic ATP production pathway 
(Brohn and Clarkson, 1978), significantly (P<0.05) increased the trypanocidal activities of most 
of the compounds and SHAM, whereas it had no effect on the efficacy of TAO-39, 47 and 50 and 
the control drugs pentamidine and diminazene (Table 6.1). These results are consistent with the 
aerobic glycolytic pathway being a target of these compounds which is expected for compounds 
inhibiting TAO. Meanwhile, TAO20 which lacks either a SHAM or a 2,4-DHB group for binding 
to TAO, displayed no differential effects against T. b. brucei in the presence of 5 mM glycerol, or 
against the AOX-OE line, indicating that indeed it was not an inhibitor of TAO. However, with 
an EC50 of just 1.8 ± 0.4 nM and a selectivity >3000 reported for it in chapter five, it might be 
worth investigating its mode of action separately. 
 
Similarly, most of the inhibitors were significantly more effective against the T. brucei cell lines 
from which both aquaporins AQP2 and AQP3 (aqp2/3 null) or all aquaporins (aqp1-3 null) were 
knocked out (Table 6.2). The effect of the compounds on the AQP knockout lines may be 
explained by a shift in metabolism of trypanosomes in the presence of the TAO inhibitors. 
Inhibition of TAO forces the parasite to produce glycerol in large quantity to survive via the 
anaerobic ATP-production pathway. In the absence of aquaglyceroporins, trypanosomes are not 
able to efficiently dispose of that glycerol, resulting in higher susceptibility to the TAO inhibitors.  
 
 
6.2.2 Lipophilic cation–TAO inhibitors strongly affect the mitochondrial membrane 
potential (Ψm)  
 
If the lipophilic cations are, as designed, accumulating in the T. brucei mitochondrion, then it is 
expected that this will impact on the mitochondrial membrane potential Ψm, as a result of (1) the 
accumulation of cations in the mitochondrial matrix, and (2) disruption of mitochondrial 
functions involved in maintaining the ion gradients. Similar effects have been shown for various 
diamidines, choline-derived dications and bisphosphonium compounds (Lanteri et al., 2008; 
Ibrahim et al., 2011; Alkhaldi et al., 2016). Thus in this section, we show the result of the Ψm of 
two representative molecules (TAO25 and TAO33) from our series of compounds.  
 
Fluorescence Activated Cell Sorting technology (FACS) was employed for the determination of 
the change in mitochondrial membrane potential (MMP) due to exposure of trypanosomes to 
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TAO25 or TAO33 by using tetramethylrhodamine ethyl ester (TMRE) (Denninger et al., 2007), 
using a cell density of 1×106 cells/mL with and without test compounds for the start of the 
experiment. 1 mL of these samples were transferred at each time point into a microfuge tube and 
centrifuged at 4500 rpm for 10 min at 4 ºC. The pellet was re-suspended in 1 mL PBS containing 
200 nM of TMRE, followed by incubation at 37 ºC for 30 min. The suspension was placed on ice 
for at least 30 minutes before analysis by a Becton Dickinson FACS Calibur using a FL2-heigth 
detector and CellQuest and FlowJo software (Ibrahim et al., 2011). Valinomycin (100 nM) and 
troglitazone (10 µM) were employed as negative (mitochondrial membrane depolarisation) and 
positive (mitochondrial membrane hyperpolarisation) controls respectively (Denninger et al., 
2007). Mitochondrial membrane potential was determined at 0, 1, 4, 8 and 12 h.  
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Figure 6.2 Histograms of TMRE fluorescence in populations of T. b. brucei trypomastigotes 
incubated with 0.005 µM TAO25, Valinomycin (100 nM) (see appendix F), 10 µM troglitazone, or no 
test compound for the indicated duration. Y-axis shows the number of cells (count) with a particular 
intensity of fluorescence as shown on the X-axis in artificial units (A.U.). A shift of the TMRE fluorescence 
to the left indicate depolarization while a shift to the right indicates hyperpolarization of the mitochondria 
membrane potential. 
 
The histograms above (Figure 6.2) are an extract from the results of the histograms for TMRE in 
the FL2H channel. The histogram results for other test compounds are presented in Appendix F.  
TA
O
25
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This assay was performed three times and the average was plotted using the GraphPad prism 5 
software as shown in figure 6.3. 
 
The result showed that TAO25 and TAO33 indeed rapidly depolarized the mitochondrial 
membrane, as measured by the fluorescent probe TMRE (figure 6.3).  
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Figure 6.3 Mitochondrial membrane potential (%Ψm) of treated and untreated T. b. brucei s427 WT 
cells. Data points represent average and SEM of flow cytometric determinations of TMRE fluorescence 
and are expressed as the percentage of cells that exhibit >200 artificial units of fluorescence intensity in the 
analyzed populations. Valinomycin and Troglitazone were used as controls for depolarization and 
hyperpolarization, respectively. Statistically significant differences from untreated control populations were 
assessed using an unpaired Student’s t-test; *P<0.05; **P<0.01; ***P<0.001. 
 
Figure 6.3 shows the percentage of cells in the population that accumulated >200 artificial units 
of TMRE fluorescence, which was set at 50% for the 0 time point of untreated cells; any increase 
in fluorescence such as induced by troglitazone signifies a hyperpolarization of the mitochondrial 
membrane and a decrease in fluorescence such as induced by valinomycin indicates 
depolarization. It is thus clear that TAO- 25 and 33 rapidly decreases T. brucei Ψm, although not 
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as rapidly as the potassium ionophore valinomycin (Figure 6.3). The reduced fluorescence is not 
simply the result of cells dying, as can be seen from the histograms of TMRE fluorescence for the 
individual determinations (Figure 6.2 and Apendix F). 
 
6.2.3 Effects of lipophilic cation-TAO inhibitors on ATP levels in T. b. brucei  
 
As mentioned in the last section, these compound series have a strong effect on trypanosomes’ 
mitochondrial function by depolarizing the mitochondrial membrane potential (Ψm).  
It is well acknowledged that the oligomycin-sensitive ATP synthase located in the mitochondrial 
membrane of bloodstream form (BSF) T. b. b. maintains its mitochondrial membrane potential, 
and it has been reported that there is a direct link between the mitochondrial membrane potential 
and ATP synthesis in BSF trypanosomes (Brown et al., 2006). Meanwhile, ATP is an essential 
source of energy for trypanosome and it obtains this from glycolysis; many trypanosome enzymes 
and functions directly depend on ATP for their metabolic function (Alkhaldi et al., 2016). 
Therefore, measurement of intracellular ATP level is fundamental to understanding cellular 
metabolism of trypanosomes in the presence and absence of the test compounds. Accordingly, 
these compounds were tested at the same concentrations as that of the mitochondrial membrane 
potential above in order to study their effect on ATP production. 
 
The intracellular ATP levels were measured using an ATP Determination Kit (Invitrogen) 
following the manufacturer protocol. ATP was determined using recombinant firefly luciferase 
and its substrate D-luciferin. This assay is based on luciferase activity which requires ATP as a 
co-factor in an enzymatic reaction to produce a luminescent light (emission maximum was 
approximately 560 nm at pH 7.8). Known amounts of an ATP standard (provided by the kit), 
prepared as a serial dilution were made and used to plot a standard curve which was eventually 
used to quantify in vivo ATP levels (Figure 6.4, panel A). 
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Figure 6.4 ATP concentrations in 107 T. b. brucei. Panel A: ATP standard curve done in parallel and 
under the same assay condition as that of the test samples, the luminescence gotten expressed as 
artificial units were plotted against ATP concentrations (10 nM – 800 nM) to generate an equation for a 
straight line from which the ATP concentrations in the test samples were extrapolated by fitting their 
luminescence to this equation; Panel B: ATP concentrations in treated and untreated 107 T. b. brucei cells 
using 50 mL extraction buffer. Incubation was for a period of 12 hours with samples taken at each time 
point. The results shown here are the averages of four independent experiments; and the error bars 
represent standard errors of 4 determinations. 
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The result shown in figure 6.4B shows the effects of TAO25, and TAO33 (at 0.005 µM, and 10 
µM, respectively) on intracellular ATP levels of T. b. brucei. It was clear from the result that 
these compounds depleted the intracellular ATP after one hour by at least 20%. This decline in 
intracellular ATP level tended to persist with time, and after 12 hours of incubation, the ATP 
levels went down to about 50% for both TAO inhibitors. Interestingly, there is a positive 
correlation between depolarisation of the mitochondrial membrane potential and intracellular 
ATP concentrations.  
 
 
6.2.4 Effects of lipophilic cation-TAO inhibitors on oxygen consumption rate in T. b. brucei  
 
The BSF trypanosomes require oxygen for respiration which is their only means of generating 
ATP via the glycerol-3-phosphate oxidase system which comprises TAO as the only terminal 
oxidase. Consequently, the oxygen consumption rate (OCR) of trypanosomes is a key indicator of 
their normal cellular function mediated by TAO. It therefore follows that trypanosomes with 
dysfunctional mitochondria, caused by treatment with a test compound targeting mitochondrial 
function, will show a reduced oxygen consumption rate when compared to untreated cells. 
 
Accordingly, the effects of selected lipophilic cation-TAO inhibitors on OCR were determined 
using the Oxygen Consumption Rate Assay Kit (Cayman chemicals, Ann Arbor MI, USA). This 
method was designed to measure extracellular oxygen consumption in mammalian cells but was 
adapted to trypanosomes following manufacturer’s protocol with substantial modifications (See 
section 2.8 of chapter 2). 
 
The result of the oxygen consumption rate assay in wild type T. brucei s427 BSF revealed that the 
various LC-TAO inhibitors tested, at concentrations close to their EC50, inhibited oxygen 
consumption when compared to the untreated control. SHAM, a known inhibitor of TAO also had 
a similar effect on the OCR of these trypanosomes (Figure 6.5).  
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Figure 6.5 Oxygen consumption assay of selected TAO inhibitors on T. b. b s427 following 2 hours 
of incubation of the cells with the respective compounds at the indicated concentration, using the 
MitoXpress®-Xtra HS kit (Cambridge Bioscience), which generates a fluorescence signal inversely 
proportional to the oxygen concentration. SHAM, No cells, Drug free and Glucose oxidase wells were 
used as controls. Blank wells were used to check background fluorescence.  
 
Following the reduction in oxygen consumption brought about by the incubation of the various 
test compounds (Fig. 6.5), it was then necessary to do a dose-dependency assay with a few of 
these compounds. 
 
The dose-dependent effects of TAO25 and TAO29 on oxygen consumption by T. b. brucei 
bloodstream trypomastigotes were tested using the same fluorescent oxygen reporter probe and it 
was found that both test compounds inhibit oxygen consumption of WT trypanosomes in a dose-
dependent manner. The dose dependence pattern of inhibition of our test compounds correspond 
well with a similar trend observed with the known TAO inhibitor, SHAM (Figure 6.6). These 
results clearly indicate a dose dependent effect of TAO25 and TAO29 on the respiration of T. 
brucei trypomastigotes. 
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Figure 6.6 Dose dependent oxygen consumption assay of TAO25 (Panel A) and TAO 29 (Panel B) 
on T. b. b s427, using the MitoXpress®-Xtra HS kit (Cambridge Bioscience), which generates a 
fluorescence signal inversely proportional to the oxygen concentration. Glucose oxidase was used 
to rapidly deplete the cell suspension of oxygen over 2 hours, generating a maximum signal for reference, 
whereas wells without cells were used to establish a null/background fluorescence level. Trypanosomes 
nearly depleted the medium of oxygen in approximately 90 min (drug free control), a rate that was dose-
dependently reduced by TAO25 and TAO 29, and also by SHAM. Symbols represent the average and SEM 
of 4 determinations. 
 
We decided to carry-out this assay on the Aquaporin 1-3 triple null trypanosome cell line (aqp1-
3 null) in order to further confirm whether the increased susceptibility of this strain to the TAO 
inhibitors reported for this strain (Table 6.2) is related to a reduction in OCR. In Chapter 5, we 
have shown that the aqp1-3 null strain is more susceptible to the inhibition of TAO mediated 
respiration by the test compounds. 
 
These compounds were tested at concentrations close to the EC50 of these compounds on the 
trypanosome aqp1-3 null cell line, which are lower than those used on the wild-type cells in order 
to allow the parasites to survive the period of incubation. However, it was found that despite this 
reduced concentration the effect of the test compounds on the OCR of aqp1-3  null cell line were 
found to be more profound (figure 6.7, Panel A) than that observed for the wild-type 
trypanosomes (figure 6.5). 
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Figure 6.7 oxygen consumption assay of TAO inhibitors on aqp1-3 triple null trypanosomes (panel 
A), and on Mammalian cells (HFF-T25) (panel B), using the MitoXpress®-Xtra HS kit (Cambridge 
Bioscience), which generates a fluorescence signal inversely proportional to the oxygen 
concentration. SHAM or Antimycin-A wells were used as positive control (Panels A and B respectively) 
while Drug free and Glucose oxidase wells were used as negative control. Blank wells were used to check 
background fluorescence. SHAM and TAO29 had no effect on mammalian respiration (Panel B) over the 2 
hours of incubation. 
 
Also because mammalian cells lack the TAO but rather depend on a cytochrome system for their 
respiration, and considering the high selectivity index obtained by our TAO inhibitors in chapter 
5, we decided to test these compounds on a mammalian cell line (Human Foreskin Fibroblast, 
HFF-T25) to further confirm this observation.  
 
The result showed that TAO29 and SHAM at a high concentration of 70 µM and 100 µM 
respectively did not inhibit the mammalian cells from respiring (figure 6.7, panel B). However, 
the well-known respiratory toxin antimycin A was used as a positive control. Antimycin A is 
known to bind to the Qi site of cytochrome c reductase, inhibiting the oxidation of ubiquinone 
and disrupting the electron transport chain between cytochrome b and c of the oxidative 
phosphorylation, which in turn leads to a cessation of respiration. Accordingly, the Antimycin A 
used in this assay fully inhibited oxygen consumption in the mammalian cells (figure 6.7, panel 
B). These results underscore the reduced toxicity/increased selectivity and safety of our TAO 
inhibitors and implicate TAO-mediated parasite respiration as the possible target.   
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6.2.5 Cell cycle analysis of lipophilic cation–TAO inhibitor exposed cells 
 
It has recently been shown that the treatment of T. b. brucei trypomastigotes with a different class 
of lipophilic cations, consisting of symmetrical bisphosphonium compounds, led to a rapid 
inhibition of the cell cycle by preventing initiation of S-phase; these compounds were shown to 
inhibit the mitochondrial FoF1 ATPase (Alkhaldi et al., 2016). We thus investigated whether the 
lipophilic cation-TAO inhibitors might have a similar effect on cell cycle progression. In order to 
establish this, the DNA content was measured over a 24 hour period. 
 
Fluorescence Activated Cell Sorting Technology (FACS) was used to study the effects of the test 
compounds on DNA content in BSF T. b. b. s427 WT. Cell density was adjusted to 1×107 
cells/mL with and without test compounds for the duration of the experiment. 1 mL of sample 
was transferred at each time point into microfuge tubes and centrifuged at 1620 × g for 10 min at 
4 °C, washed once in PBS containing 5 mM EDTA and re-suspended, then fixed in 1 mL of 70% 
methanol and 30% PBS/EDTA. The tube with the cells was left at 4 °C overnight in the dark, and 
the samples were subsequently washed once with 1 mL PBS/EDTA, re-suspended in 1 mL 
PBS/EDTA containing 10 µg/mL propidium iodide and incubated at 37 °C for 45 minutes. RNase 
A (10 µg/mL) was added before the samples were analysed by a Becton Dickinson FACSCalibur 
using the FL2-Area detector and CellQuest software. The data obtained were analysed using 
flowJo software (Flowjo LLC, Ashland, OR, USA). 
 
Figure 6.8 shows that TAO25 did not inhibit progress through the cell cycle, as 0.005 µM of 
TAO25 had no effect on the percentage of cells in G1, S or G2 phase after as much as 24 h, while 
the lipophilic bisphosphonium compounds CD38 and AHI-9 earlier reported in literature 
significantly reduced the percentage of S-phase cells after 8 and 12 h of incubation, respectively 
(Alkhaldi et al., 2016).  
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Figure 6.8 Percentage of cells at various cell division stages in populations treated or not treated 
with 0.005 µM of TAO25 over a 24 hour period. The percentages are the average of three independent 
determinations and SEM, obtained using flow cytometry after cell permeabilization and staining with 
propidium iodide.  
 
It is however possible that a higher concentration of the inhibitor would impact on the cell cycle 
or a longer incubation time would have changed the dynamics of the action of the compound 
tested on the cell cycle. Though this was not further tested and there is no report in the literature 
to support this, nevertheless, this observation which is the first of its kind as far as TAO inhibition 
is concerned, might be correct.  
 
          6.3 Discussion 
 
Our preliminary study of the MOA of these compounds showed that, contrary to the report that 
bisphosphonium salt derivatives inhibit the mitochondrial FoF1 ATPase (Alkhaldi et al., 2016), 
these compounds, although also lipophilic cations, do not appear to inhibit progression through 
the cell cycle. Since the compounds described here were designed as potential mitochondrion-
targeted molecules, we studied their effect on parasite respiration and investigated whether TAO 
might be involved in the observed antitrypanosomal activity.  
 
It has been previously reported that glycerol, whether generated endogenously or added 
exogenously, is capable of inhibiting the anaerobic glycolysis sufficiently to result in in vitro or in 
vivo cell death of BSF T. brucei. In some reports, the concomitant administration of SHAM and 
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glycerol to rats infected with T. b. b resulted in a rapid clearance of parasitaemia in rats (Clarkson 
and Brohn, 1976; Brohn and Clarkson, 1978; Yabu et al., 1998). 
 
Glycerol is known to inhibit anaerobic glycolysis and ATP generation that takes place in the 
glycosome of the BSF T. brucei by mass action. More recently, glycerol was reported to 
potentiate ascofuranone by together completely blocking the parasite’s energy production, 
therefore inhibited the in vitro growth of the trypanosome (Yabu et al., 1999). However, the 
combination of ascofuranone and the large volume of glycerol required to cure sleeping sickness 
is pharmacologically impracticable. 
 
The effects of our test compounds in combination with glycerol on the in vitro cell growth were 
also examined in this work, and it was clear that glycerol did potentiate the trypanocidal activity 
of our test compounds (Table 6.1). Earlier in vitro reports also revealed that inhibitors of TAO are 
trypanocidal when combined with the mass action of glycerol, which suppresses a glycerol-
producing pathway (Hammond et al., 1985; Kiaira and Njogu, 1989). This is because this 
combination would simultaneously inhibit both the anaerobic glycolytic pathway and the aerobic 
respiration, thus leading to a total inhibition of energy production (ATP) by the trypanosomes. 
The anaerobic respiratory pathway is mediated by the reverse action of glycerol kinase. In fact, the 
trypanosome glycerol kinase under physiologic condition does not play a crucial role in the 
trypanosome’s metabolism, and is therefore regarded as a sub-optimal drug target for 
trypanosomiasis, but it becomes essential when TAO is disabled (Verlinde et al., 2001). However, 
we observed that some of our test compounds had a strong inhibitory effect on the in vitro growth 
of trypanosomes, in the lower nanomolar range, even without glycerol. 
 
The combination of 5 mM glycerol with TAO inhibitors such as SHAM and our synthesized TAO 
inhibitors also increased the trypanocidal activity in most cases. SHAM is a well known iron 
chelator that binds iron in the di-iron centre of the TAO active site and acts as an inhibitor of this 
metallo enzyme (Grady et al., 1993; Yabu et al., 1999). However our compound was designed to 
specifically bind to TAO and avoid iron containing molecules in the biological system. It 
therefore follows that our test compounds block aerobic respiration via TAO inhibition while 
glycerol potentiated the trypanocidal activities of our test compounds by blocking the anaerobic 
respiration via a blockade of the reverse action of glycerol kinase. Indeed, most of the TAO 
inhibitors tested herein and the control, SHAM, were significantly more active against T. brucei 
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when co-administered with glycerol in vitro, indicating that the aerobic energy metabolic pathway 
may be a target of these compounds.  
 
Following the interesting result obtained from the co-administration of our compounds with 
glycerol in vitro, we decided to further test them on trypanosomes lacking the ability to export 
glycerol out of their cell (Aquaporin knockout cells). We reported some relatively small but 
significant differences using a cell line from which both AQP2 and AQP3 were knocked out – 
several compounds were significantly more effective against that cell line.  Knockout 
of all aquaporins (aqp1-3 null) made the cells clearly even more susceptible to the TAO 
inhibitors: more compounds displayed a significantly lower EC50 value, and by a larger margin. 
The explanation for the effect of the AQP knockout lines is that inhibition of TAO causes a shift 
in metabolism from TAO-mediated aerobic respiration to anaerobic respiration via the reverse 
action of glycerol kinase, thereby producing glycerol in large quantities. We speculated that 
trypomastigotes of T. brucei without aquaglyceroporins would not be able to efficiently dispose of 
that glycerol, and our observations are consistent with that hypothesis. 
 
The observation that our test compounds (TAO inhibitors) are more active against the aquaporin 
knockout trypanosomes is a positive development for an anti-trypanosomal strategy, as 
pentamidine and melarsoprol resistance in field isolates has been attributed to the loss of TbAQP2 
function (Graf et al., 2013). Wild-type AQP2 was reported to be absent in field isolates of T. b. 
gambiense, correlating with the poor outcome of melarsoprol treatment, but expression of a wild-
type copy of TbAQP2 gene in the most resistant strain completely reversed melarsoprol resistance 
and re-introduced the High Affinity Pentamidine Transporter (HAPT1) function and transport 
kinetics (Munday et al., 2015), demonstrating the importance of the aquaporins in the transport, 
effectiveness and resistance of key trypanocides such as pentamidine and melarsoprol. Therefore 
any drug that can specifically target this resistant strain will be a solution to the problem of drug 
resistance in trypanosomiasis caused by T. brucei. However, we did not test the effect of deleting 
only TbAQP2 on the effectiveness of TAO inhibitors, and expect that the impact of this will be 
limited, given the continued expression of TbAQP1 and TbAQP3. 
 
As TAO is essential for the respiration of bloodstream form trypanosomes we investigated 
whether some of the compounds were actually inhibitors of TAO mediated respiration. Several of 
the inhibitors were tested for effects on oxygen consumption using a fluorescent oxygen reporter 
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probe (kit); the compounds tested did inhibit oxygen consumption in a similar way as SHAM, and 
lower concentrations gave similar effects on the AQP knockout line. A dose-response with a few 
of the test compounds was also achieved, showing that indeed the reduced oxygen consumption is 
most likely the result of the effect of the test compounds on oxygen consumption, and the fact that 
the compounds did not affect oxygen consumption in mammalian cells clearly points to the major 
difference between BSF trypanosomes respiration and mammalian cell respiration. This 
difference is the presence of TAO in trypanosomes and its role as the sole terminal oxidase, and 
the absence of TAO in mammalian cells. Considering that TAO catalyses the reaction using 
oxygen in trypanosomes, inhibiting it therefore stood out, exactly as observed in the oxygen 
consumption assay. 
 
From our data, we can conclude at this point that the excellent anti-trypanosomal activity 
displayed by our compounds, as reported in chapter 5, is indeed via TAO inhibition. However, a 
direct inhibitory study with purified recombinant TAO (rTAO) and a study of its kinetics in the 
presence of the inhibitors would be necessary to confirm these findings. This work will be 
presented in Chapter 7. 
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Chapter 7: Direct inhibition studies with purified recombinant 
TAO lacking a mitochondria targeting signal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
166 
 
7.1 Introduction 
 
Alternative oxidases (AOXs), which are found across a broad range of organisms, including 
plants, nematodes, algae, yeast and certain disease–causing microorganisms including 
Trypanosoma brucei, are mitochondrial, cyanide–insensitive membrane-bound proteins that 
catalyse the oxidation of ubiquinol and the four-electron reduction of oxygen to water ( Young  et 
al., 2013). In T. brucei, a parasite that causes African trypanosomiasis in humans (sleeping 
sickness) and livestock (nagana) throughout sub-Saharan Africa, the trypanosome alternative 
oxidase (TAO) is unique and essential for the respiration of bloodstream form (BSF) parasites. In 
effect, in BSF trypanosomes, TAO is the sole terminal oxidase enzyme, and required to ultimately 
re-oxidize the NADH that is produced during glycolysis. As TAO has no counterpart in mammals 
and it is conserved among T. brucei subspecies (Yabu et al., 2010), it has been validated as a 
promising target for the chemotherapy of African trypanosomiasis (Yabu et al., 2003; Yabu et al., 
2006; Menzies et al., 2016).  
 
TAO is a cyanide-resistant and cytochrome-independent ubiquinol oxidase, formerly known as 
glycerol-3-phosphate oxidase, which is sensitive to the specific inhibitors salicylhydroxamic acid 
(SHAM) and ascofuranone (AF) (Grant and Sargent, 1960; Evans and Brown, 1973; Clarkson et 
al., 1989; Minagawa et al., 1997). The AOX gene in trypanosomes contains 990 nucleotides 
encoding the 330 amino acids full length protein, including the N-terminal 25 amino acid residue 
“Mitochondrial Targeting Signal” (MTS) (Appendix G). As the MTS is usually cleaved after 
transportation of the protein to the mitochondrion, the physiologically functional and relevant 
form of TAO is lacking the MTS sequence (Hamilton et al., 2014). However, only the full length 
protein has been overexpressed and studied (Shiba et al., 2012; Kido et al., 2010)  so far, in spite 
of the difficulties associated with its reduced stability, poor solubility and low yield.  
 
Because the full length TAO is not physiologically active in trypanosomes, it is imperative to 
target the physiological form of TAO and carry out direct inhibitory studies with potential 
inhibitors. It was hypothesized that rTAO without the MTS (∆MTS rTAO) would be more active, 
and more soluble, resulting in higher yield, and that this could also increase the stability and 
resolution of the protein. In addition, it was proposed that performing direct inhibitory studies of 
the ∆MTS rTAO with potential TAO inhibitors would give a clearer evidence for their in vivo 
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inhibition and kinetics than when using the full length protein, and that this could result in the 
discovery of more potent inhibitors that specifically targets the physiological form of TAO. 
 
In addition, it was reported in chapter 5 that the newly designed mitochondrion-targeted LC-TAO 
inhibitors significantly improved the activity of 2,4-dihydroxybenzoate and salicylhydroxamate 
(SHAM) against T. brucei and T. congolense strains in the lower micromolar to nanomolar range, 
and in chapter 6 that the mechanism of their antiparasite activities suggested inhibition of the 
parasites’ respiration, most likely via inhibition of TAO. Consequently in this chapter a direct 
inhibitory study has been carried out on ∆MTS rTAO to confirm whether this promising anti-
trypanosome activity is via TAO inhibition. We have used the computer program mitoprot 
(http://www.expasy.org/tools/) to predict the MTS to be 23 to 25 amino acids long and decided to 
try to produce pure TAO without the N-terminal 25 amino acids (∆MTS rTAO). 
 
Hence, in the present study, we report for the first time the production of a more active 
physiologic rTAO enzyme lacking the MTS sequence (∆MTS rTAO). We also report the novel 
use of a SUMO expression system (Appendix G) to optimise the production of rTAO. This 
∆MTS rTAO enzyme was used to study the activity of our new TAO inhibitors based on the 4-
hydroxybenzoate and 4-alkoxy benzaldehyde scaffolds (Figure 7.1). The results of rTAO 
inhibition and trypanocidal activity against several wild type and drug-resistant strains of 
trypanosomes will allow the production of structure-activity relationships (SAR) with these potent 
TAO inhibitors. 
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Figure 7.1 Summarized structures of the TAO inhibitors. Detailed full list of structures can be 
found in appendix C. 
 
7.2 Results 
 
7.2.1 Complementation by rTAO of FN102 E.coli lacking a terminal oxidase 
 
Haem is a cofactor of enzymes such as peroxidases, catalases, sensor molecules, and cytochromes 
of the P450 class. Four terminal oxidases including the quinol oxidases: cytochrome bo, and 
cytochrome bd have previously been identified in E.coli cell membranes (Shiba et al., 2012; Kido 
et al., 2010) . These four proteins catalyze similar reactions to TAO, which makes it difficult to 
measure the activity of TAO in E.coli that is engineered to express TAO. Haem is critical for the 
synthesis of all E.coli’s quinol oxidases but is not required for TAO activity. The synthesis of the 
first committed compound, 5-Aminolevulinic acid (ALA), is known to take place via two separate 
routes (Nihei et al., 2003; Shiba et al., 2012). The first is condensation of glycine and succinyl-
CoA (C-4 pathway), which occurs in fungi, and animals. The second is the conversion of 
glutamate to ALA (C-5 pathway), occurs in Archaea, plants, and most bacteria. E.coli is an 
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organism which synthesises ALA, being the first committed compound in haem biosynthesis, 
from glutamate (C-5 pathway) (Kido et al., 2010). 
 
Therefore, to remove all quinol oxidase activity of the haem-containing cytochrome complexes 
completely from the host E.coli strain, a haem-deficient E.coli strain FN102 was used for the 
overproduction of TAO. This E. coli strain was previously described by Nihei et al. (2003) and 
Elliott et al. (2014), and involved the introduction of the ∆hemA: :KmR mutation into strain 
BL21(DE3) by P1 transduction. Because the hemA-deficient mutant lacks the enzyme glutamyl-
tRNA reductase which is needed to catalyze the first committed step of haem biosynthesis in 
E.coli, the mutant would not grow aerobically without ALA, which is a precursor for protohaem 
IX biosynthesis (but does grow anaerobically). Nevertheless, the FN102 haem-deficient E.coli 
strain that was transformed with a pETSUMO plasmid vector (Figure 7.2) containing the ∆MTS 
rTAO sequence showed similar aerobic growth comparable to the wild-type even without ALA 
(Figure 7.3, panels C and D). 
 
 
 
Figure 7.2 Plasmid map showing the point of insertion of fl or ∆MTS-TAO in pETSUMO expression 
vector via the T – A cloning.  
 
 
The pET SUMO expression system (ThermoFisher Scientific) was used in this experiment with 
the aim of producing highly soluble protein in haem-deficient E. coli. It utilizes fusion with a 
small ubiquitin-related modifier (SUMO), which belongs to the growing family of ubiquitin-
related proteins, to enhance the solubility of expressed fusion proteins. In contrast to ubiquitin, 
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SUMO is involved in the stabilization and localization of proteins in vivo. After expression, the 
11 kD SUMO moiety was cleaved by the ULP-1 (Ubiquitin-like-specific protease 1) protease at 
the carboxyl terminal, producing the native TAO protein. The TA cloning - a subcloning 
technique which does not require the use of restriction enzymes - was used following the 
manufacturer’s instructions and it was easier and quicker than traditional subcloning. The 
technique depends on the ability of adenine (A) and thymine (T) on different DNA fragments to 
hybridize and become ligated together in the presence of a ligase (the T4 ligase was used in this 
experiment). PCR products were amplified using Taq DNA polymerase which favourably adds an 
adenine to the 3' end of the PCR product. The PCR-amplified insert was then cloned into 
pETSUMO, which is a linearized vector having a complementary 3' thymine (T) overhang. 
 
 
 
 
 
Figure 7.3 Comparative studies of the complementation of haem deficient FN102 E. coli by full-
length (fl) and ∆MTS-TAO. Panel A shows the PCR confirmation of ∆MTS-rTAO (lanes 1 and 3 = 915 
bp), and fl-rTAO (lanes 2 and 4 = 990 bp), while panel B is the PCR confirmation of these TAO genes in 
the plasmid (pET101) vector; NHis6SUMO-∆MTS-TAO (lane 6 = 1.26 kb), and NHis6SUMO-fl-TAO (lane 5 
= 1.34 kb). L1= BRG-100-02 DNA ladder; L2 = M2 DNA ladder (BIO-RAD) 
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Panel C is a growth curve of selected clones of haem deficient FN102 E. coli with the fl-rTAO gene; while 
panel D is for clones having the ∆MTS-rTAO. Wild type (haem deficient) FN102 E. coli were 
simultaneously grown in plus or minus 50 µg/ml ALA media and were used as controls. 
 
 
As expected, the result showed that terminal oxidase activity of the haem deficient FN102 E.coli 
was restored in all native FN102 colonies having the NHis6SUMO-pET 101 plasmid with the 
TAO insert. There was no visible aerobic growth in the native FN102 (FN102 WT) in the absence 
of ALA or NHis6SUMO-pET 101 with TAO insert (Figure 7.3). 
 
It was also observed that cultures of colonies having the TAO insert plasmid plus 50 µg/ml ALA 
displayed a better growth pattern than those having the TAO insert plasmid but without ALA and 
also better than the native FN102 cultures with 50 µg/ml ALA. This observation could be due to 
TAO restoring the terminal oxidase activities in the native FN102 cells but in addition boost the 
terminal oxidase activities in native FN102 when the normal haem synthesis pathway was 
restored in the presence of ALA (see figure 7.3). 
However, there were no significant observable difference in the growth pattern of the FN102 E. 
coli having the first 75 nucleotide sequence of TAO open reading frame deleted when compared 
with the clones having the full length TAO (fl rTAO) gene, showing that ∆MTS-TAO is fully 
active as terminal oxidase. This is consistent with the fact that the MTS is cleaved off upon 
transportation to the mitochondria in trypanosomes. This is to our knowledge the first direct 
evidence that the trypanosome alternative oxidase 75 nucleotide Mitochondrial targeting signal is 
not essential for TAO activity. 
 
Hence, this result showed recombinant TAO functioned as a terminal oxidase in the respiratory 
chain of the haem deficient FN102 E. coli complementing the function of the deleted quinol 
oxidases. 
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7.2.2 SDS-PAGE analysis of purified rTAO at various stages of purification and 
purification table for ∆MTS-TAO/fl-TAO. 
 
SDS-PAGE analysis of rTAO from various stages of purification was carried out. FN102 lysate, 
membrane fraction, flow-through, and peak fractions from TALON column were subjected to a 
discontinuous SDS-PAGE using Bio-rad protein size marker alongside (Figure 7.4). As expected, 
a band corresponding to 48 kD which is the correct size for full length TAO (NHis6SUMO-fl-
TAO) was observed in lanes 9 and 10 (duplicate). Upon cleavage of the NHis6SUMO (11 kD) 
with the highly efficient SUMO (ULP-1) protease produces the native TAO protein of interest 
with a band corresponding to 37 kD seen in lanes 12 and 13 (Figure 7.4), which is the exact size 
of full length TAO (TAO having MTS). On panel ‘A’, Lane 4 shows a band corresponding to 45 
kD, which is the size of NHis6SUMO-∆MTS-TAO. But upon cleavage of the NHis6SUMO (11 
kD)   with SUMO (ULP-1) protease, a band equal to approximately 34 kD was observed in lanes 
6 and 7 (duplicate). This is the size of TAO without MTS. 
Overall, a physiologically active TAO without the Mitochondrial Targeting Signal was 
successfully purified. 
 
 
 
Figure 7.4 SDS-PAGE for the various purification steps involved in the purification of rTAO from 
FN102 E. coli mitochondria membrane. Purification process of ∆MTS-TAO and full length (fl) TAO. 
Lane: 1 = Marker protein (Bio-rad). 2 = Lysed FN102/ NHis6SUMO-∆MTS-TAO cells. 3 = membrane 
fraction. 4 = NHis6SUMO-∆MTS-TAO. 6, 7, and 11 = ∆MTS-TAO (NHis6SUMO is cleaved). 8 = Lysed 
FN102/NHis6SUMO-fl-TAO cells. 10 = NHis6SUMO-fl-TAO. 5, 12, and 13 = fl-TAO (NHis6SUMO is 
cleaved) 
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Purified ∆MTS-TAO obtained from the column was clear while that of the fl-TAO was slightly 
turbid; this may be because the MTS is known to be slightly hydrophobic (Shiba et al., 2013). 
In addition, although the two forms of purified TAO were very active, the purified ∆MTS-TAO 
was more active than fl-TAO, and was found to be higher in total and specific activity, and yield 
(Table 7.1).  
Also, the purified ∆MTS-TAO exhibited a better specific activity, activity recovery, and fold of 
purification (392.24 µmol/min/mg, 1.27%, and 7.91 respectively) than the fl-TAO (195.74 
µmol/min/mg, 0.33, and 7.91 respectively) (Table 7.1). 
 
Table 7.1 Purification and activity table for rTAO 
 
 
Purification step. 
Total 
activity 
(µmol /min) 
Total 
protein 
(mg) 
Specific activity 
(µmol/min/mg) 
Activity 
recovery 
(%) 
Purification 
(x fold) 
Lysate ∆MTS 
TAO 
142409 3690 38.59 100.00 1.00 
Fl TAO 60900 2460 24.76 100.00 1.00 
Membrane ∆MTS 
TAO 
18492 310 59.65 12.99 1.55 
Fl TAO 7600.04 179.80 42.27 12.48 1.71 
Co – column ∆MTS 
TAO 
2211.20 8.60 257.09 1.55 6.66 
Fl TAO 335.01 2.20 152.27 0.55 6.15 
Cleaved ∆MTS 
TAO 
1802.11 4.60 392.24 1.27 10.16 
Fl TAO 203.02 1.0368  195.79 0.33 7.91 
 
 
                                                                               
7.2.3 Direct inhibitory studies with ∆MTS TAO: SAR studies with cationic and non-
cationic inhibitors. 
 
The TAO inhibitors were tested for their direct inhibitory effect on physiological TAO (i.e. 
∆MTS). These compounds were specifically made to fit into the TAO binding pocket and prevent 
the binding of Ubiquinol-1, which is the physiological substrate of TAO. The samples were 
dissolved in DMSO to make a stock solution of 10 mM, which was stored at -20 ºC and used for 
the assay. Ascofuranone and salicylhydroxamic acid (SHAM), two known TAO inhibitors were 
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used as positive controls in the assay while an equal volume of DMSO was used as negative 
control. The DMSO had no effect on TAO activity (result not shown). Control experiments were 
also carried out. In one of the control experiments, auto-oxidation of Ubiquinol-1 was carried out 
using the same protocol but without TAO. This was to check the quality of Ubiquinol-1, which 
can be re-oxidized to Ubiquinone in the presence of molecular oxygen. No auto-oxidation was 
observed. In another control experiment, the quality of the purified rTAO was tested in the 
presence of 1 mM ascofuranone which completely inhibited the conversion of Ubiquinol-1 to 
Ubiquinone-1. This result (not shown) indicates that no other oxidase was purified together with 
TAO.  
 
We are aware that some of these compounds, because of their chemical structures, may complex 
with the di-iron in the catalytic site of TAO thereby chelating it and rendering it ineffective, 
creating the possibility that these compounds also non-specifically bind with other haem-
containing proteins (in vivo) in mammalian cells, or indeed form complexes with metals in 
solution. It was because of this possibility that we decided to conduct a control assay where we 
pre-incubate 1 mM iron (II) chloride (FeCl2) and 250 nM purified rTAO for 2 minutes before 
using it for the TAO inhibition assay. This result was compared with that of TAO without 
incubation with FeCl2 under the same assay condition. There was no difference in TAO activity 
with or without FeCl2. This observation rules out the possibility for the assumption that the 
mechanism of inhibition might be via chelating of the di-iron in TAO catalytic site. 
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Table 7.2 EC50 values (µM) against T. b. brucei WT and IC50 values of inhibition of rTAO (µM) 
 
 
Compound EC50 (µM) T. b. brucei a IC50 (µM) rTAO b 
TAO18 >100 1.9 ± 0.015 c 
TAO22 32.94 ± 0.88 0.007 ± 0.00011 
TAO24 0.1 ± 0.012 1.36 ± 0.064 
TAO25 0.0015 ± 0.0002 1.46 ±  0.008 
TAO26 31.82 ± 0.93 0.15 ± 0.0051 
TAO29 49.04 ± 7.79 0.0069 ± 0.00012 
TAO30 42.12 ± 2.85 0.0157 ± 0.0013 
TAO31 14.54 ± 0.97 0.0174 ± 0.0018 
TAO32 26.71 ± 5.52 0.0123 ± 0.0041 
TAO33 11.88 ± 1.6 0.0144 ± 0.012 
TAO34 45.68 ± 1.52 0.0124 ± 0.003 
TAO35 17.59 ± 0.55 0.0728 ± 0.011 
TAO36 >200 0.2403 ± 0.020 
TAO37 3.77 ± 0.12 0.327 ± 0.23 
TAO38 14.4 ± 0.07 0.0072 ± 0.003 
TAO39 4.06 ± 0.09 0.0011 ± 0.0002 
TAO40 >200 0.0125 ± 0.0028 
TAO41 17.7 ± 0.48 0.241 ± 0.023 
TAO42 >200 0.0565 ± 0.010  
TAO43 14.58 ± 0.22 0.0065 ± 0.001 
TAO44 >200 0.011 ± 0.011 
TAO45 0.13 ± 0.003 0.221 ± 0.012 
TAO46 1.75 ± 0.01 1.23 ± 0.018 
TAO47 0.0024 ± 7.97E-04 0.081 ± 0.009 
TAO48 0.21 ± 0.02 0.0295 ± 0.029 
TAO49 0.0016 ± 4.70E-04 0.0883 ± 0.013 
TAO50 0.03 ± 0.001 0.1043 ± 0.011 
TAO51 14.72 ± 0.14 0.0295 ± 0.003 
TAO52 0.001 ± 1.20E-05 0.0303 ± 0.003 
TAO53 >200 0.45 ± 0.008 
ASFd ND 0.002 ± 0.004 
SHAMe 38.73 ± 4.78 5.93 ± 0.13 
 
aTrypomastigotes of T. b. brucei (n = 3). bPurified recombinant trypanosome alternative oxidase (n = 4). 
cStandard Error of Mean (SEM).dAscofuranone, and eSalicylhydroxamic acid were used as controls for 
TAO inhibition. Only the compounds showing some level of activity (<5 µM) against rTAO are shown in this 
table.  
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Most of the compounds tested against rTAO (25 out of 30) displayed submicromolar inhibition 
(Table 7.2). Among these, one compound (TAO39) was twice as potent as the reference drug 
ascofuranone (IC50 = 2 nM), four inhibited TAO with IC50 < 10 nM (TAO- 22, 29, 38 and 43), 
and thirteen displayed 2-digit nanomolar IC50 values (Table 7.2). The 2,4-dihydroxybenzoates 
inhibited TAO in the low nanomolar (non-cationic derivatives: TAO- 26, 31, 33, 34, 41, and 53) 
to low micromolar range (cationic compounds: TAO- 24, 25, 27, 28) (Table 7.2).  
 
With the non-cationic derivatives, a correlation between inhibitory activity and methylene linker 
length was observed, the longest linkers giving the best, low nanomolar, inhibitors (C16 > C12 
>> C10 > C6 > C4). For the C16 linker, little difference in activity was observed when changing 
the R1 group from a bromine (TAO34) to a formiate group (TAO33). However, the introduction 
of a lipocation such as TPP (TAO27) or quinolinium (TAO28) in this position was highly 
detrimental to TAO inhibition (>500-fold decrease in potency). As regards to cationic inhibitors, a 
linker with 14 methylene units was preferred (compare TAO -25/27 and TAO- 24/28). Hence, this 
linker was chosen to design the rest of inhibitors for the SAR studies.  
 
The effect on TAO inhibition of the modification of the phenyl ring substituents R2 and R3 is 
shown in Table 7.2. The introduction of a methyl group in R3 was favourable as shown by the 16- 
and 13-fold increase in inhibition of TAO49 and TAO50 compared to TAO25 and TAO24, 
respectively. In fact, the presence of a methyl group alone in R3 (i.e. without OH group in R2) was 
sufficient to get nanomolar range inhibitors (TAO- 38, 39, 47 and 48) of similar potencies 
(compare TAO- 43/38, 49/47, 50/48) indicating that the 2-OH group is not essential for binding to 
TAO. Replacement of the methyl group in R3by a fluorine atom was favourable for the cationic 
TPP derivative (TAO52 is 2.7-fold more potent than TAO47) whereas it was unfavourable for the 
non-cationic bromo analogue (TAO51 is 4-fold less potent than TAO38).  
The 4-formyl-3-hydroxyphenoxy-based inhibitors TAO- 35, 37, 45 and 46 were somewhat less 
potent than the 4-hydroxybenzoate derivatives (compare TAO35 with TAO51/43/38, 37 vs 39, 
and 45 vs 25/52/49/47) with the following order of inhibitory potency: R1 = Br > +PPh3 > OCHO 
>> quinolinium. Interestingly, the cationic TPP analogue TAO45 was 5-fold more potent than the 
quinolinium counterpart TAO46. 
 
The 4-hydroxybenzoate dimers (TAO- 22, 29, 30, 32, 40, and 44) inhibited TAO in the low 
nanomolar range (11–15.7 nM) whereas the 4-formyl-3-hydroxyphenoxy-based dimer TAO36 
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was approximately 21-times less potent inhibitor (IC50 = 240 nM) (Table 7.2). For the dimer 
series, a linker of 10 to 12 methylene units seemed to be favoured (compare TAO- 29/22 vs TAO- 
30/32) whereas the nature of R1 and R2 was less influential (compare TAO30 with TAO- 44/40).  
Importantly, for the 2-fluoro-4-hydroxybenzoate (TAO52), 2,4-dihydroxy-6-methylbenzoate 
(TAO- 49 and 50), and 4-hydroxy-2-methylbenzoate (TAO- 47 and 48) series, the addition of a 
mitochondrion-targeting lipocation in R1 hardly affected their inhibitory potency against TAO 
showing that the lipocation does not participate in the interaction with the binding pocket (or, at 
the very least, does not interfere with binding to TAO).  
 
A comparative summary of the structure activity relationship with respect to these compounds’ 
activities against T. brucei and rTAO is given in figure 7.5 (Panel A).  Unfortunately panel B of 
figure 7.5 gave a negative corrolation between the in vitro trypanocidal activity and inhibition of 
rTAO, partly because optimisation for mitochondrial targeting does not necessarily run parallel 
with optimisation of protein binding 
 
178 
 
      
 
 
 
 
 
 
 
179 
 
 
 
Figure 7.5 Comparative analysis of test compounds on rTAO inhibition. Panel A is a comparative 
summary of the structure activity relationship with respect to the test compounds’ activities against T. 
brucei and rTAO. Panel B is A scattered plot showing negative correlation between IC50 and EC50 of TAO 
inhibitors, where the log of minimum inhibitory concentration (IC50) for rTAO inhibition [-log (TAO IC50] 
was plotted against the effective concentration that brought about 50% of the maximal effect on 
trypanosomes (EC50) on the –log(Tryps EC50) axis. 
 
7.2.4 Michaelis-Menten kinetics and double reciprocal Lineweaver-Burk plots for TAO 
inhibitors 
 
Some of the TAO inhibitors were used for TAO kinetics assay. Briefly, 5 µl of a 50 ng/µl of 
∆MTS-rTAO prepared in 0.5 M Tris-HCl buffer (pH 7.3) was used, this gave a 250 nM TAO in 
the 1 ml reaction mix. The inhibitor concentration was varied and 2 µl of the inhibitor was taken 
each time. The reaction was in a total reaction volume of 1 ml 0.5 M Tris-HCl buffer (pH 7.3), 
and in a 1 cm path length cuvette. The contents of the cuvette was well mixed and quickly 
transferred to the UV- 300 double beam spectrophotometer (Shimadzu, Japan) set at 278 nM 
wavelength,   λscale (2 cm/min), scan speed 2(5), temperature was 25 ºC. The background activity 
was measured for at least 1 minute before the introduction of Ubiquinol-1 to initiate the reaction. 
Activity was measure for 2 minutes, and was recorded as units of absorbance per minutes. The 
data obtained were fitted for the Michaelis Menten plot, which were then transformed to double-
reciprocal plots for estimation of kinetic parameters. The reciprocals of the specific activity 
against that of the Ubiquinol concentration gave the double-reciprocal/Lineweaver-Burk plot. The 
enzyme inhibition constant Ki was also determined and presented below. 
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The Ki of TAO- 22, 29, 32, 33 were determined to be 41, 34, 32, and 71 µM, respectively. The 
Lineweaver–Burk analysis indicated that, similarly to SHAM (Ott et al., 2006), the compounds 
inhibit TAO non-competitively (Figure 7.6). 
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Figure 7.6 TAO kinetic determinations in the presence of varying concentrations of inhibitors and 
substrate concentration (Q1H2) (0 – 600 µM), with 250 ng TAO in a 1 ml (0.5 M Tris-HCl buffer, pH 
7.3) reaction mix. The figure shows the Lineweaver-Burk plots (main figures) for the test compounds 
(TAO- 22, 29, 32 and 33) as well as their corresponding Ki determinations (inset figures). All test 
compounds revealed a non-competitive (mixed) type inhibition. 
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While IC50 and Ki are both ways of determining an inhibitor's ability to inhibit the action of an 
enzyme, however they are not the same. The Ki value, is the true equilibrium constant, and is 
regarded as a better measure, considering that the Ki of an enzyme-inhibitor complex is always a 
constant. IC50 value on the other hand will vary depending on substrate concentration. 
Consequently, the Ki values were determined and reported in this work (inserts of figure 7. 6). 
The result showed the IC50 values of the compounds tested correlate well with the Ki 
determinations for each compounds, so that the lower the IC50 the lower the Ki. All the inhibitors 
reported here behaved as a non-competitive inhibitor (mixed type) with respect to Q1H2.  
 
7.2.5 Binding affinity of lipophilic cation–TAO inhibitor to TAO revealed by Surface 
Plasmon Resonance (Biacore) spectrometry. 
 
It was reported in the previous section that some of the inhibitors tested for their direct inhibitory 
activities on purified rTAO have a very good inhibition in the nanomolar range; also their 
affinities for rTAO were determined in terms of inhibition constants (Ki). However the direct 
inhibitory studies alone are insufficient in highlighting how tightly bound the inhibitors are to the 
rTAO, i.e. the constant of association (Ka), or their ease of dissociation from the rTAO once they 
are bound to it, i.e. constant of dissociation (Kd).  
 
It is more and more acknowledged that the rates at which drugs associate and dissociate from a 
receptor (the binding kinetics) directly affect drug efficacy and safety (Pan et al., 2013). This 
would, however, be important for the rational optimisation of kinetics during lead optimization of 
these inhibitors (Copeland et al., 2006; Lu and Tonge, 2010). 
 
Consequently, surface plasmon resonance (SPR) binding analysis was used to study the molecular 
interactions that exist between the test compounds and rTAO, following the method described in 
Drescher et al. (2009). SPR is an optical technique used for detecting the interaction between two 
different molecules where one is mobile and the other one is fixed on a thin gold film (Schuck, 
1997). In the work described here, using a single-cycle kinetics method, purified rTAO (10 mg/ml 
in 10 mM acetate buffer pH 5.5) was immobilized onto a sensor chip by an amine-coupling 
reaction (Biacore, Piscataway, NJ, USA) and it was inserted into the flow chamber of a Biacore 
T200  instrument (Biacore, Uppsala, Sweden). The Running Buffer used was made up of 10 mM 
HEPES pH 7.4, 300 mM NaCl, 0.05% Tween 20, 0.2% DMSO. The flow rate was 10 ml/min, 
183 
 
and a final response of 17914 RU, where RU is response unit, and one RU represents the binding 
of 1 pg of protein per square mm. 
The detection limit was 103 – 5×107 (1/Ms) for Ka and 10-5 – 1 (1/s) for Kd. 
 
The addition of the test compounds (0.5, 1, 2, 4 and 8 µM in running buffer), which is the flow-
through analyte, into the chamber resulted in binding of the test compound to the immobilized 
rTAO. This produced a small change in refractive index at the gold surface, which was quantified 
with exactitude. The binding affinities were then obtained from the ratio of the rate constants 
obtained, which gave a straightforward characterization of TAO-inhibitor interaction.  
 
 
The compounds tested had an unusually high bulk contribution that made the sensorgram shift 
down during the injection and shifting up during wash steps, however it did not drastically affect 
the determined Kon (Ka), Koff (Kd) and KD (Koff/Kon). 
 
Initially, an attempt was made to determine the KDs of the test compounds by fitting the 
sensorgram to a 1:1 binding model. However, the sensorgram from these compounds were fitting 
much better when using a heterogeneous ligand model (such heterogeneity may have come from a 
distinct binding site to TAO or from the immobilization procedure considering that the amine 
coupling method was used to immobilize TAO). Consequently two sets of Kon, Koff and KD were 
calculated (for comparison, data from both models are reported here).  
 
In addition, another justification for using the heterogeneous ligand model is that recently the co-
crystal structure of TAO29 with TAO was obtained (still under refinement), and surprisingly, 
TAO29 seems not to bind to the active site of the rTAO but to a different site supposed to interact 
with membrane lipids. Although, the possibility of their binding to the active site in addition to a 
second site cannot be completely ruled out, it therefore provides a "convenient" explanation to the 
heterogeneity response seen in the SPR analysis. The determined KDs varied from 0.1 to 1 µM. 
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Figure 7.7 Binding kinetics of TAO22 and TAO29 (Panels A and B respectively) into rTAO. The 
models used were a 1:1 binding (left) and heterogeneous ligand (right) models. Method: Single-cycle 
kinetics; Running buffer: 10 mM HEPES pH 7.4, 300 mM NaCl, 0.05% Tween 20, 0.2% DMSO; Analyte 
concentrations: (0.5, 1, 2, 4 and 8 mM) in running buffer; Detection limit:  Ka = 103 – 5×107 (1/Ms) and Kd= 
10-5 – 1 (1/s).
 
The full result including other test compounds is summarised in table 7.3 
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Table 7.3 Summary table for TAO inhibitors’ binding kinetics as revealed by SPR (BIACORE) 
experiments. 
 
 Model Ka 1 
(1/Ms) 
Kd1(1/s) KD1 
(nM) 
Ka2 
(1/Ms) 
Kd2 (1/s) KD2 
(nM) 
Chi2 
(RU2) 
U-
value 
TAO22 1:1 binding 4.72E+03 9.84E-04 208.6    0.225 2 
Heterogeneous 
ligand 
3.07E+03 6.42E-04 208.7 3.05E+04 1.34E-02 439.7 0.128 N/A 
TAO29 1:1 binding 2.68E+03 3.21E-03 1200    0.393 1 
Heterogeneous 
ligand 
1.73E+04 6.92E-03 399.9 4.94E+01 2.44E-03 49360 0.117 N/A 
TAO30 1:1 binding 8.06E+03 2.27E-03 280.9    0.183 2 
Heterogeneous 
ligand 
1.99E+04 5.85E-03 293.8 4.58E+02 2.66E-06 5.812 0.117 N/A 
TAO31 1:1 binding 4.87E+03 8.74E-03 1795    0.431 2 
Heterogeneous 
ligand 
1.09E+04 9.69E-03 888.9 1.29E+01 2.77E-03 215400 0.197 N/A 
TAO32 1:1 binding  3.96E+03 2.32E-03 584.9       0.413 2 
Heterogeneous 
ligand  
2.80E+04 9.83E-03 350.6 1.58E+02 3.56E-04 2256 0.0856 N/A 
TAO33 1:1 binding  7.56E+03 1.26E-03 166.4       0.128 2 
Heterogeneous 
ligand  
2.19E+04 2.79E-03 126.3 9.24E+02 3.65E-04 395.4 0.0337 N/A 
TAO34 1:1 binding  2.02E+04 1.81E-03 89.45       0.0856 5 
Heterogeneous 
ligand  
2.77E+03 4.26E-06 1.54 4.83E+04 8.31E-03 172 0.0446 N/A 
 
The chi-square value is a quantitative measure which shows the closeness of fit, so that in an ideal 
situation it will approximate to the square of the short-term noise level. The U-value was obtained using the 
1:1 binding model fitting, and it is also an additional indicator of the parameter significance. This is a 
parameter that represents the distinctiveness of the calculated rate constants and Rmax (RU), where Rmax 
corresponds to the analyte binding capacity of the surface, and this parameter is determined by testing the 
dependence of fitting on correlated variations between selected variables. Lower values indicate greater 
confidence in the results. A high value (above about 25) indicates that the reported kinetic constants 
contain no useful information (Ndao et al., 2014). 
Ka = constant of association (on rate); Kd = constant of dissociation (off rate); RU = response unit; KD = 
equilibrium dissociation constant. N/A = not applicable. 
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Figure 7.8 On-Off rate map of TAO inhibitors. This map shows a pictorial view of the Kon and Koff for all 
the test componds. It shows that apart from TAO 22, the compounds clustered closely, indicating how 
close their constants of association (Kon) and dissociation (Koff) is from one another.  
 
 
 
7.3 Discussion  
 
At the moment, neglected tropical diseases (NTDs) still remain a serious health emergency 
requiring a serious effort in the investigation of new drugs to fight them, the WHO’s ambition of 
eliminating African trypanosomiasis as a public health problem (Simarro et al., 2015), and the 
United Nations’ goal of reducing poverty, obviously will be advanced by developing a new drug 
that is affordable, safe and very effective for the treatment of both human and animal African 
trypanosomiasis. However, these road maps are still very far from realization. In fact, the drug 
development pipeline in the field of NTDs is almost dry, except for developments with 
fexinidazole and the Scynexis oxaborole presently in clinincal trials for late stage sleeping 
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sickness (Jones et al., 2015). Therefore specific targeting strategies should be exploited in order to 
identify new classes of possible drug candidates.  
 
However, it is very important when developing an efficient anti-parasitic drug to identify 
molecular targets in the parasite, one that should be critical for growth and survival of the 
parasite. Ideally this target should be absent or not important in humans or animals, and if at all 
present in humans/animal, it should be structurally distinct. We have identified an important 
target protein in African trypanosome which is important for their energy (ATP) generation and 
survival in the human host; this protein is called trypanosome alternative oxidase (TAO). 
 
We developed an integrated strategy to specifically target TAO using parallel synthesis that will 
generate compound libraries, combined with phenotypic assays that allow testing of compounds 
in a rational period of time. This strategy provides new hit compounds that can be progressed 
further to hit-to-lead, followed by the lead optimization steps in the drug discovery process. The 
target-based approach is at present regarded to be very efficient (Gilbert et al., 2011). However, as 
stated earlier, in order to rationally carry out this process of target-based drug discovery that will 
target TAO, it is of paramount importance to have significant information on the molecular target 
(TAO), and on the hit-target binding mode (TAO-inhibitor complex), so that modification on the 
hit scaffold can be reasonably guided by a combination of biophysical, biochemical, and 
computational methods. For this reason, having identified some of our molecules to be promising 
by means of various cell-based experiments, it was therefore essential to verify the potential 
target(s) using the available bioanalytical approaches. 
 
We have previous reported (Chapter 6) that in a whole-cell assay with the parasite, more than a 
half of all the test compounds were significantly more active against T. brucei when co-
administered with glycerol, or when tested against the aquaporin knockout cell lines; the 
compounds in addition also inhibited parasite respiration in an in vitro assay. A similar result was 
obtained with the TAO inhibitor SHAM (but not with control drugs that do not act on TAO), 
indicating that the test compounds are most probably acting on parasite respiration through TAO 
inhibition. This was further investigated, and confirmed, with our test compounds, which 
inhibited oxygen consumption of T. brucei WT, in a similar dose-dependent manner as SHAM, 
rapidly depolarized the mitochondrial membrane, and displayed reduced activity against a 
trypanosome line over-expressing TAO.  
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As a whole, these data are consistent with TAO being the primary target of these inhibitors in the 
parasite which led us to carryout direct inhibitory assay and study the kinetics of rTAO, which is 
reported here.  
 
The TAO gene contains 990 nucleotides encoding 330 amino acids full length protein, including 
the N-terminal 25 amino acid residue Mitochondrial Targeting Signal (MTS). For the majority of 
mitochondrial proteins, their transport into the mitochondria relies on two key fundamentals: (i) 
the presence of an MTS within the protein and (ii) the presence of some specific translocators 
within the mitochondrial membrane domain which recognize the specific signals (Bauer et al., 
2000). Basically, three types of MTS have been reported to be found in proteins that are intended 
for delivery into the mitochondria: A stop-transfer or sorting signal, an internal signal, and the N-
terminal signals (Neupert and Herrmann, 2007). The N-terminal targeting sequence, also called 
pre-sequence, is an amphipathic helix containing both hydrophobic and basic amino acid residues 
(Hamilton et al., 2014).  
 
Of the three MTS, only the N-terminal signal is usually cleaved after transportation of the protein 
to the mitochondria (Hamilton et al., 2014). Consequently, the physiological and functional TAO 
is without MTS (Bauer et al., 2000). Despite this phenomenon, only the full length protein has 
been over-expressed and studied to date. Yet, the problems of reduced stability, poor solubility 
and yield, and poor X-ray diffraction resolution of crystals of the recombinant AOX are thought to 
be due to the presence of the MTS (Shiba et al., 2013). Because the full length TAO is not 
physiologically active in BSF T. brucei, it is important to target the physiological form of the 
TAO when developing inhibitors that would target TAO and study the kinetics of the inhibitor-
∆MTS TAO complex, mimicking what would actually happen in vivo.  
 
We have reported the expression and purification of the physiological form of the alternative 
oxidase from Trypanosoma brucei (TAO) without its N-terminal 25 amino acid mitochondrial 
targeting sequence (∆MTS rTAO), and discovered that it was more soluble, stable, active, and 
was produced in a higher yield (Table 7.1). This physiologically relevant rTAO enzyme was used 
to characterize the inhibitory efficacy of 32 cationic and non-cationic compounds and develop 
structure-activity relationships with these series of 4-hydroxybenzoate and 4-alkoxybenzaldehyde 
derivatives. 
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Interestingly, the lipophilic cation (LC) compounds with C-14 methylene linker which seemed 
optimal for trypanocidal action reported in chapter five also provided improved inhibitory activity 
against the pure recombinant TAO enzyme compared to SHAM. However, the correlation 
between inhibition of purified rTAO and the trypanocidal effects of the reported LC conjugates is 
much complicated by the fact that the local concentration of the test compounds in functional, 
charged mitochondria remains unknowable for the moment. As intended, this makes the apparent 
EC50 concentration in vitro much lower than the IC50 concentration against the isolated enzyme, 
exactly as recently reported for the inhibition of the T. brucei F1Fo ATPase by lipophilic 
bisphosphonium compounds (Alkhaldi et al., 2016). Although the evidence suggests that some of 
the LC conjugates have sufficiently low IC50 values to act principally through inhibition of 
mitochondrial TAO, the possibility that (some of) the compounds also impact on other 
mitochondrial functions cannot be excluded. 
 
The kinetics of binding to TAO determined by Lineweaver-Burk plot analysis and Surface 
Plasmon Resonance (SPR) experiments indicated a non-competitive inhibition. Some of the 
inhibitors showed nanomolar IC50 values against ∆MTS rTAO in the same range as ascofuranone 
(IC50 = 2 nM) (Table 7.2). Ascofuranone has been found to be a good inhibitor of TAO (Suzuki et 
al., 2004). However, it was observed that perfect killing of the parasites can only be achieved 
when ascofuranone is given along with 5 mM glycerol in vitro. Ascofuranone, which is a 
prenylphenol antibiotic that was previously obtained from Ascochyta visiae - a phytopathogenic 
fungus, was reported to strongly inhibit both the glycerol-3-phosphate-dependent mitochondrial 
O2 consumption and glucose-dependent cellular respiration of BSF T. b. b. This inhibition was 
thought to be due to the blockade of the mitochondrial electron-transport system of the 
trypanosome, which is composed of glycerol-3-phosphate dehydrogenase (EC 1.1.99.5) including 
the alternative oxidase (TAO) (Suzuki et al., 2004, Shiba et al., 2013).  
 
Ascofuranone was also reported to noncompetitively inhibit the reduced coenzyme Q1-dependent 
O2 consumption of the T. b. b. mitochondria with regards to ubiquinol (Ki = 2.38 nM) (Suzuki et 
al., 2004). Consequently, the susceptible site was the trypanosomes’ ubiquinone redox machinery 
that links the activities of the two enzymes. We also carried out some kinetics studies on some of 
our compounds and discovered that they did have the same non-competitive mode of TAO 
inhibition as ascofuranone.  
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Salicylic hydroxamic acid (SHAM) is a known inhibitor of TAO, which non-specifically chelates 
the iron in the di-iron centre of TAO. SHAM has been comprehensively studied as an inhibitor of 
the cyanide-insensitive alternative oxidase present in the respiratory system of plants, and more 
recently it was reported to inhibit TAO, and also displayed a non-competitive (mixed type) mode 
of inhibition similar to the one reported for our compounds (Yabu et al., 1998). 
 
In conclusion, we have used the target-based approach to synthesize a number of mitochondrion-
targeted LC inhibitors of TAO, which are based on SHAM and DHB conjugated with 
triphenylphosphonium or quinolinium cations. Our initial data on this are highly encouraging, and 
revealed a great prospect for developing an effective, nontoxic inhibitor against African 
trypanosomes. In fact one of the advantages of these inhibitors/strategy is that unlike the non-
specific iron chelators such as SHAM, and 3,4-dihydroxybenzoate,  our LC-TAO inhibitors are 
specifically targeting TAO as shown by their very low toxicity to mammalian cells, and we 
showed previously that they did not affect the respiration of mammalian cells. Therefore the 
strategy for delivering these inhibitors across biological membranes as reported in this work is 
safe, and is a strategy that can be easily used for delivering other drugs across biological 
membranes to their targets, thereby reducing the risk of drug toxicity due to off-target effects. 
Considering our available data as reported in this work, we conclude at this point that the 
mechanism of action of these inhibitors is indeed via TAO inhibition. Therefore strategies to 
optimize the trypanocidal activity of these promising compounds should be given top priority.  
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The burden of parasitic disease (both human and veterinary) is still disappointingly high, 
particularly in resource-poor communities found in many less developed countries, 
notwithstanding the enormous efforts and resources put into various measures targeted at 
reducing this global burden by some organisation including the World Health Organization, 
UNICEF, the Food and Agriculture Organization of the United Nations (FAO), the Medicines for 
Malaria Venture (MMV), DNDi, Medecins-sans-Frontiers, the Consortium for Parasitic Drug 
Development, and the Bill & Melinda Gates Foundation, not leaving out the huge efforts 
generated by the Millennium Goals. 
 
These parasitic diseases include some of the most neglected tropical diseases, such as 
leishmaniasis, caused by more than 20 species of Leishmania, which affects approximately 
200 million people living in areas including Africa, Asia, South and Central America, and 
southern Europe (Barrett, and Croft, 2012). 
 
African trypanosomiasis on the other hand is a major health challenge facing the sub-Saharan 
African region, and is both a human disease (sleeping sickness) and a veterinary condition in 
livestock, including wildlife (nagana). The disease is caused by infection of humans and animals 
with parasites called trypanosomes, usually through the bite of infected tsetse flies. The 
agricultural losses alone attributed to this infection are estimated at USD 4.75 billion by the FAO, 
and threaten food security for millions of people (FAO, 2016).  
 
The disease could be fatal unless adequately treated with one of the few drugs available, as there 
is no vaccine or prophylactic medication, and insect vector control is barely effective given the 
enormous areas that are tsetse habitat. Several efforts have been made in order to control this 
disease, including the use of drugs. However, HAT is particularly problematic to treat due to the 
unacceptable toxicity and the complicated administration of the chemotherapies presently 
available for treatment. Besides, resistance to current drugs by trypanosomes is another threat to 
chemotherapy (Munday et al., 2014). 
 
A few drugs are at the moment registered for use in treating HAT: pentamidine, melarsoprol, 
suramin, eflornithine, and Nifurtimox Eflornithine Combination Therapy (NECT). NECT is the 
current recommended treatment for late stage T. b. gambiense HAT (Giordani et al., 2016). 
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However, none of these drugs are absolutely safe as all of them have certain degree of toxicity. 
Pentamidine and suramin are used in the first or early stage of T. b. gambiense and T. b. 
rhodesiense infections respectively. 
 
Meanwhile three key drugs are used to treat AAT: diminazene aceturate (DA), homidium salts 
(chloride or bromide), and isometamidium chloride (ISM). However, many problems are 
associated with the few available treatment options, these includes parenteral administration 
requiring long term hospitalization. Another challenge is the lack of guaranteed supply and high 
cost of drug in the resource-poor communities where the disease is concentrated. For instance, 
between 2002 and 2010, the average cost to treat a second-stage T. b. gambiense HAT patient 
with DMFO rose from €28 to €336 (Simarro et al., 2012), while 400 USD/treatment was spent on 
amphotericin B (AmBisome) for a patient infected with viceral leishmaniasis in Sudan (Salih et 
al., 2014). Moreover, the current drugs are very old, as most of them were discovered in the early-
to-mid-twentieth century and are becoming ineffective due to drug resistance; meanwhile 
investment in new drug development for this most neglected disease has been almost non-existent 
for decades (Barrett, 1999; Rodenko et al., 2015). 
Toxicity of some of these trypanocides is still a serious challenge; for instance, melarsoprol, a 
drug used for treating the second stage of HAT, is so toxic that it was reported to cause deaths in 
patient at an unacceptable rate of 10% due to a fatal reactive encephalopathy (Barrett 1999, 
Fairlamb et al., 1992; Burri, 2010). Other side effects include vomiting and nausea (Jannin and 
Cattand, 2004; Garcia, 2007).  
 
A major challenge facing chemotherapies of these two neglected tropical diseases is the issue of 
resistance to the current chemotherapies. For instance, melarsoprol (Delespaux and de Koning, 
2007; Graf et al., 2013) and eflornithine resistance (Vincent et al., 2010) for late stage HAT, and 
pentavalent antimonials for leishmaniasis (Sundar et al., 2008) have all been reported, this further 
reduces the available treatment options. 
 
As a result of the limitations facing existing chemotherapies, there is an urgent need for the 
development of new drugs that will replace the existing inefficient ones and that will be used for 
treating the most neglected tropical diseases, such as trypanosomiasis and leishmaniasis. 
However, it is important that the development of new anti-trypanosomiasis/leishmaniasis drugs 
should be targeted at a reasonable price, and this should lead to a significant reduction in 
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treatment costs, considering that these diseases affect mostly poor communities. Such solutions 
with the right cost/benefit balance could well include natural products research, although the 
search for new anti-trypanosomiasis/leishmaniasis drugs should by no means be limited to this 
strategy alone. However, the momentum to make new compounds from natural products, such as 
that from plant sources is considerable (Newman & Cragg, 2007). 
 
There is strong evidence in literature that medicinal plants are a rich source of drug candidates 
and leads, and, like synthetic compounds, could be exploited as anti-protozoan agents that could 
solve the present problem of drug inefficiencies (Schmidt et al., 2012). Some of the drugs in use 
today were originally from plants traditionally used for treating the same infection as now their 
isolated compounds do (Maya et al., 2007). The success story of the alkaloid artemisinin from the 
Chinese anti-malarial wormwood plant (Artemisia annua), and quinine from the bark of cinchona 
trees (Cinchona officinalis) are classic examples. Several plant-derived natural products from 
diverse structural classes including various flavonoids, alkaloids, quinonoids and terpenoids have 
been studied as anti-kinetoplastid candidates against some parasite specific metabolic pathways 
such as nucleic acid biosynthesis, biomembranes, and cytoskeletal proteins and enzymes (Wink, 
2012). 
 
In search of improved and non-toxic active antiprotozoal principles that are not cross-resistant 
with current anti-parasitics, seven plants used locally in Nigeria to treat trypanosomiasis and other 
tropical fevers were obtained and extracted with hexane, ethyl acetate and methanol. The plants 
were evaluated for activity against selected kinetoplastid parasites. Active principles were isolated 
by bioassay-led fractionation, testing for trypanocidal activity, and identified using NMR and 
mass spectrometry. The extracts and their purified compounds of three out of the seven plants 
were active in vitro against T. brucei, T. congolense, and L. mexicana.  
 
The result shows that crude extracts and isolated active compounds from Polyalthia longifolia 
and Eucalyptus maculata, in particular, display promising activity against drug-sensitive and 
multi-drug resistant T. brucei. In addition, these compounds were active against a veterinary 
trypanosome species, T. congolense, and against L. mexicana. This observation validates the 
folkloric claims that extracts of the plants from which there were isolated have activity against 
protozoan parasites. None of the isolated compounds displayed toxicity towards Human 
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Embryonic Kidney cells at concentrations up to 400 µg/mL. This is not surprising as these plants 
have been used for treating infectious disease for many years without any known side effects.  
 
Two of the isolated compounds (a diterpene and a triterpene, HDK20 and HDK40 respectively) 
were studied for their mechanism of action against a model organism, T. brucei s427 WT. It was 
observed that fluorescence microscopic assessment of DNA configuration revealed cell cycle 
defects after 8 hours of incubation with the natural compounds: DNA synthesis could not be 
initiated, leading to a dramatic increase of cells with 1 nucleus and 1 kinetoplast (1N1K). This 
shows that these compounds both affect cell cycle progression and their effect may be on the G1 
phase of the cell cycle. Nuclear DNA fragmentation also became evident after 10 hours of 
incubation with compound HDK-20 when visualised by flow cytometry.  
 
In an additional investigation into the mode of action of the HDK20 and HDK40, we tested 
whether these compounds cause DNA fragmentation via the induction of programmed cell death 
(PCD or apoptosis) in the trypanosomes. Terminal deoxynucleotidyl transferase dUTP Nick-End 
Labelling (TUNEL) assay was therefore used, revealing an increase in DNA fragmentation after 
12 hours. Thuis may indicate that a prolonged inability to progress the cell cycle could lead to the 
breakdown of DNA duplication machinery and the initiation of apoptotic process and subsequent 
nuclear DNA fragmentation. However, a conclusion of apoptosis would require substantial 
additional evidence and it is possible that these compounds interfere with some part of DNA 
replication, so as to introduce errors and breaks. Also the use of TUNEL assay to measure DNA 
fragmentation in kinetoplastids needs to be backed up with fluorescent microscopic examinations 
of the nuclear DNA and kDNA as it is also possible for normal replicating kDNA to be label by 
this method. 
 
Compounds HDK-20 and HDK-40 also induced a fast and profound depolarisation of the 
parasites’ mitochondrial membrane potential after 1 hour of incubation and this continued until a 
near complete depolarization was achieved after 12 hours, indicating that membrane 
depolarization is likely the first event in the entire process that lead to cell death. This explanation 
is likely so as it was also observed that intracellular ATP levels of T. brucei were found to be 
reduced shortly after depolarization of the membrane, indicating a direct link between 
mitochondria membrane potential and ATP generation. It thus appears that the mitochondria may 
be the primary target of the compounds, leading to reduced ATP generation and the inability to 
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initiate replication of kDNA, the essential first step in the trypanosome’s cell cycle - causing cell 
cycle arrest. 
 
Metabolomic assessment is a pointer to metabolic perturbations in the parasite and should give us 
a clue if there were any of such perturbations involved in the mode-of-action of the test 
compounds. However, metabolomic assessments of T. brucei cells incubated with HDK20 or 
HDK40 did not reveal the targeting of any specific metabolic pathway. Since the isolated 
compounds have almost no toxicity against human cells but are very active in vitro against 
multidrug-resistant trypanosomes, these compounds could serve as lead compounds towards the 
identification of more efficient anti-trypanosome drugs.  
 
Another way to develop safer and more effective drugs that will overcome the issues of toxicity 
and resistance is to have a well-defined target in the parasite, with a clear mechanism of action. 
To accomplish this, highly selective compounds that affect unique and essential molecular targets 
in the parasites should be developed. Accordingly, energy metabolism and the respiratory 
pathways of these parasites have been identified. The parasite specific cyanide-insensitive 
Trypanosome Alternative Oxidase (TAO) has been validated as a drug target in T. brucei (Yabu et 
al., 1998; 2003; 2006; Nakamura et al., 2010). TAO is considered a good chemotherapeutic target 
for drug development because this unique oxidase is very essential for the parasite’s respiration 
and survival since it re-oxidises cytosolic NADH, and because this protein is not found in the 
mammalian host but present in many obligate parasites (Nakamura et al., 2010). Earlier reports in 
the literature have shown that very simple chemical structures containing the 2,4-
dihydroxybenzoate (2,4-DHB) and salicylhydroxamate (SHAM) scaffolds did inhibit TAO 
(Clarkson et al., 1989; Grady et al., 1986; Ott et al., 2006). However, their trypanocidal activity 
proved disappointing because the inhibitors did not effectively cross the highly negatively charged 
inner mitochondrial membrane to reach their target. Hence in the second aspect of this thesis, a 
strategy to enhance the antitrypanosomal potency of these classes of TAO inhibitors based on 
their conjugation with a mitochondrion-targeting lipophilic cation (LC) using quinolinium or 
triphenylphosphonium (TPP) was developed and investigated. 
 
Their activities against WT and resistant T. brucei and T. congolense strains were studied in vitro. 
The first important result came from the low nanomolar range activities displayed by some of the 
2,4-DHB–TPP derivatives, and the submicromolar activities of the 2,4-DHB–quinolinium 
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derivatives, as compared with the micromolar EC50 values of the parent compound. In contrast, 
the SHAM–TPP derivatives displayed somewhat lower activities, even though this still 
represented an approximately 100-fold improvement in potency relative to SHAM. Superior 
antitrypanosomal activities were observed with the TPP vs quinolinium conjugates, which is 
consistent with earlier studies on diphenyl cationic trypanocides (Dardonville et al., 2015). It 
probably reflects the higher lipophilicity and charge dispersion around the phosphorus atom in the 
TPP cation, which is optimal for membrane permeation and accumulation in the mitochondrion. 
In some cases, these compounds were more active, than clinical drugs like pentamidine in vitro. 
Also noteworthy is the submicromolar activity displayed by some of the test compounds against 
T. congolense, the principal etiological agent of AAT. Their EC50 values were similar to the 
veterinary drug diminazene and their utility against AAT would be interesting to investigate  
further, as drugs against this condition are even more urgently needed than for the corresponding 
human condition (Giordani et al., 2016).  
 
A major issue for existing antiparasitic agents is drug resistance. Accordingly, resistant strains 
were used in this study as a model to determine cross-resistance between existing classes of 
trypanocides and the test compounds. This includes a multi-drug resistant strain, B48, which lacks 
both the Trypanosoma brucei aminopurine transporter TbAT1/P2 and the high affinity 
pentamidine transporter (HAPT1). There were no significant differences in susceptibility between 
the WT and both of these resistant strains, which means that cross-resistance with existing first 
line HAT and AAT drugs, including pentamidine, diminazene, cymelarsan and melarsoprol, is 
highly unlikely to appear with these compounds, despite the diamidines, at least, also having 
mitochondrial targets (Lanteri et al., 2008; de Macedo et al., 2015).  
 
Considering that resistance to these important trypanocides such as the diamidines has been 
previously linked to the loss of specific cell surface transporters such as the P2/TbAT1 and HAPT 
drug transporters (Matovu et al., 2003; Bridges et al., 2007), it therefore follows that these 
specific surface transporters are not associated with the internalisation of these test compounds, 
rather there are more likely to diffuse across biological membranes, ruling out any possibility for 
cross resistance. Lipophilic cations can cross lipid bilayers by non-carrier mediated transport and 
accumulate specifically into mitochondria driven by the plasma- and mitochondrial 
transmembrane potentials (Taladriz et al., 2012; Ross et al., 2006; Luque-Ortega et al., 2010; 
Dardonville et al., 2015). The strong accumulation of dications by the charged mitochondria 
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allows the inhibition of various essential functions with relatively low extracellular drug 
concentrations (Wilkes et al., 1997; Ibrahim et al., 2011; Alkhaldi et al., 2016). In addition, LCs 
can cross the blood–brain barrier (BBB) and generate therapeutically effective concentrations in 
the brain (Smith et al., 2003), which is particularly relevant for the treatment of late-stage 
sleeping sickness.  
 
As stated before, it is imperative when developing new chemotherapy that the new 
chemotherapeutic agent should not be toxic to human cells; therefore, their efficacy against the 
target parasites should be optimised whilst toxicity is reduced to an acceptable level, with 
increased selectivity index (SI). Consequently, the toxicity levels for the LC inhibitors tested in 
this work were determined in vitro using mammalian cells such as Human Embryonic Kidney 
(HEK) cells or Human Foreskin Fibroblast (HFF). The results show that all of the compounds 
were lower in toxicity on HEK cells, and in some cases not toxic at a concentration of up to 400 
µM in vitro. With many of them displaying an SI >200-fold.  
 
The low toxicity of the LCs tested here is similar to that reported in literature. For instance, a 
mitochondria-targeting antioxidant mitoquinone (MitoQ) comprising the lipophilic 
triphenylphosphonium (TPP) cation covalently linked to ubiquinone was developed and was 
reported to be safe and protective in animal models (Barry et al., 2010). MitoQ was also used in a 
phase 1 human clinical trial to investigate whether it could act as a disease-modifying agent in 
untreated patients with Parkinson’s disease. It was reported to be safe and well tolerated by those 
who took part in the clinical trial, further highlighting the safety of TPP-LC conjugates (Barry et 
al., 2010). 
 
The trypanocidal activity of our mitochondrion-targeting LC-TAO inhibitors, which inhibited 
trypanosome growth with EC50 in the low nanomolar range, was further enhanced in the presence 
of glycerol, and also showed enhanced activity against aqp2/3, and aqp1-3 KO trypanosomes, and 
inhibited parasite respiration dose-dependently, confirming that TAO is the cellular target of this 
compound. Consequently, these compounds were tested in a direct inhibitory assay with purified 
rTAO. More than 50% of these inhibitors effectively inhibited rTAO at concentrations as low as 1 
nM - further confirmation that TAO is the cellular target of these compounds. 
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The relationship between the biological activity of a compound and its structure is known as the 
Structure Activity Relationship (SAR). SAR analysis was performed on our library of 
mitochondrion-targeting LC compounds in order to determine the key functional groups of the 
pharmacophore responsible for it anti-trypanosome activity, this is an important tool in the further 
optimisation of the scaffold. The structural determinants for activity of the test compounds against 
TAO were similar to those previously found to be essential for TAO inhibition of some 
trypanocides. For instance the presence of the 4-hydroxyl group on the scaffold of the SHAM 
derivatives and the 2,4-dihydroxybenzoic acid derivatives were found to be a significant 
requirement for improved activity of these classes of inhibitors. A hydroxyl substituted benzoic 
acid moiety was previously reported to be the basic structural requirement needed to inhibit the 
alternative oxidase activity in plants and trypanosomes as reported for Ascofuranone and its 
derivatives (Saimoto et al., 2013). 
 
Another very important group on the scaffolds that clearly contributed to the anti-trypanosome 
activity of these classes of inhibitor as observed in this assay is the presence of the lipophilic 
triphosphonium or a quinolinium cations, as those lacking it were mostly inactive showing that 
the LC-carrier moiety effectively enhances the trypanocidal activity of the compounds. This same 
observation has been reported for some triphosphonium salts as trypanocides (Alkhaldi et al., 
2016). 
 
The number of methylene units was another key requirement for rTAO inihibition and 
antitrypanosome activity of the series of test compounds reported in this work. Because of the 
large size of the TPP cation, long spacers (14 to 16 methylene units) are needed to accommodate 
the pharmacophore in the enzyme binding-site, leaving the cationic moiety outside of the active 
site cavity. In contrast, the flat quinolinium cation seems to tolerate somewhat shorter linkers (14 
> 16 ≈ 12 methylene units) even though the tetradecane linker was optimum with both series. 
 
To investigate the mode of action of the LC - TAO compounds, various methods were employed. 
A preliminary investigation into the cellular actions of some of the compounds was performed 
using various strategies such as cell cycle progression, mitochondrial membrane potential, ATP 
content of cells, oxygen consumption assay, and DNA fragmentation. It was discovered that all 
LC-TAO inhibitors tested in this work led to a rapid reduction of T. b. brucei Ψm after 1 hour of 
incubation with the test compounds and also decreased the intracellular ATP level soon after. 
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These findings are very consistent with the mitochondria being the target of these compounds. It 
was because of these findings that the cell cycle was also studied. However, the compounds did 
not significantly affect the cell cycle at the test concentration and incubation period. 
 
In conclusion, we have successfully developed potential drug leads for the treatment of African 
trypanosomiasis. We are therefore confident that the findings from this work significantly 
enhance existing knowledge on trypanocidal strategies, with the identified hit compounds acting 
as a structural guide, and contributing to the on-going drug development against trypanosomiasis. 
We also hope that the strategies used in this work will gain application in the treatment of other 
parasitic diseases. Further work including lead optimization and in vivo assays with the most 
promising inhibitors is in progress. 
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Appendices 
Appendix A: List of selected medicinal plants used in this research 
 
                                          Plant- A: Centrosema pubescens Benth. (Family Fabaceae) 
 
 
                                       Plant-B: Moringa oleifera Lam (Family Moringaceae) 
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                                       Plant C: Tridax procumbens (L.) L. (Family Compositae) 
  
 
 
                            Plant D: Polyalthia longifolia (Sonn.) Thwaites (Family Annonaceae) 
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                           Plant E: Newbouldia laevis (P.Beauv.) Seem. (Family Bignoniaceae) 
 
                                     Plant F: Eucalyptus maculata Hook. (Family Myrtaceae) 
 
                             Plant G: Jatropha tanjorensis J.L.Ellis & Saroja (Family Euphorbiaceae) 
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Appendix B: Proton NMR of purified natural compounds. 
(HDK52)
polyalthiadioc acid
 
(HDK79)
kolavenic acid
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(HDK20)
16-α-hyroxy-cleroda-3-13(-14)Z-dien-15,16-olide
 
3β, 13β-dihydroxyurs-11-en-28-oic acid.
HDK40
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Pheophytin A: HDK28
 
Pheophytin B : HDK23
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Appendic C: Structure of synthesized TAO inhibitors 
Cmpounds 
Reference 
Number 
Structure 
TAO1 
PFG64 
1-3 
 
TAO2 
PFG53 
1-5 
 
TAO3 
PFG64 
1-6 
 
TAO4 
PFG59 
1-8 
 
TAO5 
PFG64 
1-10 
CDVI25  
TAO6 
PFG64 
1-12 
CIGI11 
 
 CDVI20 
O
O
OH
OH
Ph3P
Br-
Molecular Weight: 485,5
(CH2)5
 
TAO7 
PFG63 
1-8 
O
O
OH
OH
Ph3P
Br-
Molecular Weight: 527,6
(CH2)8
 
TAO8 
PFG63 
1-9 
O
O
OH
OH
Ph3P
Br-
Molecular Weight: 541,6
(CH2)9
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TAO9 
PFG63 
1-10 
O
O
OH
OH
Ph3P
Br-
Molecular Weight: 555,7
(CH2)10
 
TAO10 
PFG63 
1-12 
CDVI19 
O
O
OH
OH
Ph3P
Br-
Molecular Weight: 583,7
(CH2)12
 
TAO16 PFG80 
 
TAO17 PFG82 
 
TAO18 PFG83 
 
TAO19 PFG86 
O
N
H
O
O (CH2)9 CH3
HO
(CH2)9 CH3
 
TAO20 
 
PFG76  
 
TAO21 PFG95 
 
TAO22 CDVI24/F3 
 
TAO23 CIGI 2 
 
TAO24 CIGI 4 
O
O
OH
OH
N (CH2)14
Br-
Molecular Weight: 558,5
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TAO25 CIGI 5 
O
O
OH
OH
Ph3P (CH2)14
Br-
Molecular Weight: 691,7
 
TAO26 CIGI 1/F2 
 
TAO27 VBI 3 
O
O
OH
OH
Ph3P (CH2)16
Br-
Molecular Weight: 719,7
 
TAO28 CIGI 6 
O
O
OH
OH
N (CH2)16
Br-
Molecular Weight: 586,6
 
TAO29 CIGI 1/F3 
HO
OH O
O (CH2)10 O
O
OH
OH
Molecular Weight: 446,5
 
TAO30 CIGI 3/F3 
HO
OH O
O (CH2)14 O
O
OH
OH
Molecular Weight: 502,6
 
TAO31 CDVI24/F1 (CH2)12 O
O
OH
OH
Br
Molecular Weight: 401,3
 
TAO32 VBI 1/F3 
 
TAO33 VBI 1/F2 
H
O
O (CH2)16 O
O
OH
OH
Molecular Weight: 422,6
 
 
TAO34 VBI 1/F1 
 
TAO35 TDI 5/F3 
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TAO36 TDI 5/F5 
O OH
O (CH2)14 O
OH O
Molecular Weight: 470,6
H H
 
TAO37 TDI 5/F4 
O OH
O (CH2)14 O
Molecular Weight: 378,5
H
O
H
 
TAO38 TDI 7/F4 Br (CH2)14 O
O
OH
CH3
Molecular Weight: 427,4
 
TAO39 TDI 7/F5 O (CH2)14 O
O
OH
CH3
Molecular Weight: 392,5
O
H
 
TAO40 TDI 11/F5 
HO
CH3 O
O (CH2)14 O
O
OH
CH3
Molecular Weight: 498,7
 
TAO41 TDI 9/F3 Br (CH2)6 O
O
OH
OH
Molecular Weight: 317,2
 
TAO42 TDI 9/F5 
HO
OH O
O (CH2)6 O
O
OH
OH
Molecular Weight: 390,4
 
TAO43 TDI 13/F1 
Br (CH2)14 O
O
OH
CH3
Molecular Weight: 443,4
HO
 
TAO44 
TDI13/F3 
 
 
TAO45 TDI 15 
 
TAO46 TDI 16 
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TAO47 TDI 17 
O
O
CH3
OH
Ph3P (CH2)14
Br-
Molecular Weight: 689,7
 
TAO48 TDI 18 
O
O
CH3
OH
N (CH2)14
Br-
Molecular Weight: 556,6
 
TAO49 TDI 20 
 
TAO50 TDI 21 
 
TAO51 TDI 19/F2 Br (CH2)14 O
O
OH
F
Molecular Weight: 431,4
 
TAO52 TDI 26 
Ph3P (CH2)14 O
O
OH
F
Br-
Molecular Weight: 693,7
 
TAO53 LAGI 1 
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Appendix D: TUNEL assay dot plot of treated and untreated T. brucei s427 WT 
cells 
 
Samples Experiment 1 Experiment 2 Experiment 3 
 
 
 
 
 
Drug free 
 
 
 
 
 
 
 
 
Phleomycin 
 (2 µg/ml) 
 
 
 
 
 
 
 
 
 
HDK-20 
(0.3 µg/ml) 
 
 
 
 
 
 
 
HDK-40 
(1.0 µg/ml) 
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Appendix E: TUNEL assay histogram plot of treated and untreated T. brucei s427 wt cells 
 
Samples Experiment 1 Experiment 2 Experiment 3 
 
 
 
 
 
Drug free 
   
 
 
 
 
 
Phleomycin 
(2 µg/ml) 
 
 
   
 
 
 
 
HDK-20 
(0.3 µg/ml) 
 
 
  
 
 
 
HDK-40 
(1.0 µg/ml) 
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Appendix F: Mitochondrial membrane potential (%Ψm) of untreated T.b.b s427 WT cells 
 
Time 
(hour) 
Experiment 1 Experiment 2 
 
 
 
 
 
1 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
 
12 
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Mitochondrial membrane potential (%Ψm) of treated T.b.b s427 WT cells 
with Troglitozone (10 µM). 
 
 
 
 
 
 
 
    1 
 
 
 
 
 
 
 
 
    4 
 
 
 
 
 
 
 
 
     8 
 
 
 
 
 
 
 
12 
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Mitochondrial membrane potential (%Ψm) of treated T.b.b s427 WT cells 
with Valinomycin (100 nM). 
 
 
 
 
 
1 
  
 
 
 
 
 
4 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
       12 
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Mitochondrial membrane potential (%Ψm) of treated T.b.b s427 WT cells 
with TAO 25 (0.005 µM) 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
 
       12 
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Mitochondrial membrane potential (%Ψm) of treated T.b.b s427 WT cells 
with TAO 33 (10 µM). 
 
 
 
 
 
 
        1 
  
 
 
 
 
 
       4 
 
 
 
 
 
 
 
      8 
  
 
 
 
 
 
 
     12 
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      Appendix G: TAO cloning in pET SUMO showing the SUMO cleavage site. 
 
 
 
Appendix H: Gene sequences and Primer design 
 
Full length (FL) TAO 
 
ATGTTTCGTAACCACGCATCGAGGATCACTGCCGCAGCTGCGCCTTGGGTGCTCCGGACGGCTTGCCGCCA
GAAGTCTGACGCCAAAACACCTGTGTGGGGACACACTCAACTGAACCGTCTCAGTTTTTTGGAAACCGTGC
CTGTCGTTCCTTTGCGTGTTTCCGATGAAAGCAGTGAGGACCGCCCCACCTGGAGCCTTCCCGATATTGAGA
ATGTGGCCATAACGCACAAGAAGCCAAACGGCCTCGTTGATACACTCGCCTACCGCAGCGTCCGCACCTGC
CGCTGGTTATTTGACACATTCTCTCTCTACCGTTTCGGTTCCATCACGGAGAGCAAAGTCATCAGCCGCTGC
CTTTTTCTTGAAACTGTTGCCGGTGTCCCGGGGATGGTCGGTGGAATGTTGCGCCACCTTTCATCATTGCGG
TACATGACGCGCGACAAGGGTTGGATTAACACTCTTCTTGTTGAAGCAGAGAATGAGCGCATGCACCTCAT
GACGTTCATTGAACTTCGCCAACCAGGGCTCCCCCTACGCGTTTCCATCATTATTACGCAAGCCATTATGTA
CCTCTTCCTCCTGGTCGCCTATGTGATTTCCCCCCGTTTTGTACACCGCTTTGTCGGTTACCTTGAAGAGGAA
GCCGTCATTACATACACCGGCGTTATGAGAGCAATTGACGAAGGAAGGCTGCGCCCTACCAAAAATGATGT
TCCCGAAGTGGCTCGCGTGTACTGGAACCTCAGCAAAAATGCCACATTCCGCGACCTCATCAACGTGATCC
GAGCTGACGAGGCGGAGCACCGTGTCGTTAACCACACATTTGCTGACATGCACGAAAAACGCCTGCAAAA
CAGTGTCAACCCCTTCGTTGTTCTGAAGAAGAACCCAGAGGAAATGTACTCCAACCAACCAAGTGGTAAGA
CAAGGACGGATTTTGGAAGCGAAGGCGCCAAAACTGCGAGTAATGTAAACAAACACGTGTAA 
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One letter amino acid sequence for full length TAO. 
MFRNHASRITAAAAPWVLRTACRQKSDAKTPVWGHTQLNRLSFLETVPVVPLRVSDESSE 
DRPTWSLPDIENVAITHKKPNGLVDTLAYRSVRTCRWLFDTFSLYRFGSITESKVISRCL 
FLETVAGVPGMVGGMLRHLSSLRYMTRDKGWINTLLVEAENERMHLMTFIELRQPGLPLR 
VSIIITQAIMYLFLLVAYVISPRFVHRFVGYLEEEAVITYTGVMRAIDEGRLRPTKNDVP 
EVARVYWNLSKNATFRDLINVIRADEAEHRVVNHTFADMHEKRLQNSVNPFVVLKKNPEE
MYSNQPSGKTRTDFGSEGAKTASNVNKHV 
 
∆MTS TAO sequence (915 bp) 
TCTGACGCCAAAACACCTGTGTGGGGACACACTCAACTGAACCGTCTCAGTTTTTTGGAAACCGTGCCTGTCGTTCCTTTGCGT
GTTTCCGATGAAAGCAGTGAGGACCGCCCCACCTGGAGCCTTCCCGATATTGAGAATGTGGCCATAACGCACAAGAAGCCAA
ACGGCCTCGTTGATACACTCGCCTACCGCAGCGTCCGCACCTGCCGCTGGTTATTTGACACATTCTCTCTCTACCGTTTCGGTT
CCATCACGGAGAGCAAAGTCATCAGCCGCTGCCTTTTTCTTGAAACTGTTGCCGGTGTCCCGGGGATGGTCGGTGGAATGTTG
CGCCACCTTTCATCATTGCGGTACATGACGCGCGACAAGGGTTGGATTAACACTCTTCTTGTTGAAGCAGAGAATGAGCGCAT
GCACCTCATGACGTTCATTGAACTTCGCCAACCAGGGCTCCCCCTACGCGTTTCCATCATTATTACGCAAGCCATTATGTACCT
CTTCCTCCTGGTCGCCTATGTGATTTCCCCCCGTTTTGTACACCGCTTTGTCGGTTACCTTGAAGAGGAAGCCGTCATTACATAC
ACCGGCGTTATGAGAGCAATTGACGAAGGAAGGCTGCGCCCTACCAAAAATGATGTTCCCGAAGTGGCTCGCGTGTACTGGA
ACCTCAGCAAAAATGCCACATTCCGCGACCTCATCAACGTGATCCGAGCTGACGAGGCGGAGCACCGTGTCGTTAACCACAC
ATTTGCTGACATGCACGAAAAACGCCTGCAAAACAGTGTCAACCCCTTCGTTGTTCTGAAGAAGAACCCAGAGGAAATGTACT
CCAACCAACCAAGTGGTAAGACAAGGACGGATTTTGGAAGCGAAGGCGCCAAAACTGCGAGTAATGTAAACAAACACGT 
 
Primers design for rTAO production using SUMO vector. 
SUMO-TbAOX-DL-25-F1: AGCGACGCCAAAACACCTGTGTGGG 
SUMO-TbAOX-FL-F1: AGCCGTAACCACGCATCGAGG 
TbAOX-F2: CTTGTTGAAGCAGAGAATGAGCGC 
SUMO-TbAOX-Rv: TTACACGTGTTTGTTTACATTACTC 
His6-SUMO-TbAOX-FW: CACCATGGGCAGCAGCCATCATCATC 
 
Primers design for TAO over-expression in BSF T. brucei s427WT 
Forward- HDK559   GCGC AAGCTT ATGTTTCGTAACCACG 
Reverse-HDK560:     GCGGATCC TACACATGTTTGTTTACATT 
 
Primers design for qRT-PCR 
Forward-HDK637:   CGAAGTGGCTCGCGTGTA 
Reverse-HDK638:    TGATGAGGTCGCGGAATGT 
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APPENDIX I: PCR analysis of TAO overexpression, showing amplification, standard curve and 
PCR primer Efficiency. 
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